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ABSTRACT 
 
Introduction 
 
The discovery of the first antibiotic, penicillin, paved way for many other discoveries and 
developments much to the benefit of antibiotic treatment against bacterial infections. As 
years went by, the irresponsible use of antibiotic compounds in the medical, agricultural and 
veterinary fields, as well as lack of robust infection control protocols in clinical spaces, led to 
the emergence of antibiotic tolerant and resistant microorganisms. In an attempt to arrest the 
crisis, the discovery of new bioactive compounds that can be developed into potent novel 
antibiotics has been of importance. Amongst the many sources of bioactive compounds that 
have been researched for decades, microorganisms of the genus Micromonospora have 
been well documented as producers of potent bioactive metabolites, many of which have 
been successfully developed into novel commercial antibiotics. There is, however, a dearth 
of research information concerning the possibility of novel bioactive metabolites isolated from 
Micromonospora species from South Africa. Therefore, this study aimed to investigate the 
antibiotic biosynthetic potential of selected marine Micromonospora species isolated from the 
Algoa Bay region in Port Elizabeth, South Africa. 
 
Method 
 
A total of 30 Micromonospora strains isolated from Algoa Bay region, Port Elizabeth in South 
Africa were provided as frozen stock cultures at the Cape Peninsula University of 
Technology’s Biocatalysis and Technical Biology (BTB) research unit. The strains were first 
cultured on SGG and 172 F solid and liquid media, with and without artificial sea water 
(ASW). The Gram stain was performed to ensure purity of strains and to evaluate 
microscopic morphology before extracting DNA. Multi-Locus Sequence Analysis (MLSA) of 
the rpoB and gyrB housekeeping genes was performed as well as 16S rRNA gene analysis. 
Phylogenetic analysis was performed using MEGA X and phylogenetic trees were 
constructed to this effect. Eight antibiotic biosynthetic gene clusters (BGCs) were screened 
for via PCR. Gaps in the current primer sets available for BGC screening were analysed. 
Genomic data for 44 Micromonospora strains was retrieved from EzBiocloud and antiSMASH 
and these assisted with primer designing after assessing primer-knowledge gaps. The 
designed primers were designed to target BGCs encoding for bacteriocins and lanthipeptides 
and were tested on five selected Micromonosporaceae strains. The antibacterial activity of 
the top five strains was also investigated using overlay studies on solid media cultures and 
bioautography studies in liquid media cultures. In addition, the efficacy of antibiotic extraction 
was tested through the use of five different antibiotic extraction techniques. 
 
 
 
 
iii 
Results 
 
Our results demonstrated that all the strains under study were viable Micromonospora 
species. Phylogenetic analysis of the five strains chosen for further analysis identified their 
closest related validly published type strain as Micromonospora aurantiaca ATCC 27029. 
Furthermore, one of the eight BGCs that were screened for, the Type II PKS BGC, was 
positive in 28 out of the 30 strains. Genomic information of the genus Micromonospora was 
retrieved from antiSMASH which assisted in assessing gaps in current primer knowledge. 
Ultimately this led to the design of new primers to target bacteriocin and lanthipeptide BGCs. 
Four of the five strains tested gave a positive PCR result, albeit with multiple bands. The 
multiple bands on the agarose gel signified non-specificity in the binding capacity of the 
designed bacteriocin BGC primers hence there was no exclusive and convincing evidence of 
existence of this gene cluster. Negative PCR results were observed for the Lanthipeptide 
primer set. Antibacterial activity analysis on solid and in liquid culture media proved that the 
five selected strains produced bioactive compounds that were active against Gram-positive 
(Bacillus cereus ATCC 10876) and Gram-negative (Escherichia coli ATCC 25922) pathogens 
as well as yeast (Candida albicans ATCC 24433). 
 
Conclusion 
 
The Micromonosporaceae species that were under investigation in this study show great 
potential as sources of bioactive metabolites with broad spectrum antibacterial activity as well 
as antifungal activity. These should be considered as suitable candidates for whole genome 
sequencing as well as comparative genome sequence analysis for greater insights into the 
M. aurantiaca group. 
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CLARIFICATION OF TERMS 
 
16S rRNA: A constituent of the prokaryotic ribosomal 30S subunit that is present in all 
bacterial species and important in investigating bacterial species-relatedness from an 
evolutionary perspective. 
 
Actinobacteria: A Gram-positive phylum of bacteria with a very high guanine and cytosine 
content in their respective genomes. 
 
Actinomycetes: A group of mycelial forming heterotrophic microorganisms under the order 
Actinomycetales and phylum Actinobacteria that produce a vast amount of biologically potent 
compounds. 
 
Antimicrobials: Chemical compounds that are agents capable of acting against the growth 
of microorganisms or otherwise totally killing them. 
 
Antibiotics: Type of antimicrobials that either halt or stop the growth of foreign or resident 
bacteria that cause infections. 
 
Antibiotic resistance: The ability of bacteria to resist the effects of antibiotics that once 
slowed their growth or eliminated them. 
 
Average Nucleotide Identity: A measure, between two genomes, of how similar they are 
with specific reference to their coding regions at nucleotide level. 
 
Bacterial infections: The effect of the presence of bacteria in the body which are either 
foreign or normally resident but turning opportunistic to cause illness. 
 
Bioactive secondary metabolites/compounds: Useful molecules of biological potency that 
are produced by microorganisms and are not necessarily a pre-requisite of the 
microorganisms’ normal lifecycle. 
 
Biosynthetic potential: The ability of a living organism to use its metabolism to formulate 
chemical compounds. 
 
GC content: The ratio of the amounts of guanine to cytosine, usually expressed in a 
percentage, within the genome of a microorganism. 
 
Genome: The total genetic make-up of an organism 
 
Gram stain: A laboratory staining technique that is used to categorize bacteria mainly into 
two large categories, thus Gram positive and Gram negative microorganisms. 
 
Housekeeping genes: These are genes in an organism’s genome are typically expressed in 
both normal and abnormal conditions to maintain basic cellular activity and function thereof. 
 
Integrons: Mobile genetic elements that possess gene-capturing characteristics enabled by 
site-specific recombination. 
 
Marine environments: Habitats that are closely related to the seas and oceans with a great 
biodiversity relying on saltwater for sustenance. 
 
Micromonospora: A genus under the Micromonosporaceae family that is known to have 
filamentous, spore-forming and Gram-positive bacterial species. 
 
Multilocus sequence analysis: A molecular biology technique that makes use of individual 
bacterial species’ housekeeping genes. 
 
Marine drugs: Pharmaceutical products that have their origin traceable from marine, and 
other closely associated, environments. 
 
xx 
Microbes: Microorganisms that are usually bacterial (could also refer to fungi, viruses, and 
some protozoa). 
 
Natural Products: Any compound or chemical in nature that is produced by a living 
organism. 
 
Novel metabolites: Small undiscovered molecules that are by-products of the metabolic 
activities of microorganisms. 
 
Over the counter drug: Medication that does not require presentation of a Doctor’s 
prescription in order to buy it. 
 
Plasmids: Small intracellular-based molecules of DNA which can replicate independently 
from the chromosomal DNA. 
 
Polymorphisms: Differences in sequences, usually of closely related bacterial species. 
 
Terrestrial environments: The earth’s environments that are land areas together with their 
accompanying natural and human-made sub-surface features. 
 
Transposons: Mobile genetic elements within a genome, capable of altering the genetic 
function of cells that carry them. 
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CHAPTER ONE 
 
INTRODUCTION 
 
1.1 Statement of research problem 
 
The advent of antibiotics in the 1940s was a medically significant breakthrough that positively 
impacted on humankind’s ability to treat bacterial infections (Davies & Davies, 2010; Hardy, 
2016). Since then, the increased availability, use and abuse of the diverse array of antibiotics 
in the clinical, veterinary spaces and agricultural practices, has led to the emergence of 
antibiotic resistant pathogens that are harder to treat (Kumarasamy et al., 2010; Meggersee 
 
& Abratt, 2014). Amongst the various avenues being explored by Scientists to counter the 
effects of antibiotic resistance and tolerance, development of new antibiotics from novel 
metabolites that are produced by microorganisms remains critical. The aim of this study is, 
therefore, to investigate the antibiotic biosynthetic potential of the genus Micromonospora 
isolated along South Africa’s coastline. 
 
1.2 Background to the research problem 
 
There has been much progress, globally, around the isolation of bioactive metabolites from 
Micromonosporaceae (Boumehira et al., 2016; Hirsch & Valdes, 2010). Many of these 
metabolites have been developed into antibiotics such as neomacquarimicin, telomicin, 
micromonosporin A amongst many others (Boumehira et al., 2016). Despite notable output 
from Micromonosporaceae-centred drug discovery research, there have not been many 
studies focusing on Micromonosporaceae spp. isolated along South Africa’s coastline. 
 
The ongoing drug discovery and development research project at the Cape Peninsula 
University of Technology’s Biocatalysis and Technical Biology research group has seen the 
isolation of more than 500 species of marine actinomycetes from sea sponges and sea 
squirts collected from the Algoa Bay region. The screening work previously performed on 
these isolates, however, sought to evaluate only their oxidative enzyme-producing capacity. 
This research will, therefore, seek to evaluate the antibiotic biosynthetic potential of 30 of the 
isolated Micromonosporaceae strains. 
 
1.3 Research aim 
 
• To use molecular techniques to determine the antibiotic biosynthetic potential of 
selected microbial strains of the family Micromonosporaceae that were isolated from 
sea sponges and sea squirts collected from Algoa Bay. 
 
1.4 Research objectives 
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• To identify all Micromonosporaceae strains to the species level, using multi-locus 
sequence analysis. 
 
• To perform a molecular screen for eight common biosynthetic gene clusters (BGCs) 
amongst the marine Micromonosporaceae strains present in the BTB culture 
collection. 
 
• To analyse the genome sequences of Micromonospora strains to assist with the 
design of new primer sets.  
• To identify gaps in the current knowledge around primer sets available for the 
molecular screening of antibiotic biosynthetic gene clusters and the design of new 
primer sets. 
 
• To test the designed bacteriocin and lanthipeptide primer sets on five of the 
Micromonospora strains used in this study, for the presence of these gene clusters. 
 
1.5 Research questions 
 
• Is there laboratory-based evidence of the presence of viable 
Micromonosporaceae strains from samples in the BTB culture collection? 
 
• Are there any identifiable Micromonosporaceae strains, to species level, by use 
of multi locus sequence analysis? 
 
• Are there any identifiable knowledge gaps around primer sets available for the 
molecular screening of antibiotic BGCs and how would genome sequence 
analysis assist in the design of new primer sets? 
 
• To what extent are the designed primers functional /beneficial in achieving the aim 
of the study? 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1 Introduction 
 
“When I woke up just after dawn on September 28, 1928, I certainly did not plan to 
revolutionize all medicine by discovering the world’s first antibiotic or bacterial killer.” These 
were the humble words of the Scottish-born scientist, Sir Alexander Fleming, in retrospection 
of his accidental, yet significant discovery of the first antibiotic, penicillin (Hardy, 2016). This 
monumental discovery is undoubtedly one of the greatest discoveries during the history of 
humanity and it subsequently earned Sir Fleming a Nobel Prize in Physiology or Medicine in 
1945 (Nobelprize.org, 2014). Alexander Fleming’s discovery of penicillin paved way for 
greater discoveries, leading to the development of a diverse range of antibiotics. Humanity 
benefited immensely from these discoveries and people began living longer since clinicians 
finally managed to contain the crises of bacterial infections. 
 
With progressing technology and research, scientists began to understand the 
pathophysiology of previously misunderstood pathologies, hence delivery of healthcare 
improved, and patients had better outcomes. Despite notable robust and accelerated 
developments in medical innovations through technology, bacterial infections that had been 
previously easy to manage suddenly became increasingly harder to treat due to the 
overwhelming emergence of antibiotic-resistant microorganisms. From that point of antibiotic 
discovery till now, a new crisis of antibiotic resistant infections has rendered the performance 
of modern medical procedures such as organ transplantation, surgery, chemotherapy and 
dialysis among others, challenging (White house, 2015). 
 
Antibiotic resistance and tolerance are well attributable mainly to genetic and biochemical 
mechanisms within specific pathogenic bacterial species (Meggersee & Abratt, 2014). A 
global multi-dimensional approach involving clinicians, pharmaceutical retailers, scientists, 
patients and politicians is pertinent in efforts to control and reduce the effects of antibiotic 
resistance (Kumarasamy et al., 2010). From a scientific perspective, continuous discovery of 
novel drug leads, in the form of novel metabolite-producing microorganisms, has become an 
important anchor in the fight against antibiotic resistance. 
 
Habbu et al. (2016) noted the remarkable progress made in chemical synthesis and 
engineered biosynthesis of novel antibiotic compounds but went on to identify nature as the 
richest source of novel drug leads due to its vast diversity. Marine microorganisms have, over 
the past years, attracted unprecedented attention in biopharming prospects, especially 
marine actinobacteria. This is a phylum of microorganisms with a history of supreme 
biological relevancy for housing the Streptomyces genus, which accounts for up to 70% of 
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the world’s antibiotics currently within the clinical space (Habbu et al., 2016; Penesyan et al., 
2015; Zhang et al., 2005). Under actinobacteria, the genus Micromonospora has attracted 
growing research interests ever since the isolation of several of this genus’ strains as 
aminoglycoside-type antibiotic producers, most notably gentamicin from Micromonospora 
echinospora (Everest & Meyers, 2013; Kasai et al., 2000). Since microorganisms of the 
Micromonospora genus are known to be abundantly found in aquatic habitats including 
beach sands and deep-sea sediments (Cross, 1981; Kawamoto, 1989), untapped marine 
environments such as the South African coastline are thus worth exploring as harbours of 
novel metabolite-producing Micromonospora species. 
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2.2 Antibiotics, their discovery and classification 
 
2.2.1 What are antibiotics? 
 
In 1941, Selman Waksman, a scientist famous for the discovery of the antibiotic 
streptomycin, formulated the noun “antibiotic” (Bhattacharjee, 2016; Clardy et al., 2009). 
Waksman defined an antibiotic as a microorganism-derived chemical which, in solution, is 
characterized by selective potential of growth inhibition or complete elimination of some other 
microorganism (Kingston, 2004). As the science of antibiotic development broadened, 
scientists began making synthetic compounds with antibiotic properties, therefore also 
equally naming these compounds as antibiotics. This inclusion of synthetic antibiotics to fit 
into Waksman’s original definition of antibiotics faced resistance from Waksman and many 
other scientists. It was only with time that the noun antibiotic began being accepted as 
nomenclature to both natural and synthetic compounds (Bhattacharjee, 2016). 
 
Bayarski (2011) loosely defined antibiotics as a group of drugs, which either retard or 
completely halt bacterial growth. Antibiotics however fall under a broader group of drugs 
called antimicrobial drugs, which include anti-parasitic, antiviral as well as antifungal agents. 
Bhattacharjee (2016) propagated that antibiotic administration in humans and animals is 
aimed at bringing positive therapeutic outcomes in the treatment of infections, therefore, 
antibiotics ought to be selective towards host tissues. This notion led to their widely accepted 
modern day definition, which defines antibiotics as molecules with an effect of slowing the 
growth of or totally killing pathogenic microorganisms while causing the minimum possible 
harm to host tissues (Aminov, 2010; Davies & Davies, 2010). 
 
Some scientists have decided to take an all-inclusive route in defining antibiotics. For 
instance, Bhattacharjee (2016) defined antibiotics as chemicals targeting virulent agents on a 
selective inhibition basis, at the same time effecting as minimal harm to the host as possible. 
It is important to note that antiprotozoal, antiviral, antifungal as well as anticancer drugs all 
have mechanisms of action that mimic those of antibiotics hence an all-inclusive, non-
restrictive definition to suit all these compounds. Such a definition has, however, faced 
criticism in some circles with scientists specifically pointing out, as an example, cancer as a 
pathology not initiated by a foreign pathogen such as other bacterial infections. Proponents 
of the all-inclusive definition of antibiotics have pointed out the Muehlenbachs et al. (2015) 
discovery of the cancer-causing tapeworm Hymenolepis nana in response to the 
aforementioned criticism. However, for the purposes of this study, the common restrictive 
definition of antibiotics will take effect since this study focuses on antimicrobial agents strictly 
against bacteria and not any other pathogens. 
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2.2.2 Classification of antibiotics 
 
There are various approaches used in order to group antibiotics into various clusters. The 
individual characteristics that enable such classification include, but are not limited to, 
chemical and/or molecular structure, the antibiotic’s mechanism of action as well its spectrum 
of activity (Calderon & Sabundayo, 2007). 
 
2.2.2.1 Classification according to chemical structure 
 
Adzitey (2015) identified the classes of antibiotics shown in Figure 2.1 as the major antibiotic 
classes from a chemical structure point of view. It should however be noted that more 
antibiotic classes not shown below, such as the streptogramins, do exist but do not house 
antibiotics which are as common as those of the classes shown below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: A representation of the 8 major, chemically-related, antibiotic classes in clinical practice. 
The individual antibiotic compounds within each of these classes have closely related chemical 
structures hence the above-depicted classification (Adzitey, 2015). 
 
2.2.2.2 Bactericidal and bacteriostatic antibiotics 
 
When it comes to their mechanisms of action, antibiotics can be broadly categorised as 
bacteriostatic or bactericidal (Calderon & Sabundayo, 2007). Antibiotics are said to have a 
bacteriostatic mode of action when they slow the growth rate of colonising bacteria as 
opposed to killing any colonising bacteria. The latter mode of action is regarded as 
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bactericidal (Adzitey, 2015). The following antibiotic classes are examples of bactericidal 
antibiotics and their specific targets within bacterial cells: 
 
i. Penicillins and Cephalosporins: Function by targeting cell walls of a bacterial 
colony. 
 
ii. Fluoroquinolones and Sulphonamides: Function by disrupting key bacterial 
enzyme pathways. 
 
iii. Polymyxins: Function by destroying bacterial cell membrane integrity. 
 
Bacteriostatic antibiotics take a slightly different, though universal, mode of action. Their 
specific target in foreign microorganisms is the protein-synthesis biochemical machinery. If 
protein synthesis is disrupted in colonising microorganisms, it subsequently means that all 
protein-dependent processes within bacteria will suffer thus leading to a decreased growth 
rate. Classes of antibiotics that operate as such include tetracyclines, aminoglycosides and 
macrolides (Calderon & Sabundayo, 2007). 
 
2.2.2.3 Classification according to specific mechanisms of action 
 
Classification of antibiotics according to their specific mechanisms of action, as shown in 
Table 2.1, is also common. The basis of such classification lies in the fact that bacterial 
infections require the viability of their individual bacterial cells within bacterial colonies in 
order for clinical manifestation to occur. This subsequently means antimicrobial agents need 
to target the pathogenic bacteria’s cellular processes, in the treatment of bacterial infections. 
The way antimicrobials function becomes the basis of antibiotic classification according to 
mechanism of action (Korzybski et al., 2013). Cellular processes which are key for disruption 
in order to halt growth or kill the pathogenic bacteria, include protein synthesis, nucleic acid 
synthesis, cell wall synthesis, folic acid synthesis as well as mycolic acid synthesis (ibid). 
With time, as they are exposed to the same antibiotics, bacterial cells develop counter 
mechanisms which in turn escalate the rate at which the aforementioned cellular processes 
occur, thus leading to antibiotic resistance. These mechanisms of resistance are explained in 
the sections to follow. 
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Table 2.1: Antibiotic classification according to mechanisms of action (Korzybski et al., 2013). 
 
MECHANISM OF ACTION  ANTIBIOTIC CLASSES 
   
Protein synthesis inhibitors  30-S ribosomal subunit inhibitors:  
  Tetracyclines 
  Aminoglycosides 
  50-S ribosomal subunit inhibitors:  
  Chloramphenicol 
  Clindamycin 
  Macrolides 
  Linezolid 
  Streptogramins 
   
DNA synthesis inhibitors  Fluoroquinolones 
  Metronidazole 
Inhibitors of cell wall synthesis  Vancomycin 
  Cephalosporins 
  Penicillins 
  Carbapenems 
  β-lactamase inhibitors 
  Aztreonam 
  Bacitracin 
  Polymycin 
   
Inhibitors of folic acid synthesis  Trimethoprim 
  Sulphonamides 
Inhibitors of mycolic acid synthesis  Isoniazid 
RNA synthesis inhibitors  Rifampin 
 
 
2.2.2.4 Classification according to spectrum of activity 
 
Bacterial infections emanate from two kinds of broadly categorized microorganisms, viz 
Gram-positive and Gram-negative microorganisms (Baker-Austin et al., 2006). Some 
infections are regarded as mixed infections, whereby the causative bacterial species are a 
mixture of Gram-positive and Gram-negative microorganisms (Sarpong & Miller, 2015). Many 
of the antibiotics in clinical use are considered to either have a broad spectrum of activity 
(BSA) or narrow spectrum of activity (NSA) (ibid). Adzitey (2015) further pointed out that 
those antibiotics that are specifically active against either Gram-positive or -negative bacteria 
are regarded as having NSA while those active against both Gram-positive and -negative 
bacteria are considered to have BSA. Some authors, however, argue that the term “narrow-
spectrum antibiotics” can be used essentially to describe antibiotic compounds of limited 
activity, which target specific bacterial species not necessarily considering their Gram 
reaction. For instance, Guardabassi & Courvalin (2006), highlighted aminoglycosides and 
sulfonamides as narrow spectrum antibiotics as they only effectively target aerobic microbes. 
On the same basis, nitroimidazoles are also exemplified in literature as NSA antibiotics as 
they also only target anaerobic microbes (ibid). 
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It is, however, important to note that although the above explained are the most commonly 
used criteria of antibiotic classification; they do not represent the exhaustive list of antibiotic 
classification criteria. For instance, another criterion that can be used for antibiotic 
classification, according to Etebu & Arikekpar (2016), is the route of drug (antibiotic) 
administration. Classification according to the route of administration would focus on the 
three routes of antibiotic administration, which are oral, intravenous and topical (ibid). Such 
classification has a pitfall in the sense that choice of route of antibiotic administration can be 
determined by the clinical condition of a patient. For instance, an unconscious patient in need 
of antibiotic therapy can have an intravenous administration of an antibiotic, which is normally 
administered orally. It is, however, important to appreciate the overview in antibiotic 
classification provided by the above-described classification criteria. 
 
2.2.3 Discovery and evolution of antibiotics 
 
The discovery of antibiotics is noted in medical history as a significant breakthrough since 
many infectious diseases became curable and the fate of humankind took a remarkable turn 
(Aminov, 2010; Carlet et al., 2012; CDDEP, 2015; Martinez, 2014; Ventola, 2015). Ever since 
their inception into the medical and agro-based practices, antibiotics have seen wide range of 
pertinent uses. Such uses include treatment of infections, prophylactic administration in 
surgically acquired hospital infections, oncology patients with minimal immune responses as 
well as agro-based uses for healthy livestock production (CDDEP, 2015). Nathan & Carl 
(2014) highlighted that modern medical practice has significantly improved due to availability 
of antibiotics in severe infections therapy as well as in medical and surgical procedures as 
prophylaxis. 
 
This current study focuses on attempts to address the problem of antibiotic resistant and 
tolerant microorganisms with special focus on the discovery phase of antibiotic development. 
It, therefore, becomes a matter of paramount importance to look back from where it all 
began, thus the timeline of antibiotic discovery, evolution as well as the emergence of 
resistance. Such a review of these aspects of literature will allow for the appreciation of the 
gains and challenges of all era of the antibiotics story; including present day, as well as 
insights into the future. 
 
2.2.3.1 Pre-antibiotic era 
 
Since the ancient times, humankind had been seriously haunted by diseases, many of which 
were bacterial infections, which the medical fraternity found difficult to comprehend, let alone 
cure. The first bacterial infection treatments in history, as described by Keyes et al. (2003), 
saw ancient cultures resorting to substances such as mouldy bread, plants and soil among 
others for remedy. The period before the discovery of the first antibiotic was dominated by a 
pursuit of knowledge concerning the understanding of how diseases came about, their 
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progression and possible remedies. It is important to note the challenges that the scientist of 
the day had to encounter in the pre-antibiotic period. Not much literature existed since no 
breakthroughs had been made and technological research capacity was not as advanced as 
that of centuries that were to follow. 
 
As pointed out by Otten (1986), the germ theory of disease proposed and expanded by 
Girolamo Fracastoro in 1546 and Marcus von Plenciz in 1762, respectively, became an 
important foundation in the comprehension of the relationship between microbes and 
diseases. The germ theory of disease postulated that many of the diseases, which humans 
and animals suffer from, are a direct result of the actions of specific microorganisms (Bastian, 
1875). After the establishment of this theory and gradual consensus of the same, scientists 
shifted their focus from comprehending disease occurrence to finding effective ways of 
getting rid of these specific disease-causing “germs”. 
 
The present day Gram-negative bacillus, Pseudomonas aeruginosa, is recorded in the 
antibiotic history as the firstly discovered producer of pyocyanase, a by-product with 
antimicrobial activity (Levy, 2002). This observation dates back to 1888 and the 
microorganism was known as Bacillus pyocyaneus. In the year that followed, the newly 
discovered pyocyanase failed at clinical trial level after showing signs of instability and 
considerable toxicity levels to host tissues. Although this immediately disqualified this 
compound as a breakthrough antibiotic, it reemphasized the fact that selectivity and stability 
were going to be paramount for any antibiotic candidate anticipated to successfully make it 
into the clinical space (Levy, 2002). 
 
2.2.3.2 The golden age of antibiotics 
 
Scientific research has proven that exposure of humanity to antibiotics dates back to a period 
way before the commonly known “antibiotic era” (Aminov, 2010). To be specific, this period of 
humanity’s first exposure to antibiotics has been identified as the period from the golden age 
of antibiotics onwards. Bassett et al. (2010) and Nelson et al. (2010) highlighted that the 
discovery of traces of tetracycline, as an example, dating as far back as 350-550 CE in 
human skeletal remains of Sudanese origin suggested diets which contained tetracycline 
enriched foods amongst these subjects. 
 
However, the “modern antibiotic era” has Sir Alexander Fleming’s 1928 discovery of penicillin 
as its landmark (Ventola, 2015). This historic discovery came about when Sir Fleming 
realised that the growth of Staphylococcus aureus on a culture plate appeared to be halted 
by a certain unknown “mould juice” secreted by the fungus later identified as Penicillium 
notatum (Saga & Yamaguchi, 2009). Fleming’s discovery was, however, just the genesis of a 
long and rigorous set of laboratory experiments, which would include attempts to purify the 
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compound, decipher its chemistry as well as to produce it in large quantities before clinical 
trials could commence. 
 
The discovery of penicillin was a development that would be received with mixed feelings 
amongst scientists. On the one hand, it created hype and excitement, but on the other hand, 
scepticism was inevitable. The previous failed experiences of pyocyanase and another 
compound, salvarsan, made scientists approach Fleming’s penicillin very cautiously (Zaffiri et 
al., 2012). On his own part, Fleming encountered difficulties cultivating the P. notatum, as 
well as purifying what he had perceived to be the active ingredient of the fungus (ibid). 
Fleming’s experiences with P. notatum remain a key aspect in modern day research within 
the field of antibiotic development. It remains vital for any compound posing as a candidate 
for a novel antibiotic to be easily purified in large quantities. 
 
The year 1935 was another landmark year within this golden era of antibiotics. Protonsil, a 
sulfonamide developed by Gerhard Domagk, became the first sulfonamide to be 
commercially available for clinical therapeutic use after successfully passing clinical trial 
(Otten, 1986). The therapeutic successes of Protonsil are well documented in history. 
Infections such as meningitis, pneumonia and childbed fever became easily curable and 
mortality rates from these drastically declined (ibid). It is important to note how the success or 
breakthroughs reported by other scientists, work as inspiration to colleagues within similar 
fields of research. Exemplifying this notion were Howard Florey and Ernst Boris Chain who, 
under the inspiration of Domagk’s successful discovery of Protonsil, pursued the chemical 
elucidation of Fleming’s penicillin, which enabled them to produce it in large purified 
quantities successfully (Zaffiri et al., 2012). 
 
In 1940, the discovery of Actinomycin became another landmark discovery, which marked 
the genesis of the “Golden age of antibiotics” which some authors refer to as the “Great 
antibiotic era” (Murphy et al., 2012). This era resulted in the development of more than 100 
antimicrobial drugs effective against infectious diseases as well as other ailments such as 
hypercholesterolemia and carcinomas. Most notably, 1942 saw the year when penicillin hit 
the commercial market and subsequently saving millions of lives. Salyers & Whitt (2005) 
pointed out sulpha drugs, streptomycin and penicillin as the first three antibiotics that found 
use in the clinical space after successful laboratory development. 
 
Penesyan et al. (2015) and Ventola (2015) noted the immense therapeutic use of penicillin 
(Figure 2.2), amongst World War II soldiers in preventing and controlling the spread of 
infections. After the discovery of penicillin, many other antimicrobial agents were developed 
in years that followed. After penicillin, another notable antibiotic discovered was 
streptomycin, an anti-tuberculosis agent, which is a derived from Streptomyces griseus 
(Nanjwade et al., 2010). This was subsequently followed by the development of other notable 
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antibiotics, from 1940s to 1960s, which included chloramphenicol, macrolides, glycopeptides 
among others. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: A penicillin carton and vial on display at the science museum, in the United Kingdom, in 
present day (Retrieved from http://www.sciencemuseum.org.uk/broughttolife/objects/display?id=6091) 
 
The era of antibiotic discovery was subsequently followed by a phase of improvement of 
these antimicrobial compounds (Saga & Yamaguchi, 2009). It became necessary to improve 
the various discovered antimicrobial classes since this increased their therapeutic efficacy 
(ibid). It is during this phase of drug discovery that scientists became too confident in 
antibiotic use to the extent of naively declaring that infections of bacterial origin had been 
defeated for good (Penesyan et al., 2015). 
 
2.2.3.3 Beyond the golden age of antibiotics 
 
After the golden age of antibiotics, scientists began to realise that the efficacy of many 
antibiotics in the market was diminishing. Personnel within the medical and veterinary fields 
became reluctant and reckless, and the imprudent use of the newly developed antibiotics, 
such as penicillin continued unabated (Inglis et al., 2005; Luangtongkum et al., 2006). 
 
Ironically, in 1945, Sir Alexander Fleming had warned of the possibility of the emergence of 
mutant forms of the microorganisms that were no longer susceptible to penicillin due to 
misuse of the drug (Ventola, 2015). Fleming’s foresight became a reality, and by 1955 many 
countries resolved to upgrade the penicillin from an over the counter (OTC) drug to a 
prescription antibiotic (ibid). This move, however, did little to thwart the sporadic rise in 
resistance against penicillin, especially amongst staphylococci, since use of the drug had 
increased widely. The period between 1960 and 1964 then saw the pharmaceutical industry 
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and scientists alike becoming under pressure to save penicillin in the wake of growing 
resistance against this famous “miracle drug”. These efforts subsequently led to the 
development of methicillin, which is a semi-synthetic modification of penicillin (Inglis et al., 
2005). 
 
Methicillin had been developed as a solution to the resistance against penicillin but, in no 
time, S. aureus became resistant against this drug thus the infamous multi-drug resistant or 
methicillin–resistant Staphylococcus aureus (MRSA); a menace that has burdened even 
modern day medicine (Chen et al., 2017). It is important to note that in all antibiotic era; viz 
pre-golden age, golden age and post-golden age, the cycle of antibiotic discovery followed by 
emergence of resistance has been an ongoing one as shown in Figure 2.3. This observation 
is the basis of this current study; in the wake of continuous emergence of drug resistant 
microorganisms, the search for novel metabolites for the development of new antibiotics 
ought to be an equally continuous effort. 
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Figure 2.3: An account detailing the evolution of antibiotics through all three eras; pre, golden and 
post golden antibiotic discovery era. The cycle of major antibiotics discovered during specific years, 
pathogens which developed resistance against these, and subsequent antibiotics developed to 
counter such resistance is well outlined (Ventola, 2015). 
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2.3 Antibiotic resistance and its effects 
 
2.3.1 Emergence and spread of resistance 
 
The misconception that bacterial infections had been totally conquered by the discovery of 
antibiotics was discredited by the emergence of bacterial resistance to antibiotic therapy in 
the late 1970s. Scientists had become complacent and felt that the fight against antibiotic 
resistance was finally conquered. Ever since, the rapid emergence of antibiotic resistant 
organisms, and subsequently infections, has been noted as a serious public health threat, 
especially in clinical set-ups (Mulvey & Simor, 2009). Wright & Poiner (2012) pointed out the 
declining prioritisation and interest in novel antibiotic development research from a 
pharmaceutical perspective, as one other aspect that indirectly fuels the uncontrollable 
emergence of bacterial resistance to antibiotic therapy. Gould & Bal (2015) partly 
corroborated with Wright & Poiner (2012) as they summarised the push factors of antibiotic 
resistance as the following: 
 
I. Wrong prescription and over-prescription of antibiotics to patients by 
clinicians. 
 
II. A decreased developmental output of novel antibiotics by pharmaceutical 
entities due to: 
 
(a) Decreased incentives for scientists’ research efforts. 
 
(b) Stringent legislative bottlenecks along the entire process of drug 
development. 
 
The notion that there is a lack of adequate research incentives to support antibiotic discovery 
and development seems to be relatively common in literature (Grabowski et al., 1990; 
Simpkin et al., 2017; Towse et al., 2017; Williams & Bax, 2009). Until recently, there seemed 
to be limited political will, especially amongst developing countries, with respect to 
governments’ funding towards antibiotic discovery and development projects (Simpkin et al., 
2017). One of the many reasons that can be attributed to this development is the observation 
by Butler et al. (2013) and Chopra (2008) that many research and development (R&D) 
companies are inherently dumping antibiotic R&D in favour of other perceivably lucrative 
therapeutic ventures. 
 
Antibiotic resistance is triggered at either biochemical or physiological levels, or even 
combinations of mechanisms falling under these two broad categories (ibid). The activity of 
resistance-conferring genes, called r genes, is what ultimately leads to antibiotic resistance. 
Liu and Pop (2009) noted the existence of a published genomic database, formulated from 
selected bacterial genomes, which shows more than 20 000 potential r genes. They further 
highlighted that these resistance genes are of up to 400 different categories, which shows 
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how broad and diversified antibiotic resistance potentially emanates, from a genotypic 
perspective. Such an observation indeed raises great concern of returning to the pre-
antibiotic era amongst healthcare workers, scientists and medical pundits. 
 
The Centre for Disease Dynamics, Economics and Policy (CDDEP) in its 2015 state of the 
world’s antibiotics review clearly stated that the continuous emergence of highly antibiotic 
resistant microorganisms has caused serious global threats not sparing even first world 
countries (CDDEP, 2015). If any extrapolative conclusions can be made, to have first world 
countries who boast of world class healthcare systems suffering from threats of antibiotic 
resistance microorganisms, can only but point to a looming global crisis. 
 
When bacteria in a specific colony are subjected to antibiotic therapy, given sufficient time, 
they ultimately win the contest of survival within their colonies hence the emergence of 
resistance. The rise in antibiotic resistance has been attributed to many factors, chief 
amongst them being their prolonged irresponsible medical and veterinary use, lack of 
adherence to infection control programs and antibiotic management programs (Giedraitiene 
et al., 2011). Emergence of antibiotic resistant microorganisms translates into global threats 
when such microorganisms begin to spread. For instance, global human movement in the 
form of migration, emigration and tourism has been noted in literature as the primary vehicle 
of the spread of global antibiotic resistant microorganisms (CDDEP, 2015). The general 
increase in income globally also translates to increased access to antibiotics, thus an 
increase in both their appropriate and inappropriate use which contributes to a rise in 
antibiotic resistance (ibid). 
 
In 2016, the Centres for Disease Control and Prevention, (CDC), published a shocking case 
of a patient in Nevada who succumbed to the carbapenem-resistant Enterobacteriaceae 
(CRE) which was found to be resistant to 26 antibiotics (Chen et al., 2017) and progressed to 
cause septic shock. The specific CRE isolated and identified as Klebsiella pneumoniae was 
reported to be resistant to all aminoglycosides and polymyxins tested (ibid). The isolate was 
also reported to be resistant to tigecycline; a glycylcycline antibiotic developed to combat the 
exponential antibiotic resistant rate depicted by microorganisms such as S. aureus, 
Escherichia coli and Acinetobacter baumannii (Chen et al., 2017; Rose & Rybak, 2006). This 
is a classic case of multi-drug resistant microbes becoming fatal. If efforts of developing new 
antibiotics do not match such levels of emergence of antibiotic resistance, the coming 
decades may lead to a total collapse of the healthcare systems globally. 
 
Clinical setups have also been well documented to have a huge impact in the emergence 
and subsequent spread of antibiotic resistance. Brusselaers et al. (2011) propagated that 
clinical Intensive Care Units (ICUs) world over have become a dangerous source of antibiotic 
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resistant organisms due to below-par infection control, selective competence on resistant 
strains and emergence of new mutations amongst the already immune-vulnerable patients. 
 
2.3.2 Mechanisms of resistance 
 
The basis of the resistance of many bacteria to antibiotics lies within their genes (Mulvey & 
Simor, 2009). This genetic linked resistance can be either intrinsic resistance or extrinsic 
resistance (ibid). In simple terms, intrinsic resistance in bacteria is displayed when that 
specific bacteria resists the therapeutic effect of a group of antibiotics due to its natural 
genomic make up. Two good examples of such a mechanism of antibiotic resistance are 
depicted in the group streptococci which are predictably resistant to aminoglycosides as well 
as the resistance of Gram-negative bacilli to all vancomycins (Mulvey & Simor, 2009). 
 
In contrast, acquired resistance is a result of alteration in a microorganism’s genome. Such 
alterations can be in the form of mutations or acquisition of totally new genetic material in the 
form of or facilitated by plasmids, transposons and integrons (ibid). This mechanism of 
resistance is common in Mycobacterium tuberculosis, which is well known to resist the 
antibiotic isoniazid (Torrey, 2016). Ultimately, all these alterations in genomes of pathogens 
lead to biochemical modifications in bacterial cells as shown in Figure 2.4, thus effecting 
antibiotic resistance (Torrey, 2016). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: Examples of biochemical mechanisms of antibiotic resistance within bacterial cells. The 
cell wall of bacteria plays a crucial role in conferring resistance to colonising microbes. Mechanisms 
such as activation of drug efflux pumps eliminate antibiotics molecules before reaching their target 
organelles and total drug inhibition by cell wall protein modification are two key examples. Within the 
bacterial cell, several mechanisms which specifically serve to deal with antibiotic molecules which 
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would have successfully evaded cell wall inhibitory mechanisms become key in conferring resistance. 
Such examples, as shown above, include modification of the drug target and direct enzymatic 
inactivation of the antibiotic molecules (Retrieved from: Bbosa et al., 2014). 
 
2.3.3 Socio-economic impact of antibiotic resistance 
 
It is a matter of great concern to note that the discovery and development of new commercial 
antibiotics are now inversely proportional to the emergence and re-emergence of drug 
resistant infections (Martinez et al., 2014). The rapid emergence of antibiotic resistance 
impacts public health care and subsequently derails efforts of governments to offer 
affordable, accessible and quality health care especially in third world developing countries. 
 
As of March 2015, statistics from the United States of America revealed that approximately 2 
million illnesses and 23 000 deaths were being annually reported, in the United States (US) 
only, due to antibiotic resistant infections (White house, 2015). The CDC further reported that 
such figures in the US served as a backdrop of loss in economic productivity to the tune of 
$US 35 billion. In the USA, the antibiotic resistant infections crises saw the Obama 
administration initiating a national action plan that sought to analyse and integrate 
interventions by key stakeholders to counteract antibiotic resistance (White House, 2015). 
The prioritisation of the fight against Antimicrobial Resistance (AMR) in the USA under 
President Obama brought about a promising chapter globally due to the USA’s global 
influence and global public healthcare obligations. Such political will enhances research and 
development of novel antibiotics amongst scientists, a group of professionals who usually 
face unnecessary bureaucracy and bottlenecks in their attempts to influence policy to combat 
of AMR. 
 
As of 2009, in Europe, 25 000 annual deaths were reportedly attributed to antibiotic resistant 
infections. This translated to a massive € 1.5 billion, in direct and indirect related annual 
losses (ECDC, 2009). Economists at the World Bank have put it on record that the impact of 
global antibiotic resistance, by the year 2050, is likely to be as devastating as the infamous 
2008 global economic meltdown provided the current trends in AMR remain unchecked 
(Adeyi et al., 2017). Unlike the 2008 global economic crisis which was buffered by a cyclical 
recovery phenomenon, a worst-case scenario of completely antibiotic resistant infections 
would hit hard developing nations as its costly impact will most likely persist, hence pushing 
an approximate 28 million people into abject poverty (Adeyi et al., 2017). 
 
2.3.4 Antibiotic resistance in the African context 
 
African countries have not been spared from the reality of antibiotic resistance and its effects. 
For instance, it is known that the multi-resistant MRSA prevalence is considered relatively 
high in a number of African countries (Shittu & Lin, 2006). These include Morocco, Nigeria, 
Kenya and Cameroon (ibid). More notably, at the turn of the millennium, a South African 
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countrywide study revealed worrying statistics about antibiotic resistance in the context of 
tuberculosis (TB). The study noted that 1.8% cases of newly diagnosed TB patients, as well 
as 6.7% cases of known TB cases, were actually of a multi-drug resistant type (WHO, 2018). 
 
As early as 2004, the World Health Organisation (WHO) had released alarming statistics 
concerning the South African incidence rate of TB. According to a WHO 2006 report, South 
Africa’s TB incidence of 718 cases per 100 000 people in a population was the worst 
amongst the then known 22 high-burden countries. The WHO went on to further estimate 
that in 2012, up to 600 000 new TB cases would be recorded in South Africa (Brink, 2014). 
However, this turned out to be an overestimation since the number of new TB cases in South 
Africa in 2012 was later reported to be approximately 400 000 (Sotgiu et al., 2017). 
 
The effects of antibiotic resistance in Africa are exacerbated by poverty and the prevalence 
of HIV/AIDS that are rife on the continent’s developing countries. Cotton et al. (2008) pointed 
out the existence of increased antibiotic resistance infections in South Africa’s poor 
communities amongst HIV/AIDS infected children. In a comprehensive study in South Africa, 
the top multi-drug resistant pathogens identified to increase child mortality in HIV positive 
children included Streptococcus pneumonia, Moraxella catarrhalis and the 
Gammaproteobacteria, Haemophilus influenza (Cotton et al., 2008). 
 
2.3.5 Negative clinical impact of antibiotic resistance 
 
The reality of the negative impact of antibiotic resistance manifests itself in bacterial 
infections which increasingly become harder and harder to treat regardless of historically 
being successfully treatable. This can be seen as a gradual reversion to the pre-antibiotic era 
where patients died in their numbers due to lack of effective antimicrobials. 
 
The CDC, in a 2015 report, outlined that Enterococcus species and S. aureus in their 
antibiotic resistant form were the most serious global scourge. In a rather seemingly 
dramatic, yet factual analogy, Michael et al. (2014) echoed the CDC’s sentiments and 
highlighted that annual MRSA mortality rates in the USA are much more than HIV, 
emphysema, homicide and Parkinson’s disease combined. Boucher et al. (2009) noted that 
the common antibiotics historically used in the treatment of MRSA, vancomycin and 
teicoplanin, had been long resisted by the MRSA. Evolution of resistance to conventional 
antibiotic therapy within MRSA birthed the Vancomycin intermediate S. aureus (VISA), 
another teicoplanin-resistant strain (Boucher et al., 2009). 
 
Vancomycin-Resistant Enterococci (VRE) are also known to be a therapeutic menace in 
modern day medical practice (Ventola, 2015). Before developing resistance to vancomycin, 
enterococci infections were historically treatable by this antibiotic. In its analysis of the 
antibiotic resistance threats facing the USA, the CDC (2013), highlighted that annual 
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mortality attributable to nosocomial VRE infections was up to 1300 deaths. Rossolini et al. 
(2014) however mentioned the existence of alternative drugs of choice for the treatment of 
VRE infections and these include quinupristin/dalfopristin and linezolid. Other drug resistant 
microorganisms causing specific infections as well as the drugs which were once effective 
against these, are given in Table 2.2. 
 
Table 2.2: A summary of some of the common bacterial infections and the antibiotics that historically 
were a common therapy to such before alternative therapy had to be developed due to the antibiotic 
resistance crises in clinical practice. 
 
Infectious   causative   agent Antibiotics previously Alternative therapy in use  
and clinical infections  effective       
         
Streptococcus pneumonia:  • Penicillins (such as • Pneumococcal  
• Meningitis and bacterial 
 Amoxicillin).    conjugate vaccine 
• 
    (PCV13).   
 pneumonia.   Erythromycins  (such as     
• Sinusitis, septicemia, 
 Azithromycin).      
        
 ear infections.          
     
Mycobacterium tuberculosis: • First-line drugs •  TB resistant to first line 
• Often lung TB 
  (isoniazid; rifampicin)   drugs treated by second 
 
• Second-line drugs 
 line drugs.   
    
•  XDR-TB 
  
     (amikacin, capreomycin, resistant to 
     kanamycin);    almost all drugs-therapy 
    
• Fluoroquinolones 
  options limited.  
         
        
Enterobacteriaceae (such as. • Carbapenems (drugs of • Fosfomycin and 
E. coli and K. pneumoniae):  last resort).    Tigecycline  
• Difficult to treat 
     (Alternatives though not 
     significantly effective). 
 Enterobacteriaceae         
 infections.           
            
 
 
2.3.6 WHO global priority R&D list 
 
Research and scientific development of antibiotics are regarded as a very important avenue 
of combating the ever-rising global scourge of antibiotic resistant infections. It is notable that 
developing novel antibiotics and antibacterial agents comes at a cost; thus, it makes sense to 
develop priority lists to counteract only the most threatening bacterial species at any given 
time. According to a news release on 27 February 2017, the WHO announced a set of 12 
bacterial families regarded as the greatest threat to global public health (WHO, 2017). The 
WHO refers to such a list as a global priority list (GPL) (ibid). 
 
Dr Marie-Paule Kieny, from the WHO’s health systems and innovation arm, highlighted the 
fact that time is running out in the quest to get new effective antibiotics into the market hence 
the WHO’s intervention in formulating and periodically updating its R&D priority lists through 
GPLs (WHO, 2017). Such interventions by the WHO are mainly necessitated by the fact that 
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if the discovery and development of novel antibiotics are determined by market forces only, 
new drugs will not emerge on the market timeously and these drugs may not be in line with 
urgent public health needs (ibid). 
 
In a fact sheet published in October 2016, the WHO, however, stressed the fact that efforts to 
invest in the discovery and development of new antibiotics can be hindered if a global 
behavioural change is not realised in antibiotic prescription and use (WHO, 2016). A few of 
the changes that the WHO encourages to compliment an effective novel antibiotic 
development system include vaccination-based infection control, improved hygiene of food 
and water, robust promotion of safe sex practices as well as hand washing (ibid). 
 
The latest global priority pathogens list (PPL) formulated by the WHO was as a result of the 
analysis of AMR, which was carried out using a multi-criteria decision analysis approach 
(WHO, 2017). Such an analytical approach is very effective since it brings into unison expert 
opinion and research-generated data in a transparent unbiased and productive manner. The 
WHO’s recently adopted global PPL, for which an accelerated effort to develop new 
antibiotics against these pathogens is imminent, has three priority levels as shown in Figure 
2.5; viz. critical, high and medium (WHO, 2017). The role of natural products in the discovery 
and subsequent development of these urgently needed antibiotics cannot be 
overemphasised. 
 
2.4 Natural products in antibiotic discovery 
 
Ever since ancient times, natural products have been the common foundation of disease 
therapy amongst humans, to the extent of nature being referred to as an ancient pharmacy 
by some authors (Montaser & Luesch, 2011). Lahlou (2013) noted that the broad term 
“natural products” can be broken down to microbes, minerals, animals and plants. Ganesan 
(2008) corroborated with this notion and further opined that the greater quantity of 
pharmaceutical armamentarium currently on the market is sourced initially from natural 
products in comparison to the ones that are not. In essence, many infections in the veterinary 
and clinical practice are treatable by a diverse range of pharmaceutical products that have 
origins traceable to natural products (Rojas et.al., 1992; Tawiah et al., 2012). The discovery 
of penicillin, according to Singh (2014), did not only revolutionise antibiotic discovery as a 
field but also provided a focal point of scientific research in natural microbial products. 
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 Enterobacteriaceae, carbapenem-resistant, 3rd 
generation cephalosporin-resistant 
 
Acinetobacter baumannii, carbapenem-resistant 
 
Pseudomonas aeruginosa, carbapenem-resistant 
 
 
 
 
Helicobacter pylori, clarithromycin resistant  
Campylobacter, fluoroquinonole-resistant  
Enterococcus faecium, vancomycin- 
resistant 
 
Salmonella spp., fluoroquinolone-resistant  
Neisseria gonorrhoeae, 3rd generation 
cephalosporin-resistant, fluoroquinolone- 
resistant.  
Staphylococcus aureus, methicillin- 
resistant, vancomycin intermediate and 
resistant 
 
 
 
 
 
Haemophilus influenzae, 
ampicillin resistant 
 
S. pneumoniae 
Shigella 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: A representation of the WHO’s latest research and development global priority list. 
Microorganisms that are regarded as critical targets against which new antibiotics are urgently needed 
are shown in the red zone, while the orange zone represents microorganisms of high priority. The 
pathogens in the green zone are medium priority targets for which new antibiotics are urgently 
needed. 
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Akhondzadeh et al. (2003) gave typical examples of herbs that have been exploited for their 
antimicrobial therapeutic uses successfully. Some of these important secondary metabolites 
include the chemotherapeutic vinca alkaloids, the cardiac failure therapeutic drug digitoxin 
sourced from the digitalis leaf, the antimalarial drug quinine sourced from the cinchona tree 
bark, as well as the qinghaosu tree bark antimalarial derivative, artemisinin. The natural 
products that are important in antibiotic discovery are broadly categorised into two classes, 
namely terrestrial derived and marine derived natural products. 
 
Various ways exist for accessing natural products from their specific sources. Generally, 
water is used as the universal medium in which many of these extractions occur (Tawiah et 
al., 2012). Extractions of bioactive compounds from natural products usually begins with 
initial screening for bioactivity using extraction techniques that can be either in crude 
aqueous or alcohol phases (Cowan, 1999). These processes are typically followed by 
various extraction processes in the organic phase (ibid). Ethanol and methanol extraction 
methods are also commonly used to access bioactive compounds from natural products such 
as plant-derived aromatic bioactive compounds (Akhondzadeh et al., 2003). 
 
2.4.1 Terrestrial vs marine-based drug discovery 
 
The period 1950 to 1960 saw an increase in research investment annually; to the tune of 
US$10 billion, specifically into drug discovery from microorganisms, by pharmaceutical 
entities (Murphy et al., 2012). Such huge financial commitments led to massive discoveries of 
potent terrestrial microorganisms from a wide spectrum of environments ranging from arctic, 
cold temperate places, as well as tropical environments (Murphy et al., 2012). The majority of 
these discoveries came from more temperate environments (ibid). It makes sense that 
terrestrial microorganisms became the undeniable focal point of drug discovery during these 
years. This hype amongst scientists to source bioactive metabolites from terrestrial 
microorganisms was quite huge despite 70% of the earth’s surface being occupied by 
oceans thus providing vast marine spaces, which could be of equal research relevancy (Yu 
et al., 2015). 
 
Murphy et al. (2012) pointed out that the oceans and their associated environments never 
received significant attention in microbial drug discovery due to a general notion that they 
were mere “storehouses” of most microorganisms that originated from terrestrial 
environments. Yu et al. (2015) corroborated with this observation and further pointed out that 
true marine microbes did exist albeit requiring cumbersome cultivation for scientific 
manipulation and analysis. With the emergence of antibiotic resistance, research into 
microbial drug discovery shifted focus to marine microorganisms. It is imperative to note how 
research-based evidence began to strongly endorse the marine ecosystem in general as a 
source of chemical compounds that are both novel and organic (Yu et al., 2015). 
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2.4.2 The marine ecosystem in antibiotic development 
 
2.4.2.1 Why focus on marine drugs? 
 
Drugs which are referred to as “marine drugs” can be defined as those pharmaceutical 
compounds sourced from plants, animals and microorganisms which find marine spaces as 
their habitats (Doshi et al., 2011). There is increased attention towards the marine ecosystem 
as a source of metabolites that are possibly novel drug leads for antibiotic development. The 
main reason for this attention from scientists is attributable to the vastness of the marine 
ecosystem that subsequently translates to more eco-diversity as compared with other 
ecosystems such as the terrestrial ecosystem. To put this fact into figures, Das et al. (2008) 
highlighted that the oceans on our planet have a coastline stretching to an approximate sum 
of 620 000km with a combined volume of 137km3 × 106km3 hence being the largest 
ecosystem. 
 
Microorganisms that are habitual in marine environments occur in large numbers, generally. 
Murphy et al. (2012) highlighted that a millilitre of seawater could contain up to 10 million 
viruses, 1000 bacteria as well as 100 fungal species. These marine microbes are widely and 
diversely distributed within estuaries, seawater suspensions as well as sea sediments. The 
surfaces of macroorganisms also harbour marine microorganisms and so do their interiors 
(Murphy et al., 2012). Stadler and Dersch (2016) highlighted that marine environments are 
habitats to a great deal of microbial populations and biodiversity. Ellis (2001) corroborated 
with this fact and further described the oceans as “The Medicine Chest of the New 
Millennium”. Since this current study seeks to investigate the biosynthetic potential of marine 
Micromonospora species, it becomes relevant to specifically review marine-based 
microorganisms generally, with a focus on their bioactivity. 
 
2.4.2.2 Marine microorganisms as a specific source 
 
Microorganisms, in general, are well documented as prolific sources of antibiotics in both 
terrestrial and marine environments. The discovery of penicillin from Penicillium notatum in 
1928 paved way for further discovery of many other bioactive compounds from 
microorganisms. Notable examples of some antibiotics that have their foundations traceable 
to microorganisms, in general, include chloramphenicol, erythromycin, cephalosporin C, 
vancomycin, nalidixic acid and rifamycin among many others (Tawiah et al., 2012). The 
cornerstone of drug development to counteract antibiotic resistance has seen, over the past 
two and half decades, the sourcing of bioactive metabolites from terrestrial microorganisms 
gradually declining in favour of marine microorganisms. Living microorganisms are now 
known to exist abundantly within oceans, contrary to assertions of the past, which labelled 
such environments as having a dearth of life and diversity (Fenical & Jensen, 2006). To put 
this notion into perspective, Penesyan et al. (2015) further opined that the cell count in a 
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millilitre of seawater could be as much as between 106 - 109 cells. This points out to an 
environment of research relevancy with vast microbial diversity and great potential in diverse 
metabolic activity. In general, marine microorganisms remain relevant in drug discovery due 
to their vast diversity as well as vastly evolved physiological and biochemical abilities, 
courtesy of selective pressure, that resulted in them exuding bioactive metabolites (Doshi et 
al., 2011). These bioactive metabolites are also useful in processes such as communication, 
reproduction and the microorganisms’ self-protection (ibid). The South African coastline, 
therefore, is worthwhile exploring as a potential source of microorganisms capable of 
producing novel metabolites. 
 
2.4.3 The South African coastline 
 
South Africa has a biodiverse coastline that stretches over a distance of approximately 2 
500km (Atkinson and Clark, 2005). The Namibian desert border with South Africa on the 
Western coast marks a point where the coastline starts (ibid). The coastline then runs 
southwards, around the African continent tip right to the South African-Mozambique border 
on the Indian ocean, as shown in Figure 2.6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: The South African 2500km long stretching coastline depicted by the brown trail. McCarthy 
and Rubidge (2005) described this coastline as a very smooth one containing very few, minimally 
modified natural harbours. Over the past 20 million years, South Africa has extensively undergone 
geographical upliftment resulting in this remarkably smooth coastline. McCarthy and Rubidge (2005) 
further pointed out that the South African coastline developed from the once intact underwater 
continental shelf, which was characteristic of limited gorges or deep ravines. 
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Doshi et al. (2011) highlighted the fact that the world oceans harbour a vast diversity of 
microorganisms of diverse pharmacological activity. Sharma & Ohja (2005) corroborated with 
this notion and further highlighted the fact that marine-derived microorganisms have 
historically provided over 25 000 bioactive compounds for further development into possible 
novel antibiotics. It, therefore, makes sense to regard the South African coastline as a very 
relevant research focus sampling area. This is because its vast area subsequently translates 
to vast biodiversity of marine species that it harbours (Atkinson & Clark, 2005). 
 
2.4.4 Challenges in marine natural product drug discovery 
 
Marine natural products (MNPs) are mainly sourced from microorganisms and invertebrates 
such as sea squirts, sponges, corals, algae, bryozoans and coelenterates amongst many 
others (Singh, 2014). Despite the success stories of drug discovery from marine ecosystems, 
challenges in this field of science are inevitable. For instance, marine microorganisms are 
generally not easily cultivatable on routine laboratory nutrient media. They are very slow 
growers hence requiring patience as well as strict culture media and growth conditions 
optimization in some instances (Singh, 2014). 
 
Another challenge in the field of marine drug discovery and development is the high costs 
involved in the entire biotechnological process chain, from discovery of novel metabolites to 
clinical trials (Santhi et al., 2017). In some marine-based drug discovery projects, the costs 
involved in harvesting sources of targeted metabolites are huge inorder to suffice for clinical 
trial phases (ibid). A typical example is when the compound Bryostatin 1, a potential cancer 
chemotherapeutic agent sourced from Bugula neritina, had to go into the clinical trial phase 
after its discovery. As little as 18 g of this compound was produced from 13 tons of harvested 
B. neritina, a bryozoan, for the clinical trials (Mander & Hung-Wen, 2010). In such a situation, 
resources could be channelled to increase the harvest for the specific source microorganism 
but, Santhi et al. (2017) noted the devastating effect on the ecological set up such an 
intervention would have. 
 
The rediscovery of already discovered compounds is also a challenge within the field of MNP 
drug discovery. The euphoria and optimism, which usually grips scientists, involved in MNP 
discovery projects, often turns into disappointment if the purportedly novel compounds turn 
out to be known compounds (Tulp & Bohlin, 2005). Singh (2014) reported a decline in 
funding towards natural product drug discovery in recent years within the pharmaceutical 
industry. Bologa et al. (2013) shared the same sentiments and further noted other key 
reasons for the de-emphasis of MNP drug discovery from a pharmaceutical perspective. 
These include a general perception of market saturation as well as the resentment at 
regulatory bottlenecks associated with the drug development from MNPs. Despite all these 
and many other challenges, successful antibiotic development from phyla such as 
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Actinobacteria have been documented. This study focused on the search for novel 
metabolites from Micromonosporaceae, hence it is important to assess the relevance of 
microorganisms of the phylum Actinobacteria as sources of MNPs. 
 
2.5 Actinobacteria and their relevance to the study 
 
2.5.1 Basic characteristics of actinomycetes 
 
Actinomycetes are a group of Gram-positive bacteria that are classified under the order 
Actinomycetales, phylum Actinobacteria according to Bergey’s manual of systematic 
bacteriology (Atlas, 1997; Chaudhary et al., 2013; Qinyuan et al., 2016; Sharma et al., 2014). 
The term ‘actinomycetes’ is also typically reserved for those genera that exhibit filamentous 
growth. Genera that do not exhibit filamentous growth are typically referred to as 
actinobacteria. Das et al. (2008) highlighted that the term ‘actinomycetes’ is a derivative of 
two individual Greek terms viz ‘atkis and mykes’ meaning ray and fungi, which translate to 
possessing bacteria-like and fungi-like characteristics but meeting enough criteria to fall 
under the kingdom bacteria. Under the Bacteria domain, the phylum Actinobacteria is 
amongst the largest known phyla hence making this phylum a generally biodiverse one of 
research relevancy (Barka et al., 2016) 
 
These microorganisms are known to be aerobic, forming spores when they grow as well as 
showing substrate and aerial mycelium growth (Chaudhary et al., 2013). When it comes to 
cellular growth and development, actinomycetes take a rather different course as compared 
to other unicellular bacteria, which have cell enlargement and binary fission as their “modus 
operandi”. In actinomycetes, the vegetative hyphae tend to develop into highly branched 
elongated filaments without necessarily undergoing cell division (Atlas, 1997). The end 
products of this unique developmental process are well-elongated bacterial cells which house 
genomic data in multiple copies (ibid). This process precedes another process that involves 
the formation of septa, thereby effecting cytoplasmic-chromosomal separation (Atlas, 1997). 
It is, therefore, through extensive cellular structural analysis, particularly hyphal cellular 
morphology and 16S rRNA gene analysis that taxonomists confidently concluded that 
actinomycetes differ from fungi and possess clear-cut prokaryotic characteristics (Qinyuan et 
al., 2016). 
 
One of the striking microscopic characteristics of actinomycetes is their being highly 
filamentous, a characteristic which befits their vast morphological differentiation (Atlas, 1997; 
Sharma, 2014; Ventura et al., 2007). It is, however, important to note that in some instances, 
the filament growth patterns are not as pronounced, as typically expected, due to 
fragmentation and such a phenomenon is exemplified in some species of the genera 
Nocardia, Rhodococcus and Gordonia. Atlas (1997) also noted a common macroscopic 
identity confusion caused by the near resemblance of some actinomycetes to fungi during 
27 
certain stages of their lifecycle (Figure 2.7). Actinomycetes produce much narrower filaments 
compared to fungal hyphae, a pertinent characteristic that may be used to clearly distinguish 
between the two using light microscopy (ibid). Ventura et al. (2007) noted actinomycetes as a 
group of bacterial microorganisms with a rather complex life cycle that contributes to the 
diversity of both their phenotypic characteristics as well as the metabolites they produce. 
 
Actinomycetes are also known to be microorganisms with relatively large genomes which 
resemble a very high guanine to cytosine (G: C) ratio and can either be linear or circular 
(Atlas 1997). Ventura et al. (2007) reiterated this outstanding genomic size in actinomycetes 
and further noted that these large genomes can double the size of E. coli genome, which is 
about five mega base pairs. Also of pertinence within actinomycetes genomes, are plasmids 
that are involved in genomic rearrangement and data transfer, fertility as well as antibiotic 
production (ibid). However, actinomycetes have attracted so much attention and research 
interest chiefly because of their proven ability to produce a wide range of bioactive secondary 
metabolites and their character as saprophytes (Yu et al., 2015). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: Life cycle of actinomycetes that produce spores. Historically, some scientists have 
considered actinomycetes to be an intermediate between fungi and bacteria. Mycelial production in 
actinomycetes indeed does resemble the same process in filamentous fungi but as shown, individual 
actinomycete cells have chromosomes, which are the foundations of sporulation in their spore-forming 
species. These individual bacterial cells are also susceptible to antibacterial agents hence confirming 
them as independently belonging to the bacteria kingdom (Barka et al., 2016). 
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2.5.2 Classification of actinomycetes 
 
According to their scientific classification, actinobacteria represent a phylum under the 
bacteria domain, which subsequently houses the order Actinomycetales. It is each member 
of the order Actinomycetales, which is referred to as an actinomycete (Waksman et al., 
2010). Therefore, it is important to define these two terms to depict their differences contrary 
to their interchangeable use in some literature. Actinomycetes can be further classified based 
on a polyphasic approach that encompasses phylogenetic studies, phenotypic as well as 
 
genotypic characteristics. The taxonomy of actinomycetes is best achieved by 
comprehending bacterial phylogenetic relationships, which are subsequently founded in the 
16S and 23S rRNA sequence data sets. This allows for the classification of bacterial species 
that are naturally very closely related, hence the reason for employing a polyphasic approach 
to actinomycete taxonomy (Hopwood, 2007). 
 
2.5.2.1 Genotypic characteristics 
 
Genomic methods are also an important component contributing to the polyphasic taxonomy 
of actinomycetes. As pointed out by Kirby and Le Roes-Hill (2009), many of the genomic-
based methods used to decipher the genomes in the characterisation of actinomycetes are 
highly advantageous as they are applicable to both cultivable and uncultivable actinomycete 
strains. Genotypic taxonomy is approached effectively in a multi-dimensional approach, as 
shown below in Figure 2.8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8: The two broad categories of genomic taxonomy in actinomycetes are shown. Gene 
specific methods give important information about bacterial cellular structure and function, cellular 
metabolism as well as virulence factors and surface proteins associated with specific related bacterial 
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species. On the other hand, DNA-DNA hybridisation becomes key in determining the DNA relatedness 
between two species. DNA relatedness can be quantified and a relatedness of below 70% between a 
species and its phylogenetic neighbour rules out significant relatedness; hence a conclusion of two 
unique species. 
 
2.5.2.2 Multi-Locus Sequence Analysis (MLSA) 
 
MLSA is an important tool that is useful in taxonomic differentiation (Glaeser & Kampfer, 
2015). DNA sequence variations amongst specific housekeeping genes are analysed in an 
attempt to deduce a higher resolution of genus-centered inter-species relationships from a 
phylogenetic perspective (ibid). It should be noted that the widely used genetic marker for 
bacterial species relatedness, the 16S rRNA gene, has its shortcomings, which therefore 
make MLSA a complementary alternative (Papke et al., 2011). These include the fact that the 
16S gene often falls short in fully discriminating multiple species within the actinobacteria 
genera since it appears to be too conserved. MLSA, therefore, aids in taxonomic 
differentiation in Micromonospora species. Despite its shortcomings, MLSA is also 
considered an effective substitute for DNA-DNA hybridization when effecting the delineation 
of multiple species within specific genera (Papke et al., 2011).n 
 
2.5.2.3 Phylogenetics 
 
MLSA is part of the broader field of phylogenetics. The biological field of phylogenetics is 
pivotal when it comes to the classification of actinomycetes. Edwards and Cavalli-Sforza 
(1964) defined phylogenetics as a field of life sciences that relies on DNA sequencing data to 
decipher the different evolutionary relatedness and closeness amongst groups of 
microorganisms. Phylogenetic analysis makes use of the 16S rRNA gene sequences 
obtained from a PCR using standard 16S rRNA primers. These sequences are then used to 
construct phylogenetic trees by use of various methods such as the commonly used 
neighbour-joining method (Papke et al., 2011). Phylogenetic trees are central to 
phylogenetics as a field, and their ultimate goal in actinomycete classification would be to 
trace ancestral relationships amongst species within the actinobacteria phylum. 
 
2.5.3 Distribution of Actinomycetes and their relevance 
 
Actinobacteria are found both on terrestrial and in aquatic environments, with a predominant 
soil presence, where they have numerous ecological roles (Barka et al., 2016; Jose & Jha, 
2016; Bull et al., 2005). Published information derived from genome sequences of 
Actinobacteria, to date, has shown that this phylum consists of microorganisms of a very 
complex and beneficially diverse character (Ventura et al., 2007). Microbial and plant 
secondary metabolites have been reported as the best available sources of unique chemical 
diversity (Tiwari & Gupta, 2012). This, in turn, means actinobacteria can produce secondary 
metabolites that are chemically diverse, especially given their genomic complexity and 
subsequent diversity (Abdelmohsen et al., 2015). 
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The development of the majority of antibiotics in the market in present day can be traced 
back to actinomycetes (Adegboye & Babalola, 2013; Murphy et al., 2012; Udwary et al., 
2007). Janaki et al. (2012) corroborated this fact and further highlighted that approximately 
70% of the known microbial-sourced antibiotics are actinomycete-derived products. Over the 
years, it has been further pointed out that the genus Streptomyces accounts for up to 60% of 
actinomycete-derived antibiotics (Bhattacharyya & Sen, 2004; Chaudhary et al., 2013; 
Nanjwade et al., 2012; Udwary et al., 2007). The genus Streptomyces has been thoroughly 
studied due to its economic significance. Other genera within actinobacteria responsible for 
the production of up to 10% of antibiotics include Micromonospora, Streptoverticillium, 
Thermoactinomycetes and Actinomadura (Nanjwade et al., 2012). 
 
Ever since the discovery of streptomycin, researchers got encouraged to keep pursuing 
research projects focusing on beneficial natural products sourced from actinomycetes (Jose 
 
& Jha, 2016). However, it is important to note that interest in actinomycetes research 
declined at some stage and most projects on the aforementioned subject now only went as 
far as isolation and bioactivity screening of these actinomycetes (ibid). The major reasons 
attributed to this decline in interest were the dearth of adequate information with respect to 
genomics as well as the specific actinomycetes’ biosynthetic abilities (Abdelmohsen et al., 
2015). Jose and Jah (2016) however noted that interest in actinomycetes research had 
improved amongst scientists due to the advancement of technologies such as next-
generation sequencing and genome editing. 
 
Actinomycete-derived secondary metabolites have diverse antimicrobial properties, and this 
has maintained these microorganisms a case of research relevancy over the years. These 
properties include their display of antibacterial, antifungal, antiprotozoal, anticancer and 
antiviral characteristics against corresponding groups of pathogenic organisms (Janaki et al., 
2012). The chemical structures of tigecycline, daptomycin and streptomycin, some of the well 
know antibacterial derivatives of actinomycetes, are shown in Figure 2.9. 
 
Amongst the many actinomycetes with a history of producing bioactive metabolites of 
pharmaceutical interest, the genus Micromonospora remains an auspicious one. This genus 
stands out as a bio-factory for novel metabolite compound mining, and some of its well-
known antimicrobial products include gentamycins, rifamycins, and erythromycin B among 
many more others (Boumehira et al., 2016). 
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A) Tigecycline B) Daptomycin  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C) Streptomycin 
 
Figure 2.9: Image A shows the antibiotic tigecycline, which is used in the therapy of a number of 
infections such as S. aureus, E. coli and A. baumannii infections. Daptomycin, a lipopeptide antibiotic 
effective against mainly S. aureus bacteraemia, is shown in image B as a chemical structure. It is 
marketed under the name cubicin and is also used in resolving S. pyogenes and S. agalactiae 
infections. Streptomycin (Image C), is clinically used in treating TB, endocarditis and Mycobacterium 
avian complex infections amongst many others. 
 
2.6 The Genus Micromonospora 
 
2.6.1 Taxonomic classification and general characteristics 
 
In 1923, Ørskov proposed the genus called Micromonospora, which is the subsequent type 
genus of the Micromonosporaceae family (Boumehira et al., 2016; Kirby & Meyers, 2010; 
Maldonado & Quintana, 2015; Shen et al., 2014). As far back as 1905, Micromonospora 
chalcea was the first species of the genus Micromonospora to be isolated by Foulerton and 
colleagues and subsequently named Streptothrix chalcea (Foulerton, 1905). Stackebrandt et 
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al. (1997) put forward a proposition for the class Actinobacteria. This classification was based 
on chemical and molecular data and it highlighted the existence of five different subclasses 
within Actinobacteria. Hirsch and Valdes (2009) further highlighted that the order 
Actinomycetales houses the suborder Micromonosporineae which further houses the family 
Micromonosporaceae as shown in Figure 2.10 (Koch et al., 1996; Stackebrandt et al., 1997). 
 
Apart from the genus Micromonospora, the family Micromonosporaceae constitutes other 
multiple genera including Actinoplanes, Catenuloplanes, Dactylosporangium, Couchioplanes 
and Pilimelia (Boumehira et al., 2016; Hirsch & Valdes, 2009). The genus Micromonospora 
consists of more than 60 species of valid nomenclature as highlighted by Boumehira et al. 
(2016). 
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Figure 2.10: Taxonomic hierarchy showing the important taxonomic rank, which depicts how the 
genus Micromonospora fits in the class Actinobacteria. 
 
Species belonging to the genus Micromonospora are filamentous, aerobic to microaerophilic, 
Gram-positive, chemo-organotrophs that usually lack aerial mycelium (Boumehira et al., 
2016; Kirby & Meyers, 2010; Vobis, 1992). Suarez and Hardisson (1985) happen to be two of 
the few researchers who dealt with the presence and involvement of aerial mycelia in 
Micromonospora species. The occurrence of this phenomenon is regarded as extremely 
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rare, from a taxonomic perspective, due to the fact the individual spores in Micromonospora 
species are always attached to either the vegetative mycelia or the substrate mycelia 
(Maldonado & Quintana, 2015). An important genotypic trait that Micromonospora species. 
adopt by virtue of being actinomycetes, is that of a genome resembling a high Guanine: 
Cytosine (G: C) ratio (over 55%) (Trujilo et al., 2014). 
 
2.6.2 Differential characteristics of Micromonospora 
 
Microorganisms of the genus Micromonospora possess a considerable number of 
characteristics that are generally consistent with actinomycetes. However, there exists 
certain morphological, biochemical and physiological properties that help distinguish 
microorganisms of the genus Micromonospora from other actinomycetes. Kawamoto (1989) 
highlighted that some of these differential characteristics include how they grow on various 
media, their ability to use specific carbon sources as well as the mycelia-related 
pigmentation. However, Kirby and Le Roes-Hill (2009) argued that including mycelia-related 
pigments as a diagnostic feature of Micromonospora would be insufficient since these 
pigments, many at times, rather indicate various pH environments. 
 
Another important differential characteristic of Micromonospora, as noted by Holt et al. 
(2000), is the unique structure of the peptidoglycan in their cell wall. The presence of meso-
diaminopimelic acid (DAP) within the peptidoglycan polymer in the cell walls of 
Micromonospora makes these microorganisms unique. Hirsh and Valdes (2010) concurred 
with this assertion and further pointed out that meso-DAP in Micromonospora cell wall is 
sometimes found together with glycine as well as a meso-DAP 3-hydroxy derivative. It is 
important to note that mycolic acids are not part of the cell walls in Micromonospora, thus 
another important differential characteristic (Kawamoto, 1989). 
 
There are specific main phospholipids, which are also found in the cell walls of 
Micromonospora. These include phosphatidylinositol, phosphatidylinositol mannosides and 
phosphatidylethanolamine (Kirby & Le Roes-Hill, 2009). Further to the unique cell wall in 
Micromonospora, the spores associated with this genus are of diagnostic relevance. The 
vegetative mycelium grows develops alongside non-motile spores that are formed in a 
singular fashion and is often observed as a black gelatinous mass on a colony that ranges 
from yellow, red or orange (Kirby & Le Roes-Hill, 2009). 
 
2.6.3 Selective isolation and laboratory culturing of Micromonospora 
 
2.6.3.1 Selective isolation of Micromonospora colonies 
 
As characteristic of many actinomycetes, members of the genus Micromonospora are also 
widely distributed in disparate environments, most notably marine environments, albeit a not 
clearly defined ecological role within this environment (Maldonado & Quintana, 2015). 
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Humus-rich soil is also a common habitat for these microorganisms, whereby they serve as 
decomposers of organic matter (Qiu et al., 2008). It is important to note that it requires 
efficient and effective laboratory techniques for selective isolation of the desired 
Micromonospora species from within a multitude of other microorganisms that are part of 
Micromonosporaceae ecological niches. 
 
To enable effective isolation of microorganisms of the genus Micromonospora from soil 
samples for laboratory analysis, there are various techniques employed. These include the 
tunicamycin method developed by Wakisaka et al. (1982), pre-treatment heat methods, 
(Hayakawa et al., 1991), a wet-heat treatment technique as described by Terahara et al. 
(2013) amongst many others. 
 
Various isolation techniques of Micromonospora species from soil samples exist and the 
method of choice depends on many factors including convenience, affordability and intended 
use of isolated colonies. After making the desired choice of appropriate selective media, 
culturing is done and despite selectivity of media used, undesired microorganisms tend to 
grow alongside the Micromonospora species or the actinomycetes isolated, depending on 
the selectivity of the medium used. If one desires isolation of actinomycetes in general, from 
a processed and cultured soil sample, then colony morphology becomes key. The aerial 
mycelium consistent with actinomycetes results in fluffy colonies that have colours that range 
from red, pink, orange, blue, yellow or red (Kirby & Le Roes-Hill, 2009). If the medium used is 
specifically selective towards Micromonospora species, then bright orange colonies are 
representative. 
 
2.6.3.2 Laboratory culturing post isolation 
 
After Micromonospora species are successfully and selectively isolated from their natural 
habitats, it is imperative to identify appropriate nutrient culture to maintain the integrity of 
Micromonospora strains for further analysis and/or manipulation. Two such examples of 
nutrient media that are favourable for the growth and subsequent maintenance of 
Micromonospora strains are 172F and SGG media in both their solid and liquid forms (Kirby 
 
& Le Roes-Hill, 2009). Micromonospora strains in both these media typically grow as distinct 
orange colonies, which can sometimes be brown or deep brown, depending on the presence 
as well as the stage of sporulation as exemplified in diagrams A and B in Figure 2.11. A 
Gram stain is routinely performed to avoid a scenario whereby a mixed culture of 
microorganisms is mistakenly concluded to be pure Micromonospora colonies, and the 
microscopic result shows Gram-positive, highly filamentous colonies as shown in Figure 
2.12. 
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A B 
 
Figure 2.11: Typical growth characteristics of Micromonospora in both liquid and on solid media. 
Image A shows distinct orange colonies on 172F solid agar streaked out as per the technique outlined 
by Le Roes-Hill and Kirby (2010). Image B also shows bright orange distinct orange Micromonospora 
colonies after inoculation into 172 F liquid medium and incubation at 25oC for nine days. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.12: An example of a microscopic picture of the Gram stain reaction of one of the 
Micromonospora strains studied in this project. Gram-positive filaments and numerous spores can be 
seen at 100× magnification, under oil immersion. 
 
2.6.4 Bioactive products and antibiotics sourced from Micromonospora 
 
The discovery of secondary metabolites and their subsequent derived pharmaceutical 
products with antibacterial activity, amongst members of the genus Micromonospora, dates 
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back to the year 1942 (Kirby & Meyers, 2010). Amongst the pioneering discoveries from this 
genus is the antibiotic Micromonosporin, a chromoprotein isolated from soil Micromonospora 
in 1947 by Waksman et al. (1947). However, the reputation of this genus as a promising 
candidate for the screening of more bioactive compounds, amongst scientists, skyrocketed 
on the backdrop of gentamicin’s isolation from Micromonospora purpurea (Wagman & 
Weinsten, 1980). 
 
2.6.4.1 Gentamicin 
 
The research interest for antibiotics sourced from Micromonospora species grew 
tremendously after the successful discovery of the antibiotic gentamicin in 1963 (Weinsten et 
al., 1963), and its subsequent introduction into the market in 1971 (Chen et al., 2014). 
Gentamicin is a broad spectrum, aminoglycoside-complex (Figure 2.12) antibiotic used for 
the treatment of several infections such as urinary tract infections, endocarditis, pelvic 
inflammatory disease, bone infections and sepsis among many others (Chen et al., 2014). 
The two specific Micromonospora species from which gentamicin was developed from are 
Micromonospora echinospora NRRL 2985 and Micromonospora echinospora NRRL 2953 
(the species echinospora formerly called purpurea) (Piepersberg, 2007; Wagman & 
Weinstein, 1980; Weinstein et al., 1963) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
 
Figure 2.13: Image A shows an intravenous gentamicin solution which is clinically widely used. The 
chemical structure of the gentamicin complex is also shown in image B. This complex is anchored 
upon the central diaminogenouscyclitol (2-deoxystreptamine (2DOS) 4, 6- disubstituted, coupled with 
the auxiliary sugars garosamine and purpurosamine. 
 
 
 
2.6.4.2 Other antibiotics from the genus Micromonospora 
 
After the genus Streptomyces, it has been posited that the genus Micromonospora harbours 
the most bioactive metabolites within the actinomycete genera (Boumehira et al., 2016; 
Parekh et al., 2005; Hirsch & Valdes, 2010). Some antibiotic classes that are sourced from 
Micromonospora as listed by Hirsh and Valdes (2010) include the enediyne, oligosaccharide 
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and aminoglycoside antibiotics. Parekh et al. (2005) also further noted 
ribofuranosyllumichrome, retymicin, saquayamycin and galtamycin B as some individual 
known Micromonospora-sourced antibiotics. Wagman et al. (1976) also noted the 
Micromonospora floridensis-derived actinomycin complex as another success story when it 
comes to antibiotics sourced from Micromonospora species. Many more examples which 
give testimony to the genus Micromonospora as a true antibiotic “goldmine” are listed in 
Table 2.3. 
 
Table 2.3: Examples of some antibiotic molecules discovered from microorganisms of the genus 
Micromonospora over the past four decades (Boumehira et al., 2016). 
 
Antibiotic Class Strain Source Year of 
    discovery 
     
Rosamycin Macrolides M. rosaria NRRL 3718 Soil, Texas, 1972 
   USA  
     
Rifamycins Ansamysins M. lacustris ATCC 21975 Mud, 1975 
   Connecticut,  
   USA  
     
Erythromycin B Macrolides Micromonospora sp. 1225 - 1976 
     
Tetrocarcins Aminoglycosides M. chalcea KY11091 Soil, Miyagi, 1980 
   Japan  
     
Clostomicins Macrolide M. echinospora subsp. Soil, Niigata, 1986 
  armeniaca KMR-593 Japan  
     
Crisamicin A Naphthoquinones M. purpureochromogenes Mud sample, 1986 
  subsp. halotolerans RV- Philippines  
  79-9-101.   
     
Deoxydynemicin A Anthraquinone M. globosa FERM P- Soil, Japan 1990 
  10651   
     
Pyrrolosporin A Macrolides Micromonospora sp. Soil, Puerto 1996 
  ATCC 53791 Viejo, Peru  
     
Micromonosporin  A Macrolide Micromonospora sp. Thailand 2004 
     
Telomycin Macrocyclic peptide M. schwarzwaldensis Soil, Black 2013 
 lactone  Forest,  
   Germany  
     
Neomacquarimicin Carboxylic Micromonospora sp. Marine sponge, 2014 
 polyketide NPS2077 Japan  
     
 
 
 
 
2.7 Applications of Genomics in drug discovery 
 
Important information that is central to the phenotypic, hereditary and biochemical behaviour 
of humans and animals is contained within nucleic acid sequences. Heather and Chain 
(2016) defined nucleic acid sequences as long polynucleotide chains that are built up by 
smaller successions of base pairs in specific orders. The ability for scientists to utilize 
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effective sequencing methods (from a cost, time and accuracy perspective) is imperative in 
all forms of research including drug discovery from Micromonospora species. It is thus 
important to look at the genesis of methods used in DNA sequencing, the evolution thereof, 
before reviewing their role in drug discovery. 
 
2.7.1 Evolution of DNA sequencing 
 
The breakthrough in the quest to understand DNA as a nucleic acid came about when 
Watson and Crick successfully deciphered its three-dimensional structure in 1953 (Watson & 
Crick, 1953). As pointed out by Heather and Chain (2016), it is important to note that at this 
stage scientists had already successfully established methods for protein chain sequencing. 
These methods were, however, limited when it came to nucleic acids sequencing. This led up 
to the development of first-generation sequencing techniques, with a focus on pure RNA 
sequencing sourced from ribosomal or transfer RNA of microbial origin. The techniques used 
by researchers at this stage were analytical chemistry-based and they had limitations in 
establishing nucleotide order, despite being reliable in determining composition of sequences 
(Holley et al., 1961). First-generation DNA sequencing was able to decipher nucleotide 
composition but not nucleotide order in long stretches of DNA. In 1977, Sanger’s chain-
termination technique was developed. This famous technique also referred to as the dideoxy 
technique, saw the use of chemically derived analogues of dNTPs for improved sequencing 
(Sanger et al., 1977). 
 
Second-generation sequencing largely differed from first-generation sequencing in that radio-
or fluorescently-labelled dNTPs were not used during nucleotide identification (Nyren & 
Lundin, 1985 #47). A luminescent-based pyrophosphate determining technique was the 
foundation of the inference of nucleotide sequences in second-generation sequencing (ibid). 
The introduction of third-generation sequencing followed and it became the pioneering 
technology in the sequencing of non-amplified DNA, thereby reducing biases which had 
characterised previous technologies (Schadt et al., 2010). It is, however, the introduction of 
Next Generation Sequencing (NGS) technologies, which became the game-changer in 
bioinformatics. 
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2.7.1.1 Next-generation sequencing (NGS) 
 
The introduction of NGS technologies in 2005 positively influenced the work of scientists 
pursuing genomic-centred research globally (Morozova, 2008). NGS technologies were 
introduced onto the market to bridge the gaps encountered by using conventional Sanger 
sequencing. It is important to note that NGS technologies brought about a revolution in 
bioinformatics, especially in processes such as whole-genome sequencing and resequencing 
(Morozova, 2008). Some of the commercially available NGS technologies, as described by 
Metzker (2005), as well as their principles of functionality, are discussed below. 
 
2.7.1.2 The 454/Roche FLX platform 
 
This technology was developed to address the in vivo amplification step of target genomic 
fragments characteristic of conventional Sanger sequencing. This in vivo amplification step 
was previously achieved by effecting cloning within bacteria as hosts and its major pitfalls 
were being labour intensive and the emergence of biases originating from the host bacteria 
(Sanger & Coulson, 1975). The 454 NGS technology addressed this gap by using emulsion 
PCR, which is more efficient when it comes to in vitro DNA amplification. This technology 
was ceased in 2017 and its read length was between 200-300 base pairs (bp) with a 
throughput of approximately 80-120 mega-bases (Mb) per run. 
 
2.7.1.3 The Illumina/Solexa platform 
 
The Illumina/Solexa NGS technology is one of the most widely used of the NGS technologies 
within many research laboratories globally (Kchouk et al., 2017). This technology consists of 
a flow cell, which is the site of activity for all enzymatic processes and imaging steps 
(Buermans & Dunnen, 2014). The different sub-categories, into which the Illumina NGS 
technology can be divided, are based on the separate lanes used for every specific Illumina 
platform. For instance, the MiSeq platform makes use of a single lane; the HiSeq2500 
operates with two separate lanes while the HiSeq2000 and HiSeq2500 platforms make use 
of eight separate lanes (Buermans & Dunnen, 2014). It is important to note how the Illumina 
MiSeq platform has, over the years, improved accessibility of small genome sequencing 
services to many researchers since it strikes a good balance between cost-effectiveness and 
labour intensiveness and efficiency. 
 
The principle behind the Illumina NGS technology revolves around the flow cell; which is a 
solid surface upon which single stranded DNA (ssDNA) fragments are affixed in a DNA 
amplification step. This attachment of ssDNA fragments precedes a subsequent step that 
involves the bridge amplification of the established solid phase (Morozova, 2008). 
Progressive growth of the Illumina NGS technology has continued to be seen on the market 
as more R&D is carried out. For instance, in 2014 Illumina introduced the NextSeq500 and 
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the HiSeq X Ten platforms. The NextSeq500 platform came with increased outputs of 
between 40 Gg to 120 Gg in a period of 30 hours (Buermans & Dunnen, 2014). 
 
Although base substitution errors are frequently common due to the inevitable application of 
modified polymerases and reversible terminators in Illumina sequencing, this technology 
remains efficient currently with a read length of between 75-300 bp and a massive 
throughput of up to 600 Gigabyte (Gg) per run within approximately 3-10 days (Hodzic et al., 
2017). The continuous improvement in efficiency and increased capacity of NGS 
technologies such as the Illumina platform allows for effective sequencing of multiple 
genomes from various microbes, such as Micromonospora species, in order to find novel 
drug leads. Effective location and identification of biosynthetic gene clusters (BGCs) which 
possibly encode for novel metabolites within those genome sequences, is very key in drug 
discovery (Medema et al., 2011). With the advancement of bioinformatics, tools such as the 
antibiotics & Secondary Metabolite Analysis Shell (antiSMASH) have become very useful in 
identifying BGCs encoding a wide range of known classes of secondary metabolite 
compounds of research relevancy (ibid). antiSMASH is a useful online bioinformatics tool 
(available at http://antismash.secondarymetabolites.org) that compares unknown BGCs to a 
wide range of known BGCs in a bid to explore possible relatedness (Walsh & Fischbach, 
2010). 
 
Another useful BGC mining tool, which has found prominence in bioinformatics, is BAGEL. 
This web-based bioinformatics database is useful in locating ribosomally synthesised and 
post-translationally modified peptides (RIPPs) (De Jong et al., 2006). After successfully 
obtaining genomic data from NGS, it is tools such as BAGEL that are put to use in the 
identification of BGCs encoding RIPPs such as lanthipeptides. In some cases, in 
bioinformatics, the annotation of Open Reading Frames (ORFs) within genome sequences 
becomes a challenge specifically when it comes to distinguishing genes of similar 
functionality albeit with limited or zero sequence homology (Besemer & Borodovsky, 2005). 
BAGEL also comes in handy in solving such dilemmas. Other bioinformatics tools which are 
useful in BGC identification and manipulation in drug discovery include ClusterFinder, 
EvoMining and SMURF amongst many others (Weber & Kim, 2015). 
 
2.7.2 Comparative genomics 
 
Darling et al. (2008) and Touchman (2010) defined comparative genomics as an arm of 
genomics which focuses on gathering information with regards to specific genomic 
parameters amongst organisms before making comparisons of such parameters. These 
genomic parameters include genes and their order, whole genome sequences, regulatory 
sequences, as well as other key genomic parameters (Xia, 2013). Fields et al. (2016) further 
pointed out that the benefits of comparative genomics to fields of biological research, 
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including drug discovery, lie in the ability of scientists to interrogate genomic data amongst 
closely related organisms. 
 
The field of comparative genomics is principled upon the observation that features which are 
shared between different organisms, be it morphological or biochemical, are usually coded 
for by housekeeping genes which resist evolutionary biology (Hardison, 2003). It, therefore, 
makes sense that the alignment of different genome sequences to figure out the possibility of 
shared ancestry as well as extent of conservation amongst these sequences is an important 
foundation in comparative genomics. 
 
Various tools are used in the field of comparative genomics. Such tools include DNA-DNA 
hybridization (DDH), which revolutionised prokaryotic classification through the verification of 
different organisms’ genomic clusters (Ciufo et al., 2018). DDH allows taxonomists to roughly 
ascertain genomic similarity between strains despite the method being tedious and prone to 
errors. As an enhancement to the process, genomic data can be digitally derived; thus, 
Digital DDH. Another good example of a comparative genomics tool is ANItools web, which is 
the web version of the ANItools, developed by Han et al. (2016). Average Nucleotide Identity 
(ANI) is a calculation-based method used to ascertain genomic boundaries within different 
species. The average amino acid identity (AAI) is yet another tool that can be used to 
investigate relatedness between two sets of genomes (Konstantinidis & Tiedge, 2005). 
 
2.7.2.1 Relevance of comparative genomics 
 
A key characteristic of any antibiotic compound of beneficial therapeutic efficacy is its ability 
to target those genomic sequence sections which are highly conserved and commonly 
expressed, amongst various species of pathogenic bacteria (Fields et al., 2016). Robust 
identification of these specific genomic sequence portions becomes achievable by the 
application of comparative genomics. Such information can be, therefore, used to extrapolate 
any sequence homology between target bacterial genomic sequences and bacterial proteins 
of known function. Huang et al. (2014) highlighted that such an approach ultimately serves to 
identify genes of interest within pathogenic bacteria, their extent of expression during 
different stages of causing infection and how essential they are. This information becomes 
the cornerstone of drug development, a process which takes into account the important 
aspect of high-value targets within pathogenic bacteria (Fields et al., 2016). 
 
Another useful application of comparative genomics is in the elucidation of BGCs in drug 
discovery. Doroghazi and Metcalf (2013) reported on work done which showed how 
important comparative genomics could be in understanding the ecology and diversity of 
actinomycete-derived natural products. Actinomycetes are characteristic of highly similar 
genomic sequence sections which code for non-ribosomal peptide synthetases (NRPSs) and 
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polyketide synthases (PKSs). In their study of Streptomyces coelicolor as a model, 
Doroghazi and Metcalf (2013) used comparative genomics to decipher up to 102 closed 
genomes within various actinomycetes genera. This enabled them to figure out occurrence of 
the common BGCs. They concluded that the use of comparative genomics on a wide scale is 
key to the formulation of hypothesis necessary in the field of drug discovery and development 
(ibid). 
 
2.8 Conclusion 
 
A thorough review of literature undoubtedly shows that antibiotic resistant infections have 
been in our midst for long, causing serious clinical ramifications and disrupting the global 
socio-economic order. Amongst the various interventions to correct the problem, continuous 
novel drug discovery from microorganisms of the genus Micromonospora, from previously 
untapped sources such as the South African coastline, remains key. Knowledge of 
bioinformatics to the scientist of the day can never be underestimated in the quest to fulfil the 
aim of this study. Literature describes the behaviour of Micromonospora species in both their 
natural habitats and within laboratory environments. This knowledge provides the basis of 
formulation of effective laboratory methodology to answer the objectives of this research 
study, as outlined in the following chapter. 
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CHAPTER 3 
 
RESEARCH METHODOLOGY 
 
3.1 Microbial strains and reagents used in this study 
 
The microbial strains used in this study consisted of thirty actinobacterial strains obtained 
from the Biocatalysis and Technical Biology (BTB) research group’s culture collection. These 
bacterial strains were isolated from sea sponges and sea squirts previously collected from 
the Algoa Bay region, located in the Eastern Cape province of South Africa. Rhodes 
University provided marine samples and actinobacterial strains were isolated by Dr Marilize 
Le Roes-Hill. Thirty strains that exhibited ‘typical’ Micromonospora-like morphology (orange 
colony with black spore mass) and which exhibited antimicrobial activity (as determined 
during a preliminary screen), were selected for this study. 
 
The identities designated to the microbial strains are as follow: 
 
02-118#4,#5, #8; 02-128*#1, #3; 02-138#3, #6; 02-139#9, #14, #18; 02-158#10; 02-203#1; 
02-209#2, #4; 02-221#16, #26; 02-231#25;02-251#1, #10, #135, #136, #16, #253, #274, 
#322; 02-251*#36; 03-013#19; 04-015#16, #8; and 04-044 RT1. 
 
Key: 02-118, 02-128, 02-138, 02-139, 02-158, 02-203, 02-209, 02-221, 02-231, 02-251, 03-
013, 04-015 and 04-044 are the codes assigned to different marine samples collected by 
Rhodes University; the * indicates strains isolated after a pre-treatment step (material heated 
at 60 C prior to standard isolation); the numbers following the # indicate the isolate number. 
 
All reagents used in this study were of laboratory grade unless otherwise stated. Chemicals 
and solvents used in this study were obtained from Merck-Millipore and Sigma-Aldrich, 
unless otherwise stated. 
 
3.2 Solid and liquid media culturing of bacterial strains 
 
The solid and liquid media used in this research project include SGG media, SGG media 
supplemented with 50% (v/v) artificial seawater (ASW), 172 F media as well as 172 F media 
with ASW. The culture media were prepared as summarised below according to methods 
outlined by Goodfellow and Fiedler (2010): 
 
a) SGG agar (g/L distilled water): 10 glucose, 10 glycerol, 2.5 corn steep solids, 5 
peptone, 10 potato starch, 2 yeast extract, 3 calcium carbonate, 1 NaCl, 20 
bacteriological agar (pH 7.0). 
 
b) 172 F agar (g/L distilled water): 10 glucose, 5 yeast, 10 starch, 2.5 tryptone, 2.5 
tryptone, 20 bacteriological agar (pH 7.0). 
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c) ASW (g/L distilled water): 24.6 NaCl, 0.67 KCl, 1.36 CaCl2.2H2O, 6.29 MgSO47H2O, 
MgCl2, NaHCO3 (pH 8.0). 
 
For liquid media cultures: Initially, all strains that had been isolated from the marine samples 
were stored as stock cultures at -80oC and had to be cultured on fresh media to determine 
viability before further analysis. These frozen cultures were in 20% (v/v) glycerol stocks that 
had been made by mixing 600 µl of each strain’s cell culture with 40 µl of a 50% (v/v) sterile 
glycerol. Volumes of 100 µl of all strains were inoculated into the four different liquid media 
as described above and these were then incubated at 25oC while shaking on a rotary shaker 
at 160 rpm for a period of 5-10 days. After successful growth of the strains in liquid culture, 
stock cultures were prepared by inoculating 240 µl of culture into 360 µl of the 50% (v/v) 
glycerol. These were then frozen at -80 oC and -20oC for further use. 
 
3.2.1 Streaking out of bacterial strains onto solid agar media 
 
Each actinobacterial strain was streaked out onto the four different agar media (100 µl each 
culture) described in section 3.2. This streaking was systematically performed from a heavy 
vertical inoculum into horizontal lines, followed by a W streak across these established 
horizontal lines (Figure 3.1) as described by Kirby and Le Roes-Hill (2009). Strains were 
maintained on these agar plates for use during the study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Pattern of streaking out of actinobacterial strains shown after successful growth. This 
method is used as an effective method of streaking out actinobacteria on solid agar media, 
Micromonospora species included, in order to get pure colonies after incubating under optimal growth 
conditions (9-11 days at 25oC). 
 
3.3 Gram stain of liquid cultures 
 
A standard Gram stain was performed on all liquid cultures, as described by Bartholomew & 
Mittwer (1952) to ensure that the cultures used in this study were not contaminated. 
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3.4 16S rRNA gene sequence analysis 
 
3.4.1 Isolation of genomic DNA 
 
The DNA extraction method that was used is as described by Mandel and Marmur (1968). All 
the reagents used in the isolation of genomic DNA were prepared in-house before isolation 
commenced. 
 
3.4.1.1 DNA extraction reagents 
 
The reagents used for the isolation of genomic DNA include a cell suspension buffer, lysing 
solution as well as other solutions. The protocols that were followed in making up of all these 
solutions are as follow: 
 
a) Cell suspension buffer: For 100 ml – 1 ml of 1M Tris-HCl (pH 8.0); 0.2 ml of 0.5 M 
EDTA; 12 g sucrose; made up with distilled water to 100 ml. 
 
b) Lysing solution: (2×) For 100 ml – 10 ml of 1 M Tris-HCl (pH8.0); 4 ml of 0.5 M EDTA; 
6 ml of 5 M NaCl; 8 ml of 25% w/v SDS; [2 ml β- Mercaptoethanol and 500 µl of 20 
mg/ml proteinase K - added after autoclaving]. 
 
c) Other solutions used: 5 M NaClO4 (700g/l); isopropanol; 75% ethanol; 3 M sodium 
 
acetate; TE buffer; choloform-isoamyl alcohol (24:1 v/v); phenol: chloroform (2:1 v/v); 
10 µl RNase A (10 mg/ml) in 90µl TE buffer (10 mM Tris-HCl, 1 mM disodium EDTA 
at pH 8.0). 
 
3.4.1.2 DNA Extraction Methodology 
 
Prior to DNA isolation, the bacterial strains were cultured in liquid media as previously 
described. After successful culturing (cell mass production clearly visible), bacterial cells 
were collected in 2 ml Eppendorf tubes. Dry lysozyme (8 mg/ml) was added to the bacterial 
cells as well as 200 µl of 5 M NaClO4. The mixture formed a precipitate which was heated to 
50oC to get the precipitate back into solution. This was mixed uniformly to allow the cells to 
lyse. Cells were lysed overnight (12-14 hrs) at 60oC. 
 
The following day, 300 µl phenol: chloroform was added, and an emulsion was formed by 
shaking by hand before further shaking for 20 minutes on a vortex mixer. The samples were 
then centrifuged in a micro centrifuge at 12000 rpm for 10 minutes at room temperature. The 
aqueous layer was transferred to a clean, sterile 1.5 ml tube and the extraction was repeated 
twice more. Afterwards, the aqueous layer was transferred to a clean, sterile 1.5 ml tube; 0.6 
volumes of isopropanol were added to the aqueous phase of the last extractions and mixed 
gently by inversion. DNA was spooled with sterile toothpicks and transferred to a clean 
microfuge tube to which 500 µl of 76% (v/v) ethanol was added. Samples were allowed to 
stand for 10 minutes. After the 10 minute incubation, the wash step was repeated one more 
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time. The precipitate was then dried at 37oC for 15 minutes. After the drying step, the 
precipitate was dissolved in 400 µl of 1 × TE buffer (overnight at 4oC). 
 
After the overnight incubation, 5 µl of RNase A was added and incubation at 37oC carried out 
for 1 hour. Extraction was performed with 100 µl chloroform-isoamyl alcohol before 
centrifuging the mixture and subsequently saving the aqueous layer; 0.1 volumes of 3 M 
sodium acetate were added, mixed with sample (by inversion) and overlaid with two volumes 
95% (v/v) ethanol and DNA was then collected by spooling using sterile toothpicks. The 
isolated DNA was suspended in 500 µl of 1× TE buffer, pH 8, and stored at 4oC until use. 
 
3.4.2 Verification of isolated genomic DNA 
 
To determine whether DNA extraction was successful for all samples, a 1% (w/v) agarose gel 
was prepared and electrophoresed as per the manufacturer’s instructions (Bioline). In order 
to prepare the agarose gel, 1× TAE buffer needed to be first prepared from a 50× TAE buffer 
working stock [242 g Tris, 57.1 ml acetic acid, 100 ml of 500 mM EDTA (pH8) in a final 
volume of 1 L distilled water]. The 1× TAE working solution was then prepared from the 50× 
stock solution by diluting 20 ml of the 50× TAE stock with 980 ml of distilled water. The 
agarose gel was then prepared in the 1x TAE buffer (1 g agarose powder dissolved in 100 ml 
1×TAE buffer) and supplemented with 10 µl of 1 µg/ml ethidium bromide to allow for the 
visualisation of the DNA under UV. The gel was viewed under UV light (254 nm) in a Uvitec 
UV gel documentation system. 
 
3.4.2.1 Quantification of Isolated genomic DNA 
 
The quantification of the isolated genomic DNA was performed on the Genova Life Science 
Spectrophotometer at an absorbance of 260 nm. The spectrophotometer was initially blanked 
with 1 ×TE buffer (pH 8.0), which was the respective buffer used for re-suspension of the 
final extracted DNA. One microliter of each of the isolated DNA samples was pipetted onto 
the spectrophotometer’s nanodrop sample-detection area before reading the value that 
signified the DNA quantity in µg/ml. 
 
3.4.3 Amplification of the 16S rRNA gene 
 
The 16S rRNA gene was amplified for sequence analysis using a polymerase chain reaction 
(PCR) with a pair of standard 16S rRNA gene amplification primers as described by Cook 
and Meyers (2003). The primers used were the forward (F1) primer and the reverse (R5) 
primer, which have sequences as given below: 
 
F1 (Forward Primer, 20-mer); 5’_AGAGTTTGATCITGGCTCAG-3’ 
 
R5 (Reverse Primer, 21-mer); 5’_ACGGITACCTTGTTACGACTT-3’ 
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Note: I = inosine 
 
The PCR was set up with the different components in specific proportions as shown in Table 
3.1. The components needed to be defrosted on ice and the PCR reaction was subsequently 
set up on ice. The PCR reaction was performed in a Standard Techne Touchgene Gradient 
PCR machine under the phase-specific conditions, as summarised in Table 3.1. 
 
Table 3.1: Setup and reaction cycle conditions of the individual 16S rRNA gene amplification PCRs. 
 
PCR SET UP  PCR CYCLE CONDITIONS  
       
PCR ingredients  Volume (µl) Step Temp/oC Duration Cycles 
       
Forward (F) primer (10 µM)  2.5 Initial denaturation 96 2 sec 30 
       
Reverse (R) primer (10 µM)  2.5 Denaturation 96 30 sec 30 
       
Taq Ready Mix  25 Annealing 57 30 sec 30 
       
Sterile nuclease-free water  18 Extension 72 2 min 30 
       
Template DNA (Undiluted)  2 Final Extension 72 5 min 1 
       
Total volume  50 Hold 10 ∞ 1 
       
. 
 
To determine whether amplification of the target 16S rRNA gene was successful, a 1% (w/v) 
agarose gel was run as per the manufacturer’s instructions (Bioline). A 25 µg/ml Fast DNA 
ladder (Biolabs) was also included upon loading the gel. The gel was viewed as previously 
described in section 3.4.2 and sample lanes evaluated for the presence of expected band 
size (1423 bp) (Kirby & Le Roes-Hill, 2009). 
 
3.4.4 16S rRNA gene sequencing and analysis 
 
3.4.4.1 16S rRNA gene sequencing 
 
Prior to sequencing of the amplified 16S rRNA gene, the individual amplicons were purified 
using the MSB® Spin PCRapace kit (Stratec Molecular) as per the manufacturer’s 
instructions. Gene sequencing services for the 16S rRNA gene were outsourced to inqaba 
biotecTM, a genomics company based in Pretoria, South Africa. All necessary procedures 
and protocols from the quality control of submitted PCR amplicons to the generation of raw 
gene sequence data were performed according to the standard operating procedures (SOPs) 
of inqaba biotecTM. 
 
3.4.4.2 Analysis and processing of raw sequence data 
 
The sequences, post 16S rRNA gene sequencing, were provided by inqaba biotecTM in the 
form of .abi data files. The Chromas Lite (Version 2.6) programme (Technelysium) used to 
 
48 
open these files, was downloaded from the Technelysium website: 
http://www.technelysium.com.au/chromas.html. The chromatograms of the sequences were 
edited and during this process, incorrect base-calls were changed by typing in a new letter or 
deleted accordingly to correct any base coding anomalies. The edited chromatograms were 
then exported as .seq files into DNAMAN Version 4.13 (Lynnon BioSoft). 
 
The reverse sequences were converted, saved and re-loaded to enable the final assembling 
of the full sequence. After uploading the sequences, the sequences were assembled and 
used for further analysis. The consensus sequences were used to determine the novelty of 
 
the individual strains by performing a BLAST analysis at 
http://blast.ncbi.nlm.nih.gov/Blast.cgi?CMD=Web&PAGE_TYPE=BlastHome. In addition, 
sequences were also submitted to EzBiocloud (https://www.ezbiocloud.net) to determine 
relatedness to type strains (Yoon et al., 2017). 
 
3.5 Multi-Locus Sequence Analysis (MLSA) 
 
Multi-locus sequence analysis was performed by targeting four genes within the five best 
Micromonospora strains’ individual genomes (strains selected based on antibacterial activity 
studies; see section 3.8). The genes targeted included recA, rpoB, atpD and gyrB. The PCR 
protocols used were a variation of the protocols outlined by Carro et al. (2011). 
 
The gyrB gene was amplified by targeting two overlapping regions that would enable 
obtaining a final composite sequence measuring up to 1110 nucleotides (Garcia et al., 2010). 
This meant that targeting this gene for amplification required two sets of primers, as shown in 
Table 3.2. All PCR reactions effected in the MLSA study followed the protocol outlined in 
Table 3.3 with the specific annealing temperatures for the specific genes highlighted in Table 
3.2. 
 
The amplicons were analysed using 1% (w/v) agarose gel electrophoresis as previously 
described in section 3.4.2. Prior to sequencing of the amplified genes, the individual 
amplicons were purified using the MSB® Spin PCRapace kit (Stratec Molecular) as per the 
manufacturer’s instructions. As for the MLSA genes, sequencing services were outsourced to 
inqaba biotechTM and sequence data was provided in the form of .abi data files and a similar 
process of data manipulation and analysis was followed as described previously. 
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Table 3.2 Primer information for the primers used in the MLSA study 
 
PRIMER SEQUENCE GENE ANNEALING EXPECTED 
  TARGETED T/
oC AMPLICON SIZE 
ATPDF1g 5’-AAGGGSMASGTMTTCAA-3’ atpD 57
OC 850 bp 
     
ATPDF2g 5’-TGGTCSATYCACCGCAAG-3’ atpD 57
OC 850 bp 
     
RAUj 5’-GGYAARGGYKCBGYNATGCG-3’ recA 57
OC 510 bp 
     
RADj 5’-CTTVRMSCGGGTGCGGTT-3’ recA 57
OC 510 bp 
     
MYCOFi 5’-GGYAAGGTCACSCCCSAAGGG- rpoB 56OC 575 bp 
 3’    
     
MYCORi 5’-ARCGGCTGCTGGGTRATC-3’ rpoB 56
OC 575 bp 
     
GYF3gh 5’-ACSGTCGACTTCGACTTCCA-3’ gyrB 54
OC 900 bp 
     
GYR3Bgh 5’-CAGCACSAYCTTGTGGTA-3’ gyrB 54
OC 900 bp 
     
GYF1gh 5’-TCCGGYGGYCTGCACGGCGT-3’ gyrB 62
OC 500 bp 
     
GYR1Bgh 5’-CGGAAGCCCTCYTCGTGSGT-3’ gyrB 62
OC 500 bp 
     
 
 
Table 3.3 PCR protocol used in the MLSA study for the amplification of all target genes 
 
PCR SET UP  PCR CYCLE CONDITIONS  
      
PCR ingredients Volume (µl) Step Temp/
oC Duration Cycles 
      
Forward (F) primer (10 µM) 2.0 Initial denaturation 94 2 sec 1 
      
Reverse (R) primer (10 µM) 2.0 Denaturation 94 30 sec 35 
      
Taq Ready Mix 25 Annealing Refer to 1 min 30 
   Table 3.2   
      
Sterile distilled water 19 Extension 72 2 min 30 
      
Template DNA 2 Final Extension 72 7 min 1 
      
Total volume 50 Hold 4 ∞ 1 
      
 
 
3.6 Phylogenetic analysis 
 
For the phylogenetic analysis of the amplified DNA sequences, the top twenty sequences 
from BLAST or EzBioCloud analysis were used along with the sequences of the strains of 
interest. MEGA version X (Kumar et al., 2018) was used to align amplicons with sequences 
downloaded from NCBI and/or EzBioCloud. The aligned sequences were used in generating 
a neighbour-joining (NJ), minimum evolution and maximum likelihood tree with a bootstrap 
value of 1000. All three trees were analysed to determine whether the grouping on the NJ 
tree are conserved. For the MLSA, a concatenated sequence of the 16S-gyrB-rpoB was 
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generated for the five strains and the top 20 hits. The alignment and tree generation was 
performed as previously described. In both cases, the NJ tree was used for presentation. 
 
3.7 PCR screening for the presence of Biosynthetic Gene Clusters (BGCs) 
 
From the DNA isolated in section 3.4.1, eight known BGCs were screened for in separate 
PCRs using primer sets as given in Table 3.4. Information pertaining to the specific genes 
that were being targeted as well as their respective expected band sizes are summarised in 
Table 3.4. 
 
Table 3.4: Primer sets for the amplification of targeted sequences in antibiotic BGCs 
 
Biosynthetic Primer sets Expected Reference 
gene targeted  band size  
    
Cytochrome P450 F PEH-1 5’-   
hydroxylase,  TGGATCGGCGACGACCG(G/C)(A/G/C)(T/C)CGT-3’ 350 bp Hwang   et 
polyene antibiotics R PEH-2 5’-  al., 2007 
   CCG(T/A)A(G/C)AG(G/C)A(T/C)(G/C)CCGTCGTACTT-3’   
     
Epoxidase,    Wang et al., 
polyether ionophore EPO-F: 5’-GGSTGGCARYAYCGYTTYCC-3’ 700 bp 2011 
   EPO-R: 5’-SCCRTGSCCGTRSAYSGGRTTG-3’   
      
P450      
monooxygenase, Foxy: 5’-CTGGTCGGCAACCTGATGGAC-3’ 591 bp Wood et al., 
glycopeptide  Roxy: 5’-CAGGTACCGGATCAGCTCGTC-3’  2007 
     
Ketosynthase alpha    
and ketosynthase ARO-PKS-F: 5’-GGCAGCGGITTCGGCGGITTCCAG-3’ 492-630 bp Wood et al., 
beta, Type II ARO-PKS-R: 5’-CGITGTTIACIGCGTAGAACCAGGCG-3’  2007 
polyketides     
     
3-amino-5-     
hydroxybenzoic acid ANSA-F: 5’-CC(C/G)GC(G/C)TTCAC(C/G)TTCATCTC-3’  Wood et al., 
synthase,  ANSA-R: 5’-AI(G/C)(C/T)GGAICATIGCCATGTAG-3’ 641 bp 2007 
ansamycins     
     
Isopenicillin N Pcb03-F: 5’- CGAGTCCTGGTGCTACCTGAACC-3’  Bervanakis, 
synthase, β-lactams Pcb03-R: 5’- TCATCGACACGTCCAGGTGGTC-3’ 355 bp 2008 
     
dTDP-glucose    Bervanakis, 
synthase,  StrD01-F: 5’- CTTCGCCATGTATCTCGGCGACAA-3’ 370 bp 2008 
aminoglycosides StrD01-R: 5’- TGCCGGTGTCCTTCCAGTAG-3’   
    
Ketosynthase,  Type KSM-F: 5’- GCSTCCCGSGACCTGGGCTTCGACTC-3’  Bervanakis, 
I polyketides  ATM-R: 5’- AGSGASGASGAGCAGGCGGTSTCSAC-3 750 bp 2008 
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3.7.1 PCR reaction components and conditions 
 
The reaction setups for the BGC PCRs and the individual cycle conditions are given in Table 
3.5. 
 
The amplicons were analysed by gel electrophoresis using the same setup as for previous 
PCR analyses. Sequencing was not performed, as this section was merely a screening 
experiment. 
 
3.7.2 Primer alignments with target genes 
 
Target genes from the Micromonospora genomes were accessed via a searchable sheet for 
all coding sequences on EzBiocloud. After accessing these target genes, multiple sequence 
alignments between these target genes and the BGC primer pairs (Table 3.4) were set up in 
DNAMAN version 4.13. This exercise sought to investigate whether or not there was any 
alignment signifying binding of primers to intended targets and if not, whether there would be 
alternative BGCs that could be explored. 
 
3.8 Primer design and testing of designed primers 
 
3.8.1 Retrieval of genomic data: EZBioCloud 
 
In order for the gaps in primer knowledge to be established for the purposes of primer 
designing, the genomic data of published species of the Micromonospora genus was 
retrieved and assessed. This was performed by searching EZBioCloud (Yoon et al., 2017), 
an online database available at www.ezbiocloud.net, using “Micromonospora” as the search 
term. The “Genome” option was then selected as a filter in order to retrieve data of only those 
species that had published genomic data. Each species was individually selected to explore 
its genomic information. Strain and genome information was retrieved and tabulated into an 
Excel spreadsheet. This information included, for each species, Taxon name, Strain name 
(Strain information) and status, Number of coding regions (CDSs), mean length of CDS and 
mean length of the intergenic region. Sequences of contigs provided as FASTA files were 
also downloaded. 
 
3.8.2 Predicting of BGCs: antiSMASH 
 
antiSMASH bacterial version, available online at https://antismash.secondarymetabolites.org, 
was used to predict the known and unknown gene clusters within the downloaded genome 
FASTA files (Medema et al., 2011). Data was input from extracted FASTA files and analysis 
options were made to include known clusters blast, cluster blasts, subcluster blasts, smCoG 
analysis, active site finder, detect TTA codons and whole-genome PRAM analysis. For each 
species, the particular BGCs and their types, that did not have any known predictable “most 
similar clusters” were identified and tabulated. These would form the basis for primer design. 
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Table 3.5 PCR protocols and cycle conditions for BGC analysis 
 
 
   25 µl PCR SETUPS          PCR CYCLES CONDITIONS          
                               
 20   µM 20   µM 2× Kappa 1mg/ml  Sterile DNA Initial  Denaturation Annealing  Extension  Final    Hold   
Gene 
Forward Reverse Taq BSA or dH2O Templ Denaturation            Extension      
Primer Primer Readymix DSMO or  ate                        
targeted 
   
Glycerol 
 
(µl) 
                        
(µl) (µl) (µl) 
 
(µl) 
T D C T D C T D  C T D  C T  D  C T  D C 
        
 
(µl) 
                         
                            
       
/OC sec 
 
/OC sec 
 
/OC sec 
  
/OC sec 
  
/OC 
 
sec 
  
/OC 
 
sec 
 
                   
                              
Cytochrome 0.5 0.5 12.5 2.5 of 8 1 96 300 1 96 60 45 60 30  45 72 45  45 72  300  1 4  ∞ 1 
P450    1mg/ml BSA                          
hydroxylase                               
                              
Epoxidase 0.5 0.5 12.5 1.5 DSMO 9 1 95 480 1 95 45 32 59 45  32 72 60  32 72  600  1 4  ∞ 1 
                               
P450 0.5 0.5 12.5  - 10.5 1 96 120 1 96 45 30 60 30  30 72 120  30 72  300  1 4  ∞ 1 
monooxygen                               
ase                               
                               
Type II PKS 0.5 0.5 12.5  - 10.5 1 96 120 1 96 45 30 64 30  30 72 120  30 72  300  1 4  ∞ 1 
                               
Ansamycins 0.5 0.5 12.5  - 10.5 1 96 120 1 96 45 30 56 30  30 72 120  30 72  300  1 4  ∞ 1 
                               
Isopenicillin 0.5 0.5 12.5  - 10.5 1 94 480 1 94 60 30 65 60  30 72 120  30 72  600  1 4  ∞ 1 
N-synthase                               
                               
dTDP- 0.5 0.5 12.5  - 10.5 1 94 480 1 94 60 30 65 60  30 72 120  30 72  600  1 4  ∞ 1 
glucose                               
synthase                               
                              
Ketosynthas 0.5 0.5 12.5 1.25 DSMO, 4.25 1 94 300 1 94 45 30 60 60  30 72 120  30 72  420  1 4  ∞ 1 
e    5 Glycerol                          
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3.8.3 Retrieval of gene sequences and primer design 
 
Twenty selected Micromonospora strains were used to identify unique BGCs for which there 
are no known published primer sets specific for this genus. Only those genomic regions 
coding for lanthipeptides and bacteriocins were considered as the basis of primer design. 
The respective regions were individually selected, and their core BGCs were further selected 
to reveal comprehensive gene details. The required nucleotide sequences were then 
retrieved for each coding region. The specific genes targeted for primer design were the 
Lant_dehydr_C gene for lanthipeptides and the DUF692 gene for bacteriocin. 
 
Primer design was then achieved by performing separate multiple sequence alignment of the 
lanthipeptides and bacteriocins using DNAMAN version 4.13 (Sievers et al., 2011). The 
consensus sequences were then obtained for each of the target genes and these would 
provide the basis for the design of the forward and reverse primers for the lanthipeptides and 
bacteriocins. Following the rules for effective primer design, specific regions on the 
consensus sequences were located the designing of the forward and reverse primers. The 
primers were designed to be a maximum of 28 bp and to be able to amplify a product of at 
least 200bp (Yu et al., 2013). In order to analyse the designed primers to ensure their proper 
 
functionality, the IDT oligoAnalyzer tool available at 
https://www.idtdna.com/pages/tools/oligoanalyzer was used. After the design and analysis of 
primer pairs, a request for oligo-synthesis was submitted to Inqaba Biotec in Pretoria, South 
Africa. 
 
3.8.4 Testing of designed primers 
 
The chosen five Micromonospora strains used in this study were going to be the focal point 
for the testing of the designed primers. The primers were first tested on genomic DNA 
samples of the chosen five Micromonospora strains using the PCR programme given in 
Tables 3.6 and 3.7. Optimisation of PCR conditions, specifically the addition of BSA and 
employing of the gradient PCR method, were performed depending on initial amplification. 
 
After running the PCRs for the target genes, 1% (w/v) agarose gels were prepared in both 
cases and electrophoresis was subsequently performed for 1 hour at 100 V. Viewing of these 
gels was performed under UV light by the Molecular Imager Gel Doc XR+ Imaging system 
(BIO-RAD). The amplicons were then purified using the MSB® Spin PCRapace kit (Stratec 
Molecular) as per the manufacturer’s instructions. Sequencing of these amplicons was 
outsourced to inqaba biotecTM. The sequence data was then processed as outlined in 
section 3.4.4.2 and inferences were drawn from the findings. 
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Table 3.6 Setup and reaction cycle conditions of the Bacteriocin gene amplification PCR 
 
PCR SET UP  PCR CYCLE CONDITIONS  
        
PCR ingredients  Volume (µl) Step Temp/oC Duration  Cycles 
        
Forward (F) primer (10 µM)  2.5 Initial denaturation 96 2 sec  30 
        
Reverse (R) primer (10 µM)  2.5 Denaturation 96 30 sec  30 
        
Taq Ready Mix  25 Annealing 51 30 sec  30 
        
Sterile nuclease-free water  18 Extension 72 2 min  30 
        
Template DNA  2 Final Extension 72 5 min  1 
        
Total volume  50 Hold 10 ∞  1 
       
Table 3.7 Setup and reaction cycle conditions of the Lanthipeptide gene amplification PCR  
     
PCR SET UP  PCR CYCLE CONDITIONS  
      
PCR ingredients  Volume (µl) Step Temp/oC Duration  Cycles 
        
Forward (F) primer (10 µM)  2.5 Initial denaturation 96 2 sec  30 
        
Reverse (R) primer (10 µM)  2.5 Denaturation 96 30 sec  30 
        
Taq Ready Mix  25 Annealing 55 30 sec  30 
        
Sterile nuclease-free water  18 Extension 72 2 min  30 
        
Template DNA  2 Final Extension 72 5 min  1 
        
Total volume  50 Hold 10 ∞  1 
         
 
 
3.9 Antimicrobial studies 
 
3.9.1 Antibacterial activity in solid media 
 
3.9.1.1 Preparation for testing antibacterial activity 
 
Each of the bacterial strains under study (total of 30) was stab-inoculated into the following 
agar plates (using sterile toothpicks): SGG, SGG with ASW, 172 F and 172 F with ASW (that 
were prepared as described in section 3.2). The plates were incubated for 11 days at 30oC to 
allow the actinobacteria to grow and produce their antibiotics. 
 
3.9.1.2 Inoculation of test bacteria 
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Three microbial test strains were used in the antibacterial activity analysis of actinobacteria 
on solid agar media. These were Escherichia coli ATCC 25922 (Gram-negative), Bacillus 
cereus ATCC 10876 (Gram-positive) and Candida albicans ATCC 24433 (eukaryote). The 
test strains used were first incubated at 30oC (B. cereus and C. albicans) or 37oC (E. coli) for 
24 hours, from liquid cultures onto nutrient agar plates to ensure their growth and viability by 
the time of analysis. 
 
A day prior to the overlays, a large loopful of each of the test strains was inoculated from 
their respective agar plate cultures into 5 ml nutrient broth. These mixtures were vortexed 
vigorously to disperse the bacteria until a turbid suspension was produced. These nutrient 
broth cultures were incubated overnight at their respective temperatures with shaking on a 
rotary shaker, 160 rpm (14-18 hours). Test strain cultures consistent with high cellular density 
were diluted with sterile nutrient broth before taking a reading on the spectrophotometer at 
600 nm. The reference guideline-ratios for the dilution of test bacteria cultures was as 
outlined by Kirby and Le Roes-Hill (2009). These reference guideline dilution ratios used 
were derived from Mycobacterium aurum, E. coli and Enterococcus faecalis. The test strains 
used had their cell densities theoretically estimated to these given standards (Kirby & Le 
Roes-Hill, 2009), before making dilutions accordingly. 
 
a. M. aurum dilute 1-in-6 
 
b. E. coli dilute 1-in-10 
 
c. E. faecalis (and most other enteric bacteria) dilute 1-in-4 
 
The B. cereus and C. albicans strains were diluted as per the M. aurum and E. faecalis 
dilutions respectively. 
 
3.9.1.3 Antimicrobial activity analysis (overlay technique) 
 
Nutrient agar was prepared according to the manufacturer’s instructions, but with a 0.7% 
(w/v) agar content, and 6 ml of the agar was aliquoted into 10 ml McCartney bottles to form 
sloppy agar. The sloppy agar was then autoclaved and thereafter cooled to 60oC in a water 
bath. The optical density of the test strain cultures (OD600), was taken into account to ensure 
homogeneity in the concentration of cells in the sloppy agar from one overlay experiment to 
the next. The volume of test culture used per 6 ml sloppy-agar overlay was such that when 
multiplied by the volume of bacterial culture used per sloppy-agar tube by the OD600 of the 
culture, the following approximate standard values were obtained (these values have been 
determined empirically and vary for the different test bacteria). 
 
a) M. aurum 160 OD600.μl 
 
b) E. coli 4 OD600.μl 
 
c) E. faecalis 160 OD600.μl 
 
 
56 
An appropriate amount of test culture, as determined by prior calculations, was pipetted into 
a sloppy-agar tube and gently vortexed. This mixture was then poured onto a stab-inoculated 
actinobacterial culture plate. The plate was then gently swirled in order to distribute the 
sloppy agar evenly over the entire surface of the plate (from the edge of the plate right up to 
the edge of each actinobacterial colony on the plate). The sloppy-agar was then allowed to 
solidify and all plates were then turned with the agar-side up. The plates were incubated 
overnight at the test strains’ respective temperatures. 
 
For all strains that were tested, the medium on which the strain was grown and the duration 
of the incubation before the overlay test was performed were recorded. For those strains 
exhibiting antibacterial activity, the diameter values of the actinobacterial colony and that of 
the zone of growth inhibition were measured, to enable the determination of the area of the 
inhibition zone (mm2). Based on the activity of the strains under study in solid media cultures 
(overlay technique), the five best strains were chosen for analysis of antibiotic production in 
liquid cultures as well as multi-locus sequence analysis (as described in section 3.5). 
 
3.10 Antibiotic production in liquid cultures 
 
3.10.1 Preparation of secondary metabolite extracts for use in bioautography; 
 
For the five strains selected for antibiotic production in liquid cultures, 10 ml of 172F liquid 
media cultures were prepared in duplicate following the 172F liquid media preparation 
protocol outlined in section 3.2. These were inoculated with the respective strains and then 
kept shaking at 160 rpm, on a rotary shaker for 5-7 days. Incubation was performed at a 
temperature of 25oC-30oC to enable optimal cell mass production. These cultures were used 
as pre-cultures to inoculate the flasks for testing antimicrobial production. 
 
Aliquots (100 µl) of each of the pre-cultures were inoculated into 10 ml liquid cultures (in 
duplicate; 172F liquid media; 10 flasks per strain). These were then incubated at 25oC-30oC 
with continuous shaking at 160 rpm. After 3, 5, 7, 10 and 12 days of growth, two flasks of 
cultures per each strain were removed from the incubator and an equal volume (10 ml) of 
ethyl acetate added to each flask. These cultures were then incubated overnight at 30oC 
while shaking at 160 rpm. The cultures were then removed from the shakers and allowed to 
settle. The upper ethyl acetate layer was removed and placed in a clean glass McCartney 
bottle. The ethyl acetate was allowed to evaporate in a fume hood and the dried extract 
recovered for use in bioautography. A set of two flasks with media only was included in the 
extraction process that would serve as a media control. 
 
3.10.2 Bioautography 
 
The dried extracts prepared above were re-suspended in 200 µl ethyl acetate for use in 
bioautography. The bioautography method used in this study is a variation of the one 
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outlined by Betina (1973). This protocol suits non-polar compounds that are not readily 
soluble in 40% (v/v) DMSO. Five microliter volumes of the concentrated extracts were 
spotted onto clearly labelled silica gel 60 F254 TLC plates (Merck Millipore). These TLC plates 
had grids drawn onto them, with small square areas measuring 1 cm × 1 cm. The spots were 
left to dry to completeness before the TLC plates could be used in bioautography. 
 
The three test strains used in bioautography included B. cereus ATCC 10876, E. coli ATCC 
25922 and C. albicans ATCC 24433. B. cereus and C. albicans were cultured in nutrient 
broth that was made according to the manufacturer’s instructions. E. coli was cultured in 
Tryptic Soy Broth (Sigma-Aldrich) that was also prepared according to manufacturer’s 
instructions. C. albicans and B. cereus were both incubated at 30oC with shaking at 160 rpm 
overnight while E. coli was incubated at 37oC, also with shaking at 160 rpm. After 
confirmation of the purity of the cultures through standard Gram staining, the optical densities 
of the test bacterial cultures were determined by use of a Rayleigh UV-9200 
spectrophotometer at a wavelength of 600 nm, before adjusting the OD600 to 0.5 using the 
respective sterile liquid media used during culturing. 
 
The test bacteria were then applied to the surfaces of the TLC plates with sterile absorbent 
cotton wool, placed in plastic sealable containers lined with moist paper towel and incubated 
at 37oC overnight (E. coli) and 30oC for the Bacillus and Candida strains. Thiazolyl blue 
(MTT, Sigma) dissolved in phosphate-buffered saline (4.26 g Na2HPO4.7H2O, 2.27 g KH2PO4, 
8.00 g NaCl per litre, pH to 7.0) at a final concentration of 0.25% (w/v) was then sprayed onto 
the TLC plates and incubated at the respective temperatures for 2 to 3 hours. Colour 
changes were monitored and recorded. 
 
3.10.3 Accessing secondary metabolites using other extraction techniques 
 
Based on the activity profiles of each of the five strains observed in section 3.9.2, an optimal 
incubation time and growth medium were selected and applied to each of the five strains for 
further antimicrobial studies. These studies were premised upon the application of four 
different extraction techniques to see whether different extraction techniques would result in 
accessing different bio-activities (eight flasks were prepared per strain). 
 
3.10.4 Extraction techniques 
 
3.10.4.1 Whole culture extraction 
 
An equal volume of ethyl acetate was added to each culture after the strain’s specific 
optimum incubation period and further incubated at 30oC overnight while shaking at 160 rpm. 
The ethyl acetate layer was removed and subsequently dried down under a fume hood. The 
dried extract was stored at 4oC prior to use in bioautography. 
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3.10.4.2 DIAION treatment and extraction 
 
For this extraction, 0.5 g DIAION (Supelco) [a non-polar copolymer styrene-divynilbenzene 
adsorbent resin] was added to the culture after each strain’s specific established optimum 
incubation period and further incubated at 30oC overnight whilst shaking at 160 rpm. The 
following day, the cultures were filtered, and the filtrate discarded. The cells and DIAION 
were then washed twice with distilled water. The washed cells and resin were transferred to 
50ml flasks and 10ml methanol was added. This mixture was then incubated at 30oC with 
overnight shaking at 160 rpm. The extracts were then filtered and subsequently dried to 
completeness in the fume hood. The dried extracts were stored at 4oC. 
 
3.10.4.3 Ethyl acetate extraction on cells and filtrate 
 
The culture was filtered after each strain’s specific established optimum incubation period to 
enable extraction on the cells and filtrate separately. For the filtrate, an equal volume of ethyl 
acetate was added, and incubation repeated as in section 3.9.4.1. For the cells, 5 ml of ethyl 
acetate was added, and incubation was similarly performed as for the filtrate. The ethyl 
acetate layers were removed, dried down and stored at 4oC. 
 
3.10.4.4 Ammonium sulphate precipitation and dialysis 
 
For each of the strains, the culture was first filtered after the specific established optimum 
incubation period and the filtrate retained. Ammonium sulphate (5.59 g) was added to 10 ml 
of filtrate and the resulting mixture was stirred at 20oC for 1 hour. Centrifugation at 10000 x g 
was performed using the Sigma 1-14 bench top centrifuge (Lasec) for 10 minutes and the 
pellet was retained. The pellet was re-suspended in 10 ml 50 mM potassium phosphate 
buffer (pH 7.5) and dialysis was performed against 50 mM potassium phosphate buffer at 
4oC overnight using the Thermo Scientific SnakeSkin Dialysis tubing. The dialysate was 
removed, and extraction was performed with an equal amount of ethyl acetate as for other 
extractions. The ethyl acetate was then removed, dried down and stored at 4oC for further 
use in bioautography. 
 
3.10.5 Bioautography 
 
After all the extracts had been obtained using the different extraction techniques outlined in 
sections 3.9.4.1 to 3.9.4.4, re-suspension of these extracts in 200 l ethyl acetate was 
performed. The extracts were then spotted onto a TLC grid and bioautography was 
performed using the same test strains and following the same protocol as outlined in section 
3.9.2. 
 
In the following chapter, the results that were obtained from the methods outlined in this 
chapter are presented. These are then fully discussed in Chapter 5 of the study. 
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CHAPTER 4 
 
RESULTS AND FINDINGS OF RESEARCH STUDY 
 
4.1 Growth of strains in solid and liquid cultures 
 
The growth and morphological characteristics of the Micromonospora strains were 
macroscopically examined after their respective incubation periods. These observations were 
made in both liquid and on solid media with examples shown in Figures 4.1 A and 4.1 B. On 
172F and SGG solid media, distinct orange colonies were observed (Figure 4.1 A) on the 
agar plates. It was also observed that the bacterial colonies initially assumed a light-orange 
shade on solid media before progressively changing to deep-orange, red and in some cases 
even brown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
 
Figure 4.1: A) shows growth of Micromonospora colonies (strain 02-139#18) on 172 F solid agar after 
an 11-day incubation period at 25oC. B) shows four different Micromonospora strains in 172 F liquid 
medium after incubation at 25oC with continuous shaking at 160 rpm. In image B, the difference in 
colour shades of the orange Micromonospora strains is visible. 
 
4.2 Gram stain of liquid cultures 
 
Upon viewing the Gram-stained slides at 100× magnification under oil immersion, all the 
strains were found to be Gram-positive, filamentous strains. Two examples, as seen under oil 
immersion, are given in Figure 4.2. 
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A B 
 
Figure 4.2: As shown in A), strain 02-203#1 is Gram-positive and highly filamentous under oil 
immersion (100× magnification). B) shows strain 02-251#1’s Gram-positive result, also under oil 
immersion. The two strains are clearly in different stages of sporulation as depicted by the numerous 
dot-like spores in B compared to the isolated spores in A (spores shown by arrows in each images). 
 
4.3 Verification of genomic DNA isolation 
 
After DNA isolation, agarose gel electrophoresis was performed on all strains and Figures 
4.3, 4.4 and 4.5 were generated upon viewing the agarose gels under UV light (254 nm) in a 
Uvitec UV gel documentation system. The keys below each gel image reference the numbers 
annotated on the specific gel to the original identity of the individual samples as given in 
section 3.1. Figure 4.5 shows an agarose gel picture generated from the re-isolation of DNA 
from samples 10, 11, 15, 26 and 27. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Verification of DNA for isolates 1 to 15. The bands on the gel show the respective DNA 
isolated from the respective strains as given in the key. 
 
KEY: L:Fast DNA Ladder; 1: 02-158#10; 2: 02-138#6; 3: 02-128*#3; 4: 02-139#9; 5: 02- 
 
209#4;  6:  02-138#3;  7:  02-139#18;  8:  02-118#4;  9:  02-251#1;  10:  02-221#16;  11:  02- 
 
251#253; 12: 03-013#19; 13: 02-128*#1; 14: 02-118#5; 15: 04-044RT1 
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Figure 4.4: Verification of DNA for isolates 16 to 30. The bands on the gel show the respective DNA 
isolated from the respective strains as given in the key. 
 
KEY: L: Fast DNA Ladder; 16:02-251#136; 17: 04-015#8; 18: 02-118#8; 19: 02-139#14; 20: 
 
02-203#1; 21: 02-209#2; 22: 02-221#26; 23: 02-231#25; 24: 02-251#10; 25: 02-251#135; 26: 
 
02-251#16; 27: 02-251#274; 28: 02-251#322; 29: 02-251*#36; 30: 04-015#16  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Verification of DNA for isolates 10,11,15,26 and 27. The bands on the gel show the 
respective DNA isolated from the respective strains as given in the key. 
 
KEY:  L: Fast DNA Ladder; 10: 02-221#16; 11: 02-251#253; 15: 04-044RT1; 26: 02-251#16; 
 
27: 02-251#274 
 
4.4 Quantification of isolated genomic DNA 
 
The results for the spectrophotometric quantification of isolated genomic DNA (gDNA) of all 
strains are tabulated in Tables 4.1 and 4.2. 
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Table 4.1: Isolated genomic DNA quantities for the bacterial strains under study. 
 
Assigned identity Original sample identity DNA Quantity (µg/ml) 
   
Sample 1 02-158#10 45.00 
   
Sample 2 02-138#6 21.72 
   
Sample 3 02-128*#3 65.80 
   
Sample 4 02-139#9 32.57 
   
Sample 5 02-209#4 20.40 
   
Sample 6 02-138#3 111.60 
   
Sample 7 02-139#18 95.87 
   
Sample 8 02-118#4 80.93 
   
Sample 9 02-251#1 54.00 
   
Sample 10 02-221#16 9.75 
   
Sample 11 02-251#253 97.21 
   
Sample 12 03-013#19 147.20 
   
Sample 13 02-128*#1 22.94 
   
Sample 14 02-118#5 29.28 
   
Sample 15 04-044RT1 6.25 
   
Sample 16 02-251#136 43.05 
   
Sample 17 04-015#8 22.38 
   
Sample 18 02-118#8 88.25 
   
Sample 19 02-139#14 114.00 
   
Sample 20 02-203#1 45.56 
   
Sample 21 02-209#2 55.21 
   
Sample 22 02-221#26 88.64 
   
Sample 23 02-231#25 111.37 
   
Sample 24 02-251#10 75.20 
   
Sample 25 02-251#135 77.33 
   
Sample 26 02-251#16 49.75 
   
Sample 27 02-251#274 56.70 
   
Sample 28 02-251#322 120.37 
   
Sample 29 02-251*#36 55.21 
   
Sample 30 04-015#16 79.58 
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Table 4.2 DNA concentrations for re-extracted bacterial strains 
 
Assigned identity Original sample identity DNA Quantity (µg/ml) 
   
Sample 10 02-221#16 22.35 
   
Sample 11 02-251#253 105.72 
   
Sample 15 04-044RT1 27.80 
   
Sample 26 02-251#16 62.57 
   
Sample 27 02-251#274 22.40 
   
 
 
4.5 16S rRNA gene amplification 
 
After running the PCR for the amplification of the 16S rRNA gene, the agarose gel pictures 
that were generated can be seen in Figures 4.6 and 4.7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: The agarose gel picture for amplification of the 16S rRNA gene using F1/R5 primers for 
samples 1-22. The bands on the gel show the respective 16S rRNA gene amplicons from the 
respective strains as given in the key. 
 
KEY: L: Fast DNA Ladder; 1: 02-158#10; 2: 02-138#6; 3: 02-128*#3; 4: 02-139#9; 5: 02-  
209#4;  6:  02-138#3;  7:  02-139#18;  8:  02-118#4;  9:  02-251#1;  10:  02-221#16;  11:  02-  
251#253; 12: 03-013#19; 13: 02-128*#1; 14: 02-118#5; 15: 04-044RT1; 16: 02-251#136; 17:  
04-015#8; 18: 02-118#8; 19: 02-139#14; 20: 02-203#1; 21: 02-209#2; 22: 02-221#26; N:  
negative control. 
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Figure 4.7: The agarose gel picture for amplification of the 16S rRNA gene using F1/R5 primers for 
samples 18-30. Samples 18-22 were included in this amplification for the second time since they had 
been amplified already as shown in Fig 4.6. The bands on the gel show the respective 16S rRNA gene 
amplicons from the respective strains as given in the key. 
 
KEY: L: Fast DNA Ladder; 18: 02-118#8; 19: 02-139#14; 20: 02-203#1; 21: 02-209#2; 22: 
 
02-221#26. 23: 02-231#25; 24: 02-251#10; 25: 02-251#135; 26: 02-251#16; 27: 02-251#274; 
 
28: 02-251#322; 29: 02-251*#36; 30: 04-015#16; N: Negative control. 
 
All the bands that were observed under UV illumination required size interpretation against 
the reference FAST DNA ladder shown in Figure 4.8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: An image showing the demarcations, on the Fast DNA ladder (Biolabs), that are used to 
estimate the size of amplicons [in kilobases (kb)] of amplicons generated. 
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Sequences from the amplicons generated from 16S rRNA gene PCR identified the strains to 
belong to the genus Micromonospora, with the exception of strains 02-251#136 and 02-
251#135 (Table 4.3). 
 
Table 4.3 Top hits of proven similarity-based searches of Micromonospora strains against quality-
controlled databases of 16S rRNA sequences (EzBioCloud) 
 
Strain Original ID Hit Taxon name Hit Strain Similarity Sequence GC 
No.   name % Length (bp) % 
       
1 02-158#10 Micromonospora tulbaghiae DSM 45142 98.82 1 366 60.1 
       
2 02-138#6 Micromonospora aurantiaca ATCC 27029 100.00 1 351 60.2 
       
3 02-128*#3 Micromonospora aurantiaca ATCC 27029 100.00 1 362 60.5 
       
4 02-139#9 Micromonospora tulbaghiae DSM 45142 98.82 1 368 60.1 
       
5 02-209#4 Micromonospora aurantiaca ATCC 27029 100.00 1 348 60.2 
       
6 02-138#3 Micromonospora aurantiaca ATCC 27029 100.00 1 350 60.1 
       
7 02-139#18 Micromonospora tulbaghiae DSM 45142 100.00 1 366 60.1 
       
8 02-118#4 Micromonospora citrea DSM 43903 98.52 1 363 60.1 
       
9 02-251#1 Micromonospora aurantiaca ATCC 27029 100.00 1 351 60.2 
       
10 02-221#16 Micromonospora aurantiaca ATCC 27029 100.00 1 362 60.1 
       
11 02-251#253 Micromonospora tulbaghiae DSM 45142 99.78 1 368 60.1 
       
12 03-013#19 Micromonospora aurantiaca ATCC 27029 100.00 1 361 60.3 
       
13 02-128*#1 Micromonospora aurantiaca ATCC 27029 100.00 1 361 60.3 
       
14 02-118#5 Micromonospora tulbaghiae DSM 45142 98.82 1 352 60.5 
       
15 04-044RT1 Micromonospora chokoriensis DSM 45160 98.59 1 294 60.0 
       
16 02-251#136 Jishengella endophytica 202201 97.19 1 366 60.5 
       
17 04-015#8 Micromonospora tulbaghiae DSM 45142 100.00 1 366 60.1 
       
18 02-118#8 Micromonospora aurantiaca ATCC 27029 100.00 1 351 60.2 
       
19 02-139#14 Micromonospora tulbaghiae DSM 45142 99.78 1 366 60.0 
       
20 02-203#1 Micromonospora citrea DSM 43903 99.41 1 363 60.3 
21 02-209#2 Micromonospora aurantiaca ATCC 27029 100.00 1 355 60.1 
       
22 02-221#26 Micromonospora aurantiaca ATCC 27029 100.00 1 361 60.3 
       
23 02-231#25 Micromonospora tulbaghiae DSM 45142 99.41 1 352 60.5 
       
24 02-251#10 Micromonospora tulbaghiae DSM 45142 99.41 1352 60.5 
       
25 02-251#135 Jishengella zingiberis PLAI 1-1 99.93 1366 60.0 
       
26 02-251#16 Micromonospora aurantiaca ATCC 27029 100.00 1348 60.2 
       
27 02-251#274 Micromonospora aurantiaca ATCC 27029 100.00 1348 60.2 
       
28 02-251#322 Micromonospora citrea DSM 43903 99.38 1302 60.3 
       
29 02-251*#36 Micromonospora aurantiaca ATCC 27029 100.00 1337 60.1 
       
30 04-015#16 Micromonospora aurantiaca ATCC 27029 100.00 1 352 60.2 
       
 
 
* * The strains in bold and red are the five top strains according to antimicrobial activity 
performed (as described in the relevant sections). 
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4.6 Multi-Locus Sequence Analysis (MLSA) 
 
The gel pictures for those PCRs that were positive (as viewed under UV light) in the MLSA 
study are shown in Figures 4.9 a, b and c. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 a: The agarose gel picture for amplification of the rpoB gene using MYCOFi / MYCORi 
primers for strains 1, 2, 4, 5 and 8. The bands on the gel show the respective rpoB amplicons from the 
respective strains as given in the key. 
 
KEY: L: Fast DNA Ladder; 1: 02-128*#1; 2: 04-015#16; 4: 02-128*#3; 5: 02-251*#36; 8: 02- 
 
209#4; N: negative control; X: 500 bp  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 b: The agarose gel picture for amplification of the gyrB gene using the GYF1 /GYR1B 
primer pair for strains 1, 2, 4, 5 and 8. The bands on the gel show the respective gyrB amplicons from 
the respective strains as given in the key. 
 
KEY: L: Fast DNA Ladder; 1: 02-128*#1; 2: 04-015#16; 4: 02-128*#3; 5: 02-251*#36; 8: 02- 
 
209#4; N: negative control; X: 1 kb 
 
67 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 c: The agarose gel picture for amplification of the gyrB gene using the GYF3 /GYR3B 
primer pair for strains 1, 2, 4, 5 and 8. The bands on the gel show the respective gyrB amplicons from 
the respective strains as given in the key. 
 
KEY: L: Fast DNA Ladder; 1: 02-128*#1; 2: 04-015#16; 4: 02-128*#3; 5: 02-251*#36; 8: 02- 
 
209#4; N: negative control; X: 1 kb 
 
4.7 Phylogenetic analysis 
 
The four phylogenetic trees (for the genes gyrB, rpoB and 16S rRNA genes, as well as the 
concatenated tree) that were constructed using the MEGA X programme are given in Figures 
4.10, 4.11, 4.12 and 4.13. The tree algorithm presented in all these figures is the neighbour-
joining algorithm. The maximum likelihood and minimum evolution tree algorithms for all the 
phylogenetic trees given in Figures 4.10 to 4.13 are presented in Annexures A (16 S rRNA 
gene phylogenetic trees), B (gyrB phylogenetic trees), C (rpoB phylogenetic trees) and D 
(Concatenated sequences phylogenetic trees) . 
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Figure 4.10: The phylogenetic relationships between the 16S rRNA gene sequences of the Micromonospora 
strains 02-128*3, 02-209#4, 02-128*1, 02-251*36, 04-015#16 with 30 other type strains of other Micromonospora 
species are shown in the Neighbour-joining tree (Saitou & Nei, 1987). Strains 02-128*3, 02-209#4, 02-128*1, 02-
251*36 and 04-015#16 are shown in red. The Kitasatospora aburaviensis NRRL B-2218 was used as an 
outgroup. The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances 
used to infer the phylogenetic tree. The evolutionary distances were computed using the Maximum Composite 
Likelihood method and are in the units of the number of base substitutions per site. This analysis involved 36 
nucleotide sequences. All ambiguous positions were removed for each sequence pair (pairwise deletion option). 
There were 1338 positions in the final dataset. Evolutionary analyses were conducted in MEGA X (Kumar et al., 
2018). 
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Figure 4.11: A Neighbour-joining phylogenetic tree (Saitou & Nei, 1987), is shown between the MLSA 
derived composite sequences of the 5 Micromonospora strains (02-128*3, 02-209#4, 02-128*1, 02-
251*36, 04-015#16) and Type strains of other Micromonospora genus. During the construction of this 
particular tree, the 5 Micromonospora strains were presented as concatenated sequences obtained by 
combining their individual 16S sequences, gyrB and rpoB gene sequences from the MLSA study. The 
same order of sequence assembly was maintained for all the strains. Strains 02-128*3, 02-209#4, 02-
128*1, 02-251*36 and 04-015#16 are shown in red. The tree is drawn to scale, with branch lengths in 
the same units as those of the evolutionary distances used to infer the phylogenetic tree. The 
evolutionary distances were computed using the Maximum Composite Likelihood method and are in 
the units of the number of base substitutions per site. This analysis involved 24 nucleotide sequences. 
All ambiguous positions were removed for each sequence pair (pairwise deletion option). There were 
a total of 2837 positions in the final dataset. Evolutionary analyses were conducted in MEGA X (Kumar 
et al., 2018). 
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Figure 4.12: An unrooted Neighbour-joining phylogenetic tree (Saitou & Nei, 1987), is shown between 
the rpoB gene sequences of the 5 Micromonospora strains (02-128*3, 02-209#4, 02-128*1, 02-
251*36, 04-015#16) and strains of other Micromonospora genus. The tree is drawn to scale, with 
branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic 
tree. The evolutionary distances were computed using the Maximum Composite Likelihood method 
and are in the units of the number of base substitutions per site. This analysis involved 24 nucleotide 
sequences. All ambiguous positions were removed for each sequence pair (pairwise deletion option). 
There were a total of 602 positions in the final dataset. Evolutionary analyses were conducted in 
MEGA X (Kumar et al., 2018). 
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Figure 4.13 An unrooted Neighbour-joining phylogenetic tree (Saitou & Nei, 1987), is shown between the gyrB 
gene sequences of the 5 Micromonospora strains (02-128*3, 02-209#4, 02-128*1, 02-251*36, 04-015#16) and 
strains of other Micromonospora genus. The tree is drawn to scale, with branch lengths in the same units as those 
of the evolutionary distances used to infer the phylogenetic tree. The evolutionary distances were computed using 
the Maximum Composite Likelihood method and are in the units of the number of base substitutions per site. This 
analysis involved 32 nucleotide sequences. All ambiguous positions were removed for each sequence pair 
(pairwise deletion option). There were a total of 987 positions in the final dataset. Evolutionary analyses were 
conducted in MEGA X (Kumar et al., 2018). 
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4.8 antiSMASH genomic information 
 
The antiSMASH analysis to predict the BGCs present in the genomes of published Micromonospora species was carried out and the outcome 
is presented in the info graphics presented in this section. For each species, the sequential arrangement of the predicted BGCs is given and 
below that, identities of the actual BGCs predicted are given. A key to define the necessary BGC, which are provided in short form, is provided 
at the end of the section. 
 
Micromonospora auratinigra  
 
 
 
 
 
1)NRPS,T1PKS__2)NRPS-L__3)Ter__4)T2PKS__5)Thio__6)Oligo,PKS-L,T2PKS__7)T1PKS__8)NRPS,T1PKS__9)T1PKS__10)Ter,Bac__11)Ter__12)T3PKS__13)Ter__14)Ter__15)NAGGN 
 
Micromonospora coriariae  
 
 
 
 
 
1)Ter__2)Ter__3)T3PKS__4)Ter__5)Bac,Ter__6)Sid__7)T2PKS__8)Ary__9)Ter__10)NRPS,T1PKS11)Thio,LAP 
 
Micromonospora aurantiaca  
 
 
 
 
 
1)Ter__2)Ter__3)NAGGN__4)NRPS__5)NRPS,T1PKS__6)T1PKS__7)Sid,NRPS,T1PKS,PKS-L__8)NRPS,T1PKS__9)Ter__10)T2PKS__11)NRPS,Oli,Ter__12)PKS-L,NRPS,T-PKS__ 
 
13) Oli, T2PKS__14) Lan__15) Ter, Bac__16) Ter__17) T3PKS__18) Lan 
 
Micromonospora chersina  
 
 
 
 
 
1)T3PKS,NRPS__2)T2PKS__3)Lan__4)Ter__5)Bet__6)NRPS,T1PKS__7)Sid__8)NRPS__9)NRPS,T1PKS__10)NAGGN__11)Ter__12)Ter__13)T1PKS__14)T3PKS__15)Ter__16)Bac__17)PKS-L 
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Micromonospora chokoriensis  
 
 
 
 
 
1)LAP,Bac__2)Sid__3)Ter__4)T3PKS__5)Ter__6)Bac__7)NRPS,T1PKS,Ter__8)T1PKS,Thi,LAP,T2PKS__9)Sid__10)T2PKS__11)Lan__12)Ter__13)T1PKS,Beta__14)Lan 
 
Micromonospora echinaurantiaca  
 
 
 
 
 
1)Ter__2)Bac__3)Sid__4)NRPS-L__5)Thi,LAP__6)NRPS__7)Ter__8)NRPS__9)T2PKS,Aryl__10)NRPS,T1PKS__11)NAGGN__12)T3PKS__13)Ter 
 
Micromonospora coxensis  
 
 
 
 
 
1)Ter__2)Lan__3)NRPS__4)Lan__5)T2PKS__6)NRPS,T1PKS__7)Ter,Bac__8)Ter__9)T3PKS__10)Ter__11)Ter__12)NAGGN__13)Sid__14)NRPS-L__15)NRPS,T1PKS__16)NRPS,T1PKS__ 
 
17) NRPS__18) NRPS 
 
Micromonospora inositola  
 
 
 
 
 
1)NAGGN__2)Ter__3)Ter__4)T3PKS__5)Ter__6)Bac,Ter__7)T2PKS__8)Ter__9)Beta 
 
Micromonospora echinofusca  
 
 
 
 
 
1)NRPS-L__2)Ter__3)Bac,Ter__4)Lan__5)NRPS__6)Bac__7)NRPS,Lan__8)T1PKS__9)T2PKS__10)NRPS__11)Beta,NRPS__12)Ter__13)Lan__14)T1PKS,NRPS,Side__15)NRPS__16)Lan__ 
 
17)NRPS,T1PKS,LAP,NRPS-L__18)NAGGN__19)NRPS__20)T1PKS,NRPS__21)Ter__22)NRPS__23)T1PKS__24)Ter__25)NRPS, T1PKS__26)T3PKS,Thi,LAP 
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Micromonospora echinospora  
 
 
 
 
 
1)NRPS__2)NAGGN__3)T1PKS__4)Sid__5)Ter__6)Ter__7)Lan__8)Amg__9)T3PKS__10)NRPS-L__11)T3PKS__12)Ind__13)Ter__14)Bac,Ter__15)NRPS,T1PKS__16)NRPS__ 
 
17)T1PKS__18)NRPS,T1PKS,nuc__19)Lan,Bac__20)NRPS__21)T1PKS,hgIE-KS,Bac__22)NRPS__23)NRPS,T2PKS__24)NRPS,T1PKS,Beta,Lass,PKS-L__25)NRPS,T3PKS__ 
 
26) T3PKS, T1PKS, NRPS__27) NRPS, T1PKS__28) T2PKS, PKS-L, T1PKS. 
 
Micromonospora eburnea  
 
 
 
 
 
1)Ter__2)Ter__3)Thio__4)T2PKS__5)Ter__6)T1PKS,NRPS__7)Sid__8)T1PKS__9)Ter__10)NRPS,T1PKS__11)T1PKS,NRPS,__12)Lan,NRPS__13)Lan__14)NRPS,T1PKS__ 
 
15)Lan,T1PKS,PKS-L__16)Ladd,PKS-L,T1PKS,Oligo,NRPS,Amg__17)Ter,Bac__18)Ter__19)Ect__20)T3PKS 
 
 
KEY    
NRPS-L: NRPS-like PKS-L: PKS-like Lan: Lanthipeptide 
Ter: Terpene Bac: Bacteriocin Beta: Betalactone 
Thio: Thiopeptide Sid: Siderophore Ect: ectoine 
Oligo: Oligosaccharide Aryl:  Arylpolyene Amg: Amglyccycl 
Ind: Indole nuc: nucleoside Lass: Lassopeptide 
t-PKS: transAT-PKS Lad: Ladderane Ect: ectoine 
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4.8.1 PCR screening for Biosynthetic Gene Clusters (BGCs) 
 
Only two out of the 30 strains tested were negative for the amplification of the Type II PKS 
gene. However, all PCR screening for BGCs required for the production of polyene 
antibiotics, polyether ionophores, glycopeptides, ansamycins, beta-lactams, aminoglycosides 
and Type 1 PKS were negative, even after performing gradient PCR and the addition of BSA 
or DMSO. The positive amplification of the Type II PKS gene can be seen in Figure 4.14. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14: The agarose gel picture for amplification of the Type II PKS gene using the ARO-PKS-
F/ARO-PKS-R primer pair for samples 1-30.The bands on the gel show the respective Ketosynthase α 
and Ketosynthase β amplicons from the respective strains as given in the key. 
 
KEY: L: Fast DNA Ladder; 1: 02-158#10; 2: 02-138#6; 3: 02-128*#3; 4: 02-139#9; 5: 02- 
 
209#4;  6:  02-138#3;  7:  02-139#18;  8:  02-118#4;  9:  02-251#1;  10:  02-221#16;  11:  02- 
 
251#253; 12: 03-013#19; 13: 02-128*#1; 14: 02-118#5; 15: 04-044RT1; 16:02-251#136; 17: 
 
04-015#8; 18: 02-118#8; 19: 02-139#14; 20: 02-203#1; 21: 02-209#2; 22: 02-221#26. 23: 
 
02-231#25;  24:  02-251#10;  25:  02-251#135;  26:  02-251#16;  27:  02-251#274;  28:  02- 
 
251#322; 29: 02-251*#36; 30: 04-015#16 
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4.8.2 Analysis of BGC primer sets and known Micromonospora strains 
 
Analysis of BGC primer sets against known Micromonospora strains was an exercise done to 
establish primer knowledge gaps. As a starting point, the BGCs that were targeted by primer 
sets used in the study were searched for within the set of BGCs that were predicted within 
known Micromonospora species in antiSMASH. From this analysis, it was observed that the 
BGCs in our primer sets that were predicted in antiSMASH analysis were Type I and Type II 
PKS. This information would become handy in interpreting the outcome of the PCR-based 
screen. 
 
4.8.3 Alignments for primer design 
 
The sections used for primer design for lanthipeptides [Figure 4.15 a) i) and 4.15 a) ii)] and 
bacteriocins [Figure 4.15 b) i) and 4.15 b) ii)] were found within the alignments of the 
sequences that were downloaded from the genome sequences that were analysed via 
antiSMASH. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15 a) i): Multiple-sequence alignment extract (DNAMAN) that was used as the basis for 
lanthipeptide forward primer design. Positions 21-39 was the exact location of the sequence used. 
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Figure 4.15 a) ii): Multiple-sequence alignment (DNAMAN) that was used as the basis for 
Lanthipeptide reverse primer design. The exact location of the section selected was from position 
1289 to 1307.  
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Figure 4.15 b) i): Multiple-sequence alignment extract (DNAMAN) that was used as the basis for 
bacteriocin forward primer design. Position 85-103 was the exact location of the sequence used.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15 b) ii): Multiple sequence alignment extract (DNAMAN) that was used as the basis for 
bacteriocin reverse primer design. Position 767-785 was the exact location of the sequence used. 
 
4.9 Primer design outcome and oligo-analysis 
 
After the design of the bacteriocin (BAC-F/BAC-R) and lanthipeptide (LAN-F/LAN-R) primers 
based on the multiple-sequence alignments, analysis of these primer pairs was performed. 
The comprehensive results of the design and analysis of the oligonucleotides, which were 
supplied to inqaba biotecTM for oligo-synthesis, are given in Table 4.4. 
 
The synthesis reports for the designed primers were supplied by Inqaba Biotech. The 
synthesis reports for the bacteriocin and lanthipeptide primer pairs are attached as 
Annexures E and F respectively. 
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Table 4.4 Primer design outcome and analysis 
 
   GC  Molecular Expected 
Primer Sequence Length Content Melting weight amplicon 
  /bp % T/oC /g/mole sizes/bp 
       
 5'-CTGCGCTTCGTCGAGGTC- 18 66.70 58.7 5482.6  
BAC-F 3'     400 
       
 5'-CATCAGGGGCAGCGCAAG- 18 66.70 59.7 5558.7  
BAC-R 3'      
       
 5'-TACCIGCIGGAGACCCTG-3' 18 61.1 % 61.3 ºC 5495.6  
LAN-F      850 
       
 5'-CTCGTAGIGGGCGTIGIG-3' 18 61.1 % 62.2 ºC 5607.6  
LAN-R       
       
 
 
4.10 Verification of targeted gene amplification 
 
Both primer sets (BAC-F/BAC-R and LAN-F/LAN-R) did not yield any product upon testing 
them on genomic DNA. Gradient PCR and DMSO enhancement of the PCRs were then 
employed for both primer sets. The lanthipeptide primer pair did not give any sign of product 
amplification even after optimisation. However, a positive product amplification result (420bp-
500bp) of the bacteriocin primer pair, as observed upon performing agarose gel 
electrophoresis, is given in Figure 4.16. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16: The agarose gel picture for the optimised amplification of the bacteriocin gene cluster 
using the designed BAC-F/BAC-R primer pair for strains 1, 2, 4, 5 and 8. The genomic DNA was used 
as PCR template in this case. 
 
KEY: L: Fast DNA Ladder; 1: 02-128*#1; 2: 04-015#16; 4: 02-128*#3; 5: 02-251*#36; 8: 02-  
209#4; N: negative control 
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4.10.1 Sequencing of Bacteriocin amplicons 
 
After processing of the raw sequence data generated from the sequencing of the positive 
bacteriocin gene cluster amplicons, the data was uploaded into BLAST. The results for the 
top sequences that were seen to produce significant alignments are presented in Table 4.5b. 
 
Table 4.5 Sequences producing significant alignments after blastx searches of bacteriocin sequences 
 
 Top sequences producing significant 
Strain identity alignments.   
  
 Dienelactone  hydrolase  [Micromonospora  sp. 
Strain 1 (02-128*#1) CNZ309]   
  
 Daunorubicin resistance protein DrrA family ABC 
Strain 2 (04-015#16) transporter ATP-binding protein 
 [Micromonospora]   
 Daunorubicin resistance protein DrrA family ABC 
Strain 4 (02-128*#3) transporter ATP-binding protein 
 [Micromonospora]   
 ATP-binding cassette domain-containing protein 
Strain 5 (02-251*#36) [Micromonospora sp. B006]  
     
 
 
4.11 Antimicrobial activity studies 
 
The overlay studies carried out to investigate antimicrobial activity were performed on solid 
agar media. The antimicrobial activity of only those strains that showed activity was 
determined by taking the following measurements: colony diameter, diameter of inhibition 
zone and the area of inhibition zone (Figure 4.17 and Figure 4.18). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17: An SGG agar plate for strain 02-251#253 showing two zones of inhibition around the 
bacterial colonies after stab inoculation, incubation and overlaying with Escherichia coli ATCC 25922. 
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Figure 4.18: A 172 F agar plate for strain 02-128*#1 showing the zones of inhibition and bacterial 
colonies after stab inoculation, incubation and overlaying with E. coli ATCC 25922. 
 
The results obtained for the different solid media overlay studies and the three test strains, 
are summarised in Tables 4.6-4.8. Notably, only two strains (04-015#16 and 02-118#8) 
showed activity against the Gram-negative E. coli ATCC 25922 strain only. Five strains (02-
138#3, 02-221#16, 02-138#3, 02-139#18 and 02-251#322) only showed activity against the 
Gram-positive Bacillus cereus ATCC 10876 strain, while strain 02-118#5 is unique in that it 
only showed activity against Candida albicans ATCC 24433. 
 
Most importantly, four strains (02-128*#3, 02-251*#36, 02-139#18 and 02-251#274) depicted 
activity against all three test strains, thus Gram-positive and -negative bacteria as well as a 
yeast. Overall, strains 02-128*#1 (against E. coli ATCC 25922) and 02-128*#3 (against B. 
cereus ATCC 10876) showed the highest activity and this was both in media with and without 
artificial seawater (ASW), respectively. 
 
Table 4.6 shows those Micromonospora strains that showed activity against the E. coli ATCC 
25922 strain. Out of the 30 Micromonospora strains under investigation, twelve strains 
showed bioactivity against E. coli ATCC 25922. The range of activity observed was from 
weak to moderate activity. Strain 02-128*#1 showed moderate activity whilst the rest of the 
strains depicted weak antibacterial activity against the ATCC 25922 strain. 
 
The findings of the antibacterial activity of our Micromonospora strains against B. cereus 
ATCC 10876 are shown in Tables 4.7a and 4.7b. Out of the 30 strains under study, a total of 
twelve were recorded as having some form of activity against B. cereus. Out of the twenty-
eight Micromonospora colonies that showed some form of activity, twelve showed presence 
of aerial mycelium, before overlaying with test strains, on visual inspection. 
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Table 4.6 Activity of Micromonospora strains against E. coli ATCC 25922 
 
 Strain Medium Mycelium Colony diameter Diameter of Area of inhibition zone  
    (mm) inhibition (mm
2)  
     zone(mm)   
 02-128*#1 172F With ASW Present 15,5 41 1130,99  
   Present     
 04-015#16 172F With ASW  6 30,5 701,99  
   Present     
 02-209
*#6 172F  13,5 32,5 686,09  
 02-128*#3       
  SGG Present 5,5 25,5 486,70  
   Present     
 02-251*#36 172F With ASW  4,5 23,5 417,62  
 02-251*#36  Present     
  172F  8,5 24,5 414,48  
 04-015#16 SGG Nil 5 23 395,64  
   Present     
 02-118#4 172F With ASW  7,5 23,5 389,36  
   Present     
 02-139#18 172F With ASW  7 23 376,80  
 04-015#16       
  SGG With ASW Nil 6,5 22 346,77  
   Present     
 02-251#274 172F With ASW  6,5 20,5 296,73  
 02-251#274  Present     
  172F  9,5 21,5 292,02  
 02-251#1 172F With ASW Present 8 19 233,15  
 02-251#1  Present     
  172F  8,5 19 226,67  
 02-128*#1       
  172F Nil 11,5 20 210,18  
 02-118#4       
  172F Present 10,5 19 196,84  
 02-118#8 172F With ASW Nil 3,5 13,5 133,45  
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Table 4.7 a Activity of Micromonospora strains against B. cereus ATCC 10876 
 
Strain Medium Mycelium Colony diameter Diameter of Area of inhibition 
   (mm) inhibition zone (mm
2) 
    zone(mm)  
02-128*#3      
 SGG Nil 4,5 39 1178,09 
02-128*#3      
 172F With ASW Nil 5,5 34 883,71 
02-209#4      
 SGG With ASW Nil 5,5 27,5 569,91 
02-251#274      
 172F With ASW Present 5 26 511,04 
02-138#3      
 SGG With ASW Nil 6 25,5 482,19 
02-221#16      
 SGG With ASW Nil 5,5 24 428,41 
02-251#1      
 SGG With ASW Present 6,5 21 313,02 
02-221#16      
 SGG Nil 5 20,5 310,27 
02-251#253      
 SGG With ASW Present 5 20 294,38 
02-128*#1      
 172F With ASW Nil 3,5 19 273,77 
02-138#6      
 SGG With ASW Nil 5 17,5 220,78 
02-128*#1      
 172F Nil 9 18,5 205,08 
02-251#253      
 172F With ASW Present 5 16,5 194,09 
02-139#18      
 172F Present 16,5 21 132,47 
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Table 4.7 b Activity of Micromonospora strains against B. cereus ATCC 10876 
 
Strain Medium Mycelium Colony diameter Diameter of Area of inhibition 
   (mm) inhibition zone (mm
2) 
    zone(mm)  
02-209#4 172F With ASW Nil 4,5 13 116,77 
02-128*#3 172F Nil 5 13 113,04 
02-221#16 172F With ASW Nil 3,5 12,5 113,04 
02-251#1 172F With ASW Nil 5,5 13 108,92 
02-251#253 172F Present 7,5 13,5 98,91 
02-138#3 172F With ASW Present 4,5 12 97,14 
02-139#18 SGG With ASW Present 3 11,5 96,75 
02-139#18 SGG Present 3,5 11,5 94,20 
02-251#1 172F Present 5 11,5 84,19 
02-251#322 172F Present 4 11 82,43 
02-251*#36 SGG With ASW Nil 6 11,5 75,56 
02-138#6 172F With ASW Nil 4 10,5 73,99 
02-139#18 172F With ASW Present 4,5 10,5 70,65 
02-251*#36 172F Nil 6,5 8,5 23,55 
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Table 4.8 Activity of Micromonospora strains against C. albicans ATCC 24433 
 
    Diameter of  
   Colony diameter inhibition zone Area of inhibition 
Strain Medium Mycelium (mm) (mm) zone (mm
2) 
02-128*#3 SGG With ASW Nil 4,5 24 436,26 
02-251#253 172F Nil 3 19,5 291,43 
02-251#274 172F Nil 3,5 19 273,77 
02-128*#3 172F Nil 4,5 19 267,49 
02-209#4 SGG Nil 9,5 18,5 197,82 
02-128*#3 172F With ASW Nil 4,5 16 185,06 
02-118#4 172F Nil 10,5 18,5 182,12 
02-139#18 SGG Nil 7 16,5 175,25 
02-139#9 172F Nil 3 14,5 157,98 
02-128*#3 SGG Nil 5 14 134,24 
02-139#18 172F With ASW Nil 7,5 15 132,47 
02-118#5 172F Nil 5 11,5 84,19 
02-118#4 SGG With ASW Nil 6,5 11,5 70,65 
02-138#6 172F Nil 3,5 10 68,88 
02-251*#36 172F With ASW Nil 4 9 51,03 
02-251#274 SGG Nil 3,5 8,5 47,10 
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4.12 Bioautography 
 
For this part of the work, the strains were cultured in 172F liquid media. Uninoculated sterile 
media was used throughout as a negative control. Figure 4.19 shows a typical image of the TLC 
plate upon which bioautography against E. coli ATCC 25922 was performed. Figure 4.20 shows 
a heatmap chart, which is a representation of an actual TLC plate (Fig 4.20), for the 
bioautography against C. albicans ATCC 24433. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19: A TLC plate showing the bioautography profiles of the five Micromonospora strains under 
study against E.coli ATCC 25922. The Micromonospora extracts used in bioautography had been 
obtained from liquid cultures cultivated over a 12-day period. 
 
KEY: D3- Extracts from 3-day incubation; D5- Extracts from 5-day incubation; D7-Extracts from 
7-day incubation; D10- Extracts from 10-day incubation; D12- Extracts from 12-day incubation. 
 
S1: 02-128*#1; S2: 04-015#16; S4: 02-128*#3; S5: 02-251*#36; S8: 02-209#4; Ctrl: Media  
Control; Yellow arrows: Typical areas where antibiotic compounds kill test bacteria. 
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Figure 4.20: A heatmap chart showing the bioautography profiles of five Micromonospora strains under 
study against C. albicans ATCC 24433. The Micromonospora extracts used in bioautography has been 
obtained from liquid cultures cultivated over a 12-day period. 
 
KEY: D3- Extracts from 3-day incubation; D5- Extracts from 5-day incubation; D7-Extracts from 
7-day incubation; D10- Extracts from 10-day incubation; D12- Extracts from 12-day incubation. 
 
White spots on the TLC plate signifying typical areas where antibiotic compounds kill 
test bacteria. 
 
 
 
 
Purple spots on the TLC plate. 
 
 
 
S1: 02-128*#1; S2: 04-015#16; S4: 02-128*#3; S5: 02-251*#36; S8: 02-209#4; Ctrl: Media 
Control 
 
To determine whether the type of antibiotic extraction method plays a role in the bioactivity 
observed (Figures 4.21 and 4.22), strains were cultivated for their optimal time periods as 
determined from results reported above. Optimal cultivation periods were specific to the test 
strains used in the experiment above. For bioactivity against C. albicans ATCC 24433, strains 1 
and 8 were both cultivated for 12 days. Strains 2, 4 and 5 were cultivated for 10 days, 5 days 
and 3 days, respectively. For bioactivity against E. coli ATCC 25922, strains 1, 2 and 8 were 
cultivated for 3 days and strains 4 and 5 were cultivated for 7 days and 5 days respectively. 
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Figure 4.21: A TLC plate showing the bioautography profiles of five Micromonospora strains under study 
against C. albicans ATCC 24433. The bioautography profiles of the strains represent activities of extracts 
obtained by different extraction techniques. 
 
KEY: A-Extracts from whole-cell extraction; B- DIAION treatment extracts; C-Cell extracts; D-
Culture filtrate extracts; E-Extracts after dialysis; F-Media control 
 
1: 02-128*#1; 2: 04-015#16; 4: 02-128*#3; 5: 02-251*#36; 8: 02-209#4; Yellow arrows: Typical 
areas where antibiotic compounds kill test bacteria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.22: A TLC plate showing the bioautography profiles of five Micromonospora strains under study 
against E. coli ATCC 25922. The bioautography profiles shown are of the strains that were isolated using 
extracts obtained by different extraction techniques. 
 
KEY: A-Extracts from whole cell extraction; B- DIAION treatment extracts; C-Cell extracts; D-
Culture filtrate extracts; E-Extracts after dialysis; F-Media control 
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1: 02-128*#1; 2: 04-015#16; 4: 02-128*#3; 5: 02-251*#36; 8: 02-209#4; Yellow arrows: Typical 
areas where antibiotic compounds kill test bacteria. 
 
It is important to note that after performing bioactivity analysis using multiple extraction 
techniques, the filtration technique, particularly the filtrates, was observed to give the best 
activity results. 
 
This Chapter focused on presenting all the results obtained in this study comprehensively. It is 
important to interrogate these findings in a manner that seeks to make reference to what has 
been reported in other studies on the current subject matter. Chapter 5, therefore, seeks to fulfil 
this aim and in the process possibly singling out new insights that can be highlighted from the 
study, as well as providing scientific arguments from which conclusions will be drawn in Chapter 
6. 
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CHAPTER 5 
 
DISCUSSION OF FINDINGS 
 
5.1 Introduction 
 
The search for novel antibiotics from various bioactive microbes has become a topical research 
area in recent times, in the wake of the scourge of drug resistant infections such as multi-drug 
resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) amongst 
many others (Carro et al., 2019). Research interest around the biosynthetic potential of the 
Gram-positive, filamentous, spore-producing microorganisms of the family Micromonosporaceae 
has grown of late due to their known biosynthetic potential. For instance, it is an incontrovertible 
assertion from many sources that after streptomycetes, Micromonosporaceae portray the 
greatest specialised bioactivity amongst the Actinobacteria (Habbu et al., 2016; Penesyan et al., 
2015; Zhang et al., 2005). This has led to the phenomenal increase in the description of novel 
species of the genus Micromonospora from as little as 14 in 2000 to 84 at the time of writing 
(http://www.bacterio.net/micromonospora.html; Carro et al., 2012; Kasai et al., 2000; Parte, 
2018). 
 
The family Micromonosporaceae falls under the phylum Actinobacteria and its type genus, as 
proposed by Ørskov, is Micromonospora (Anzai et al., 2012; Carro et al., 2012; Everest & 
Meyers, 2013; Igarashi et al., 2011). Microorganisms of this genus are diversely distributed over 
a wide range of natural habitats on terrestrial environments and marine environments. The last 
half decade has seen the isolation and description of over 20 new Micromonospora species, the 
majority having been isolated from mangrove environments (Wang et al., 2019). The mangrove 
environments are characteristic of abnormally elevated levels of saline, moisture, wind as well as 
osmotic pressures (Jiang et al., 2013). Such strenuous and harsh environments have a strong 
influence on how the microbial population habitant in these areas evolves for the purposes of 
adapting ecologically. This quest for environmental adaptability is the reason why the metabolic 
pathways of Micromonosporaceae progressively evolve to unique sophistication levels (Jiang et 
al., Xu, 2011). Consequently, Micromonosporaceae have been well documented as producers of 
diverse and unique novel bioactive metabolites (Wang et al., 2019). 
 
Examples of commercially available antibiotic compounds that justify Micromonosporaceae as 
biotechnologically important microorganisms include the aminoglycoside antibiotics: sisomicin, 
gentamicin and sagamicin developed from Micromonospora inyonensis, Micromonospora 
echinospora (formerly Micromonospora purpurea) and Micromonospora sagamiensis 
respectively (Kasai et al., 2000; Kyeremeh et al., 2014; Weinstein et al., 1963; Weinstein et al., 
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1970). Micromonospora griseorubida and Micromonospora nigra are also noted in literature as 
sources of two macrolide antibiotics mycinamicin and megalomicin, respectively (Carro et al., 
2018). Other examples of antibiotics from Micromonosporaceae include calicheamicin, netamicin 
and telomycin (Zhao et al., 2017). 
 
Recently, novel marine-sourced bioactive metabolites that have been isolated from 
Micromonosporaceae include the compound rifamycin S, produced by Micromonospora 
rifamycinica AM105, which shows efficacy against methicillin-resistant Staphylococcus aureus 
(MRSA) strains. Another example is butremycin, which is sourced from Micromonospora sp. 
k310 and potent against S. aureus (Wang et al., 2019). Besides antibiotic compounds, 
Micromonosporaceae are also reputable sources of anti-tumour compounds such as lupinacidins 
A and B from Micromonospora lupini (Hirsch & Valdes, 2010). This chapter therefore aims to 
give an interpretation and evaluation of the results obtained in this study, in light of what is 
known in this particular field of research as well as highlighting any new insights. 
 
5.2 Solid and liquid culturing and Gram staining 
 
One of the main objectives of this study was to perform a molecular screen of the marine 
Micromonosporaceae strains present in the BTB culture collection. This, therefore, meant that 
laboratory evidence of the existence of viable Micromonosporaceae strains in the BTB culture 
collection would be the starting point of the study. Thereafter, performing the Gram stain on the 
bacterial strains under study served as an important indicator with regards to their broad Gram-
based categorisation and analysis of culture purity. Consequently, the strains under study were 
cultured and examined on both solid and in liquid media for typical growth patterns and 
morphological characteristics consistent with the genus Micromonospora before performing a 
standard Gram stain. 
 
5.2.1 Solid and liquid media culturing 
 
On solid media, particularly SGG with artificial seawater (ASW) and 172F with ASW, the strains 
presented as bright orange colonies and in some cases with black spore mass upon maturation. 
In liquid cultures, the colonies ranged from bright orange pellets to typically brownish, reddish 
and black pellets similar to patterns reported by Kroppenstedt et al. (2005). Some solid agar 
media plates also showed these range of colony colours. This different range of colony colours 
can be best explained by the different sporulation stages that Micromonosporaceae species 
undergo upon culturing (Ichiwaki et al., 2017). As also highlighted by Trujillo et al. (2010), 
Micromonospora colonies in our study generally became deeper in colour as incubation 
prolonged due to progressive spore production. 
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However, it is important to highlight that the identification of Micromonosporaceae species based 
on colony morphology only is insufficient and inadequate. This is because upon culturing, these 
microorganisms are capable of forming indistinct colony patterns that mimic those of 
microorganisms of the order Actinomycetales. However, given the fact that the strains were 
stored as frozen stock cultures at -80oC prior to commencement of this study, there was 
undoubtedly sufficient laboratory evidence of viable strains, as shown in Figure 4.1. The 
fundamental question being, were these strains indeed from Micromonosporaceae species as 
suggested by the title of our study? 
 
In a molecular-based study such as this one, the need for extraction of a good quality DNA yield 
from bacterial cells can never be overemphasised. Henceforth, as a starting point, it was 
important to have convincing growth of the strains in liquid cultures. Microorganisms of the 
genus Micromonospora and other genera in the family Micromonosporaceae are noted in 
literature as generally slow growers (Carro et al., 2012; Cross, 1981; Kirby & Meyers, 2010). 
Although this corroborated with what was observed in our study, it goes without doubt that the 
quantity of growth (at least 0.5 ml cell mass per strain) we observed in liquid cultures was going 
to be sufficient in yielding a sufficient genomic DNA quantity upon extraction. In fact, it was 
observed that incubating the cultures for 2-3 days longer than the prescribed timeframes for both 
solid and liquid media under the same conditions improved yield. These observations can also 
be explained by the bacterial growth curve shown in Figure 5.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: A bacterial growth curve showing the four phases of bacterial growth within colonies (Rolfe et 
al., 2012). The growth curve typically outlines the progression of growth of bacterial colonies in culture 
media as incubation time progresses. 
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It was generally observed that under optimal culture conditions, the strains followed a typical 
growth curve pattern. The first 2-3 days of incubation of liquid cultures did not result in any 
noticeable macroscopic changes in terms of both colony count and discolouration of the liquid 
media. This would be the lag phase of the liquid cultures. As the incubation period progressed 
over 4-10 days, distinct numerous large orange pellets rapidly increased in the liquid cultures. 
This phase is the exponential phase shown in Figure 5.1. It is characteristic of rapid metabolism 
and exponential consumption of culture media nutrients by cultured bacteria, thus leading to the 
macroscopically visible increase of colonies and discolouration of the agar media from clear to 
brownish-orange (Rolfe et al., 2012). 
 
Employing a slight increment in incubation period to 12-13 days ensured an even better DNA 
yield since this equated to the stretching of the exponential phase to full capacity to ensure a 
comprehensive cell mass yield. The death phase on the curve signifies a period of limited 
nutrients due to increased competition for survival as growth diminishes gradually to a halt. 
However, the growth of strains in liquid media cultures was sufficient (more than 0.5 ml cell mass 
could be harvested) for successful DNA extraction. 
 
5.2.2 Gram stain 
 
It is noted in literature that microorganisms of the genus Micromonospora, being members of the 
order Actinomycetales, are Gram-positive in nature (Chaudhary et al., 2013; Sharma et al., 
2014). Further to this, Micromonosporaceae are known to exhibit numerous filaments and 
spores upon observing their Gram stain as highlighted by Das et al. (2008). It was, therefore, 
imperative in this study to perform the Gram stain to observe whether the outcome was 
consistent with literature. In fact, the classification of microorganisms is a multifaceted process 
that is better and more accurately done by considering both genotypic and phenotypic traits, thus 
polyphasic taxonomy (Chuny & Rainey, 2014). 
 
The Gram stain also served as a technique to ascertain the purity of the liquid cultures in this 
study, as mentioned earlier. In the event that two Micromonospora strains co-existed in a single 
colony, this would be picked up at 16S rRNA gene sequence analysis, whereby chromatograms 
generated as sequencing output would reveal a lot of background sequencing noise. Consistent 
with the Gram stain findings of Micromonospora cremea sp. nov. and Micromonospora 
zamorensis sp. nov. as described by Carro et al. (2012), all 30 strains in this study were 
observed to be Gram-positive. Some of the isolates such as strain 02-251#1 (Figure 4.2 B) 
showed spores under oil immersion (100x magnification), while many isolates such as 02-203#1 
showed numerous filaments with isolated spores (Figure 4.2 A). 
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The visualisation of Gram-positive isolates with multiple filaments and spores was consistent 
with what other studies have reported (Carro et al., 2012; Everest & Meyers, 2013; Hisch & 
Valdes, 2009; Kirby & Le Roes-Hill, 2009). However, the Gram stain as a sole technique is not 
adequate and conclusive in conferring any identity to a particular genus of microorganisms such 
as Micromonospora. Other supporting confirmatory tests that could be carried out include 
determining whether the isolates have the characteristic DAP isomer (meso-diaminopimelic acid) 
and whole-cell sugars (xylose and arabinose) for the genus (Thawai et al., 2018). Further to this, 
the Micromonospora strains could have also been characterised by physiological and 
biochemical methods as described by Chantongcome et al. (2009). These approaches were, 
however, not pursued for strain characterisation in this study. This is because these 
chemotaxonomic methods are outdated and the newer DNA-based methods, such as 16S rRNA 
gene sequencing and MLSA, are superior and have better strain resolution. 
 
5.3 Verification and quantification of isolated DNA 
 
5.3.1 Verification of isolated DNA 
 
After successful culturing of the strains under study in liquid cultures, DNA isolation was 
performed as outlined in section 3.4.1 using the method described by Mandel and Marmur 
(1968). Two factors that were going to be of paramount importance in the study are the quality 
and quantity of the extracted DNA from the Micromonospora strains (Weber et al., 2017). In a 
molecular based research study involving extraction of DNA from bacterial cells, the ability to 
separate DNA fragments is of uttermost importance. Sambrook and Russell (2001) highlighted 
agarose gel electrophoresis (AGE) as the most efficient laboratory technique to achieve such 
separation. Lee et al. (2012) corroborated with this notion and further highlighted that DNA 
fragments of up to 25kb are separable by AGE. 
 
Figure 4.3 shows an agarose gel picture of genomic DNA extracted from Micromonospora 
strains 1 to 15 under UV light. With the exception of strains 10 (02-221#16) and 15 (04-044RT1), 
all other lanes on this gel show successful DNA extraction as depicted by the distinct brightly 
illuminated genomic-DNA (gDNA) bands under UV light. The illumination of these gDNA bands 
under UV is due to the intercalation of ethidium bromide in the gel. 
 
Strain 11 (02-251#253) showed a smeared band on agarose gel under UV light. This does not 
entirely signify failure in extraction, but rather extracted DNA of poor quality. Such smearing can 
be caused by various shortcomings, chief amongst them degradation of gDNA by nucleases, 
elevated salt concentrations within samples and excess sample to loading dye ratio (Kirkpatrick, 
1991). From the gel shown in Figure 4.3, it meant that strains 10, 11 and 15 had to undergo 
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gDNA extraction again. It was, however, also an option to re-run the same DNA samples for 
strain 11 in order to figure out whether the reason for smearing on agarose was pre-extraction or 
post-extraction related. 
 
The gel picture in Figure 4.4 shows the gDNA of strains 16 to 30 under UV light after 
electrophoresis. Strains 26 and 27 also showed smeared DNA product and had their DNA re-
extracted. After performing repeat DNA extractions on samples 10, 11, 15, 26 and 27, an 
agarose gel picture was run and captured, as shown in Figure 4.5. In this gel picture, all 5 strains 
showed distinct DNA bands under UV light signifying successful DNA extraction. It is however 
notable that strain 27 still gave a faint band on agarose, likely due to a possible low DNA 
concentration. 
 
5.3.2 Quantification of isolated genomic DNA 
 
Quantification of the extracted gDNA was performed using the Genova Life Science 
spectrophotometer and the results are shown in Tables 4.1 (original extraction) and 4.2 (re-
extractions). On this particular instrument, an extracted DNA quantity of at least 20 µg/ml is 
regarded as sufficient for further use in PCRs (Bibby Scientific, 2017). As shown in Table 4.1, 
the DNA quantities for the majority of the strains were above the required 20 µg/ml level. The 
notable exceptions were strains 10, 11, 15, 26 and 27. DNA quantities of samples 10 and 15 
corroborate with the faint DNA bands, as shown on the agarose gel in Figure 4.3. Samples 11, 
26 and 27 did not necessarily have low DNA quantities as also shown in Table 4.2; instead, their 
DNA smeared on electrophoresis hence the decision to re-isolate the gDNA. 
 
Figure 4.5 shows successful DNA extraction as signified by the brightly illuminated distinct bands 
on agarose, which corroborates with DNA quantities shown in Table 4.2. Sample 27’s DNA 
quantity of 22.40 µg/ml, was deemed sufficient for further analysis as per the manufacturer’s 
instructions (Bibby Scientific, 2017). 
 
5.4 16 S rRNA gene analysis 
 
The objectives of this research study were based on the precept that the microorganisms under 
study were of the genus Micromonospora, family Micromonosporaceae. Despite partly 
elucidating the morphological characteristics of the strains under study, the morphological 
features observed under a light microscope in section 5.2.2 do not provide conclusive evidence 
of the genus’s identity of the microorganisms. Therefore, it became imperative to amplify the 16S 
rRNA gene for all the strains and analyse the sequences thereof. 
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5.4.1 16S rRNA gene sequencing 
 
The study of phylogeny and taxonomy in bacterial species is a process in which the use of the 
16S rRNA gene sequencing is of uttermost importance (Carro et al., 2017; Case et al., 2006; 
Janda & Abbot, 2007). The importance of the 16S rRNA gene is centred upon the fact that it 
contains hypervariable regions that are species-specific, hence important in the identification of 
bacterial strains. The 16S rRNA gene is, therefore, well conserved. The primer pair used for 
gene sequencing of the 16S rRNA gene ought to be universal in nature to enable them to match 
the highly conserved regions of the gene (Janda & Abbot, 2007). 
 
Fundamentally, it is important to note that the entire technique of 16S rRNA gene sequencing 
and analysis finds its basis in the detection of polymorphisms within the 16S rRNA genes of 
closely related species. The focal points of such detection within the 16S rRNA genes are the 
hypervariable regions (Carro et al., 2017). The use of the universal F1/R5 16S rRNA primers 
described by Cook and Meyers (2003) allowed us to be able to successfully amplify the near full 
length 16S rRNA genes of the 30 strains under study and identify the genera to which they 
belonged. 
 
Figure 4.6 shows an agarose gel image for the 16S rRNA gene amplification for strains 1 to 22, 
as well as the Fast DNA ladders. All strains show positive 16S rRNA PCR product as signified by 
the illuminating DNA bands on the gel. Using the FAST DNA ladder as a fragment size 
reference, the established DNA bands for samples 1 to 22 were estimated to be 1400 bp 
(Thanaboripat et al., 2015). Kirby and Le Roes-Hill (2009) highlighted that a sequence of at least 
1350 bp is sufficient when describing novel species. This meant that, depending on the 
percentage similarity of the strains under study in comparison to published strains, strain novelty 
was a possibility. 
 
Figure 4.7 shows an agarose gel image for samples 18-30. All strains on this agarose gel image 
showed a positive 16S rRNA PCR product which also had an estimated band size of 1400 bp as 
referenced to the FAST DNA ladder shown in Figure 4.8. The next important stage after 
amplifying the 16S rRNA gene was to sequence the gene for all strains, and analyse the 
sequences generated. 
 
5.4.2 16S rRNA gene sequence output analysis 
 
A vast amount of inferences can be made from sequence data derived from the sequencing of 
the 16S rRNA gene. Many credible bioinformatics tools have been used by taxonomists to 
objectively identify novel bacterial species based on the 16S rRNA gene (Chun et al., 2007). 
However, in this study, we used the EzTaxon gene database as the preferred database to 
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analyse the 16S rRNA gene sequences of the strains under study. The choice of EzTaxon over 
common public databases such as Genbank, was based on the fact that EzTaxon only contains 
sequence data that is peer-reviewed for type strains, thus providing more reliable filtered 
sequences (Clayton et al., 1995; Mellmann, 2003). 
 
As shown in Table 4.3, 28 of the 30 strains (93.3%) in our study were found to belong to the 
genus Micromonospora. Two of the 30 strains (6.7%) under study were found to belong to the 
Jishengella genus. However, it should be noted that the genus Jishengella belongs to the family 
Micromonosporaceae and the morphological features of this genus resembles that of 
Micromonospora (Thawai et al., 2018; Xie et al., 2011). This, therefore, validated the culture-
based morphological findings and the Gram stain findings in sections 5.2.1 and 5.2.2 
respectively, which pointed out to typical Micromonosporaceae characteristics amongst all the 
strains under study. Consequently, all 30 strains in our study were found to belong to the family 
Micromonosporaceae according to sequence data generated from 16S rRNA gene sequencing 
and analysed by EzTaxon. 
 
The closest published strains similar to the strains under study are also shown in Table 4.3. 
From the table, it can be observed that the similarity of the 16S rRNA sequences between our 
strains and their established closest known counterparts ranges between 97.19% and 100%. 
The highest similarity of 100% was seen between 15 of the strains (02-138#6, 02-128*#3, 02-
209#4, 02-138#3, 02-251#1, 02-221#16, 03-013#19, 02-128*#1, 02-118#8, 02-209#2, 02-
221#26, 02-251#16, 02-251#274, 02-251*#36, 04-015#16) and the strain Micromonospora 
aurantiaca ATCC 27029T. The 16S rRNA gene sequence of one strain under study (02-139#18) 
was also found to have a 100% similarity with that of the strain Micromonospora tulbaghiae DSM 
45142T. The strain under study that showed the lowest match of its 16S rRNA gene sequence 
with that of its closest match (Jishengella endophytica 202201) was 02-251#136 with a match of 
97.19% and may represent a novel species. 
 
The description and reporting of any species, as novel, requires a particular 16S rRNA gene 
sequence of a strain to be at least less than 97.5% similar to its closest neighbour in a sequence 
alignment (Kirby & Le Roes-Hill, 2009). A gene sequence-similarity value above the 97.5% cut-
off would require the performance of DNA-DNA hybridisation (DDH) and/or genome sequencing 
before a species is concluded to be novel. Only five of the 30 Micromonosporaceae strains 
shown in Table 4.3 were included in a phylogenetic tree, together with validly published type 
strains of the genus, as described in section 3.6, mainly because these strains served as the 
basis for extended antimicrobial activity testing. 
 
98 
It is notable that all the strains in Table 4.3, except strain 02-251#136, depict gene sequence-
similarity values over the 97.5% cut-off for novel sequence description. This implies that only 
strain 02-251#136 would qualify as a candidate for novelty designation without necessarily 
undergoing DDH and/or genome sequencing (Kirby & Le Roes-Hill, 2009). However, the 
uniqueness of a particular strain cannot be solely argued around the basis of its 16S rRNA gene 
sequence being less than 97.5% similar to its closest phylogenetic neighbour. The uniqueness 
should be beyond reasonable doubt phenotypically, genotypically and biochemically, hence 
polyphasic-based novelty. 
 
It can, therefore, be noted that 16S rRNA gene sequencing and analysis becomes handicapped 
at the species level (Yoon et al., 2017). In other words, we cannot use the information in Table 
4.3 as exclusive evidence of gene sequence-similarity with existing type strains even in cases 
whereby their 16S rRNA gene sequences have a 100% match. The same can be said about 
decisions on strain novelty based on 16S rRNA gene sequence similarities with closest 
phylogenetic neighbours. Therefore, the use of 16S rRNA sequence-sequence comparisons is 
merely a way of identifying bacterial strains that fall into similar genera without necessarily giving 
information of their interspecies relatedness (Kim, 2014; Quast et al., 2013) 
 
Table 4.3 also shows a column where sequence lengths for all the strains’ 16S rRNA gene were 
recorded. The sequence lengths ranged from 1294 bp to 1368 bp with a calculated median of 
1353 bp. On average, the sequence length of the 16S rRNA gene is 1400 bp (Ichiwaki, 2017). 
The range of the 16S rRNA sequences obtained in our study is close to the known average. It is 
important to note that this slight deviation is possibly encountered during editing of sequences in 
Chromas Lite (Version 2.6) programme (Technelysium), post-sequencing. The sequences tend 
to get slightly shorter due to base eliminations in cases of ambiguity and mismatch, and this is 
carried over to sequence assembly. 
 
Micromonosporaceae are known to have a high GC content in their genomes (Atlas, 1997; 
Ventura et al., 2007). A high genomic GC content would typically be 60% and above (Doroghazi 
 
& Metcalf, 2013). Table 4.3 shows that for all our strains, the GC content of the sequenced 16S 
rRNA gene was slightly above 60% with an observed variation within the 0% - 0.5% range. It 
should, however, be noted that the high GC content that is referenced in literature as a typical 
characteristic of the Micromonosporaceae family, is total genomic GC content as opposed to 
16S rRNA GC content. This is because the 16S rRNA, being a highly conserved gene, has a GC 
content that remains fairly constant in terms of size, a concept which corroborates with our 
findings as shown in Table 4.3. The GC content of strains in our study suggests that all of them 
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had a high GC content, consistent with what is known about the Micromonospora genus (Carro 
et al., 2012; Maldonado & Quintana, 2015; Trujilo et al., 2014). 
 
5.5 Phylogenomic analysis 
 
After establishing the genus that our 30 strains were classified under, five of the strains that were 
chosen for further study based on their bioactivity had selected sequences analysed through the 
use of phylogenetic trees to explore their evolutionary relatedness. This was achieved by 
constructing phylogenetic trees based on 16S rRNA gene sequences and the genes sequences 
targeted in the MLSA study, outcome of which is discussed in this section. 
 
5.5.1 16S rRNA phylogeny 
 
16S rRNA gene sequencing performed in this study aided in identifying the strains under study 
to genus level. In order to get better insight into the evolutionary relatedness of the five 
Micromonospora strains selected for further study and type strains of the Micromonospora 
genus, the 16S rRNA sequences were incorporated into a Neighbour-joining phylogeny tree 
presented in Figure 4.10. This tree is supported by the maximum likelihood and minimum 
evolution tree algorithms presented in Annexure 1. From the phylogenetic tree, it was observed 
that all five strains were deduced to be closely related to the strain Micromonospora aurantiaca 
ATCC 27029T. 
 
5.5.1.1 The significance of Micromonospora aurantiaca 
 
The representative genome for the strain M. aurantiaca, as deposited into GenBank is that of its 
type strain M. aurantiaca ATCC 27029T. Six other strains of this species have also been 
described and these are M. aurantiaca 110B, M. aurantiaca DSM 45487, M. aurantiaca L5, M. 
aurantiaca NRRL B-2673, M. aurantiaca RV43 and M. aurantiaca WMMB 235 (Wang et al., 
2019). 
 
The strain M. aurantiaca 110B was isolated by Wang and colleagues from China’s Fujian 
province (Wang et al., 2019). From this strain, three novel glycosides were structurally 
elucidated post isolation before investigating their bioactivity against the hepatocarcinoma 
causing HepG2 cell line, the lung tumour-causing A549 cell line and the colon tumour cell line, 
HCT116 (ibid). Further to this, the bioactivity of the compounds against the test strains C. 
albicans, MRSA and E. coli was investigated. Although average cytotoxic activity was reported 
for the three compounds, no significant bioactivity was reported against the bacterial test strains 
and fungi. In this study, antiSMASH analysis was performed for the genomes of the six 
published M. aurantiaca strains (Table 5.1). 
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Fourteen gene cluster types were observed in the antiSMASH results amongst all the M. 
aurantiaca strains as shown in Table 5.1. The predicted BGCs were found to be similar amongst 
all strains except the arylpolyene, transAT PKS-like and Betalactone BGCs that were predicted 
only in some strains. This information would be handy in consideration of gaps in primer 
knowledge in the BTB culture collection, whereby the choice for targets for primer design would 
be amongst those BGCs found within all strains. However, the issue of relevancy of the chosen 
BGC as determined by literature would also be a factor in this regard. 
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Table 5.1 Comparison of BGCs predicted by antiSMASH in the different strains of M. aurantiaca 
 
   M. aurantiaca strains   
BGCs predicted 
       
110B DSM 45487  L5 NRRL B- RV43 WMMB 
 (2018)    2673  235 
        
NRPS ✓ ✓  ✓ ✓ ✓ ✓        
        
T3PKS ✓ ✓  ✓ ✓ ✓ ✓        
        
Terpene ✓ ✓  ✓ ✓ ✓ ✓        
        
Lanthipeptide ✓ ✓  ✓ ✓ ✓ ✓        
        
Siderophore ✓ ✓  ✓ ✓ ✓ ✓        
        
Oligosaccharide ✓ ✓  ✓ ✓ ✓ ✓        
        
TransAT-PKS-like X x  X ✓ ✓ x    
        
NAGGN ✓ ✓  ✓ ✓ ✓ ✓        
        
T2PKS ✓ ✓  ✓ ✓ ✓ ✓        
        
T1PKS ✓ ✓  ✓ ✓ ✓ ✓        
        
PKS-like ✓ ✓  ✓ ✓ ✓ ✓        
        
Bacteriocin ✓ ✓  ✓ ✓ ✓ ✓        
        
Arylpolyene x x  X X ✓ x   
        
TransAT-PKS ✓ ✓  ✓ ✓ ✓ ✓        
        
Betalactone ✓ ✓  ✓ X x x     
        
 
Key: 
✓
 BGC predicted within the strain’s genome 
 
x BGC not predicted within the strain’s genome 
 
The evolutionary relationships established between our five strains and M. aurantiaca ATCC 
27029T as per phylogenomic studies warranted the analysis of BGC distribution within the 
genome of M. aurantiaca. antiSMASH analysis of the genome revealed the presence of a 
diverse array of BGCs spanning over 18 coding regions dominated by gene clusters for 
terpenes, NRPS, T1PKS, siderophore, bacteriocin and lanthipeptide. This finding gives a good 
insight into the possible biosynthetic capabilities of the five strains which were found to be 
closely related to the M. aurantiaca ATCC 27029T strain. Given that limited studies are looking at 
the antimicrobial compounds produced by this strain, it subsequently means any compound 
potentially isolated from any of its closely related five Micromonospora strains would likely be 
novel (Carro et al., 2018). Above all, the variation of BGCs observed amongst various strains 
consequently means that if these Micromonosporaceae species are isolated from different 
marine samples, there is an increased chance of diversity of BGCs that can be accessed. 
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Local alignment between each of the five Micromonospora strains’ 16S rRNA gene and that of 
M. aurantiaca ATCC 27029T was performed in DNAMAN and in all cases sequence similarities 
between 99% and 100% resulted. This, therefore, meant that it would have been helpful to make 
use of DNA-DNA hybridisation or genome sequencing in the quest to conclude on the five 
strains’ novelty. Despite not being within the current scope of this study, biochemical tests, 
particularly physiological characterisation, would also have further elucidated the relationship 
between each of the five Micromonospora strains and their closest evolutionary comparisons; M. 
aurantiaca ATCC 27029T and Micromonospora chalcea DSM 43026T. 
 
5.5.1.2 The significance of Micromonospora chalcea 
 
Micromonospora chalcea is well-known for being the producer of the group of macrolide 
antibiotics known as juvenimicins as well as everninomicin (Hatano et al., 1976). One of the 
compounds produced by M. chalcea, juvenimicin A3, was reported to exhibit bioactivity against 
both Gram-positive and Gram-negative microorganisms, hence broad-spectrum activity (ibid). 
This was important for our strains as it was a hint that due to similar ancestry, we could possibly 
observe one or more of our five strains exhibiting broad-spectrum activity similar to M. chalcea. 
 
5.5.2 Multi-Locus Sequence Analysis study 
 
In order to zoom into the interspecies relationships between the Micromonospora species more 
effectively, performing MLSA studies of housekeeping genes is recommended (Carro et al., 
2018). MLSA analysis is advantageous in that it results in the construction of more robust trees 
(higher bootstrap values) and better resolution (longer branch lengths). The MLSA in our study 
was performed as outlined by Carro et al. (2012) and the housekeeping genes that were 
targeted included recA, atpD, rpoB and gyrB. After optimisation of all PCR reactions, at least the 
rpoB and gyrB genes successfully amplified and their Neighbour-joining phylogenetic trees were 
successfully constructed as given in Figures 4.12 and 4.13, respectively. These are supported 
by the Maximum likelihood and Minimum evolution tree algorithms presented in Annexure 1. 
Fundamentally, the successful amplification of the rpoB and gyrB genes was a positive finding 
since these two have been reported as useful markers in interspecies delineation within the 
Micromonospora genus (Carro et al., 2012). In fact, Hirsch and Valdes (2009) alluded to the fact 
that because of its higher evolutionary rate than the 16S rRNA gene, the gyrB gene is a better 
option in elucidating interspecies relatedness than the 16 S rRNA gene. 
 
As shown in Figure 4.13, the phylogenetic tree incorporating gyrB sequences confirmed the 
ancestral relationships between strains 02-128*3, 04-015#16, 02-128*1 and 02-251*36 with the 
type strain M. aurantiaca ATCC 27029T. This is similar to the evolutionary relationships between 
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these strains and M. aurantiaca ATCC 27029T, established in the 16S rRNA phylogenetic tree 
presented in Figure 4.10. However, strain 02-209#4 positioned as more closely related to the 
type strain Micromonospora echinofusca 43913T than M. aurantiaca ATCC 27029T. The 
difference in the topology of the phylogenetic trees between the gyrB and 16S rRNA sequences 
is an occurrence that is not unusual and has been reported before (Carro et al., 2012; Kirby & 
Meyers, 2010). 
 
Figure 4.12 shows the phylogenetic tree that was constructed based on rpoB sequences. In 
general, this phylogenetic tree confirms the close evolutionary relationships between all 
Micromonospora strains and M. aurantiaca ATCC 27029T, which corroborates with the 
evolutionary relationships presented in the 16S rRNA phylogenetic tree. The only exception is 
strain 02-209#4 which is observed to group more closely with Micromonospora echinofusca 
43913T thus confirming the evolutionary relationships also noted in the gyrB phylogenetic tree. 
The concatenated phylogenetic tree presented in Figure 4.11 shows that the five strains which 
were identical in the 16S rRNA phylogenetic tree begin to differentiate. This observation 
subsequently means that the inclusion of additional housekeeping genes in phylogenetic 
analysis has a capability of resolving intra-strain relationships. The tree was more robust, as 
shown by longer branch lengths. 
 
In order to avoid any ambiguity with regards to the interspecies relatedness of the five strains 
that appear very closely related from phylogenetic studies, their genetic diversity could be 
analysed by performing BOX-PCR and amplified rDNA restriction analysis (ARDRA) (Carro et 
al., 2012). However, these experiments were not pursued in the current study considering the 
cost, tediousness, as well as the main objectives of this study. 
 
5.6 PCR screening for Biosynthetic Gene Clusters (BGCs) 
 
Another important objective of this study was to perform a molecular screen amongst the 
Micromonospora strains, in order to investigate the presence of any of eight BGCs within their 
genomes. This was performed to get insights into the biosynthetic potential of the strains under 
study with reference to common BGCs. The eight BGCs that were screened for are listed in 
Table 3.4. 
 
All of the Micromonospora strains under study, except sample 4 (strain 02-139#9), showed a 
positive PCR reaction for the Type II PKS BG. The Type II PKS BGC was targeted by the use of 
the ARO-PKS-F and ARO-PKS-R primer pair as described by Wood et al. (2007). Using the 
FAST DNA ladder demarcations in Figure 4.8 as a point of reference, the band sizes of the 
amplicons were roughly 600 bp, consistent with what has been reported in other studies (Das & 
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Khosla 2009; Zhang et al., 2017). Since the 16S rRNA gene for strain 02-139#9 amplified 
successfully (Figure 4.5), the failure of amplification of its Type II PKS BGC cannot be attributed 
to PCR inhibitors (Wawrik et al., 2005). Similarly, the sufficiency of the strain’s DNA yield could 
not be singled out as a possible hindrance to the gene cluster amplification. This is because the 
established DNA quantity for strain 02-139#9 was 32.57 µg/ml (Table 4.1), and this had been 
deemed sufficient for further analysis. Based on the positive screen of the Type II PKS gene in 
29 out of 30 strains under investigation, it is important to interpret this finding from a relevancy 
point of view. A new question therefore arises; being the only BGC that was found to be positive 
in the molecular screen, what significance does the presence of the Type II PKS BGC have in 
the broader aim of the study? 
 
5.6.1 The Type II PKS BGC 
 
In broader terms, polyketide synthases (PKSs) are sophisticated enzymes that are involved in 
the synthetic pathways that yield biologically potent metabolites (Selvin et al., 2016). These 
enzymes are subsequently coded for by the Type II PKS BGC, which comprises of the 
ketosynthase-alpha and ketosynthase-beta genes. Khosla et al. (1999) defined PKSs as a group 
of complex enzymes comprising of multiple domains, which are well known for subsequently 
producing secondary bioactive compounds known as polyketides. 
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Figure 5.2: An antiSMASH extract showing the genomic region housing the Beta-ketoacyl synthase core 
biosynthetic genes (locus tag ctg_1 563 and ctg_1 564), which includes ketosynthase alpha and 
ketosynthase beta genes encoding for the Type II PKS gene in M. aurantiaca WMMB 235 T. 
 
In general, bacterial PKSs exist in three distinct groups that are Type I, Type II and Type III. The 
Type II PKSs are involved in the biosynthesis of biologically potent compounds such as 
doxorubicin and tetracycline (Gomez et al., 2013). The biologically potent derivatives of Type II 
PKS enzymes have a wide range of activity such as antibacterial, antiviral, anti-tumour and 
enzyme inhibitory activities (Sun et al., 2012). In the analysis of the antiSMASH results that were 
generated for the published Micromonospora strains, the Type II BGC was predicted in almost 
all of the strains that were selected for analysis, an example of which can be seen in Figure 5.2. 
 
Zhang et al. (2017) further highlighted the significance of the Type II PKS in the synthesis of 
bacterial aromatic polyketides such as pentangular polyphenols and anthracyclines amongst 
many others. The significance of the Type II PKS gene in Micromonospora is seen in many 
examples whereby useful antibiotic compounds have resulted from the secondary metabolites. 
One good example is the polyketide antibiotic maklamicin, which is produced by 
Micromonospora sp. NBRC 110955, with a chemical structure shown in Figure 5.3 (Igarashi et 
al., 2011). 
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Figure 5.3: A chemical structure of Maklamicin, a spirotetronate antibiotic developed from the 
actinobacteria Micromonospora sp. NBRC 110955. The antibiotic is known to be potent against Gram-
positive microorganisms such as Micrococcus luteus. 
 
This antibiotic is effective against a vast range of Gram-positive bacteria such as Micrococcus 
luteus (Igarashi et al., 2011). From the bioactivity observed for the five strains against Bacillus 
cereus, it is therefore, possible that this activity observed could be due to the production of Type 
 
II PKS compounds. After establishing the relevance of the Type II PKS gene, it can be 
concluded that 29 of the 30 strains that had a positive screen for this particular gene have great 
potential of producing other bioactive metabolites, which directly resonates with the aims of this 
study. 
 
5.6.2 Additional BGCs screened for 
 
The section on molecular screening of BGCs focused on eight BGCs in total. As discussed 
already, only one out of these eight BGCs screens yielded a positive outcome, significance that 
has already been outlined. However, it is important to be able to relate the significance of the 
additional BGCs screened for to what we observed in the antiSMASH analysis of known 
Micromonospora strains. Amongst the eight BGCs that were screened for, only Type 1 PKS and 
Type II PKS BGCs were predicted in the antiSMASH results of the known Micromonospora 
species analysed. It is important to note that in some instances, a database such as antiSMASH 
becomes limited as it may predict the absence of certain BGCs within genomes of specific 
microbes, especially if such genomes are incomplete (Medema et al., 2011). Therefore, to cover 
this gap, PCR screening methods are used as an alternative despite possible biases associated 
with these methods. A typical bias with the PCR BGC screening method is that primers may be 
specific to a particular genus/family and will only amplifying genes from these limited taxa. Many 
of the primers in our study were designed specifically for streptomycetes as opposed to 
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Micromonosporaceae. We, therefore, cannot rule out this fact as a causative of negative 
amplification of the intended BGCs (Bervanakis, 2008; Hwang et al., 2007; Wang et al., 2011; 
Wood et al., 2007). However, given the effect of horizontal gene transfers (HGT) of biosynthetic 
genes between different genera and families, it is expected that streptomycete genes will not 
necessarily be confined to this genus. This was the rationale behind using streptomycete-
designed primers in our Micromonospora strains. 
 
Nevertheless, it remains imperative to discuss the rationale behind screening of the rest of the 
BGCs. This is because these BGCs are of immense interest to researchers in novel drug 
discovery for reasons discussed in sections 5.6.2.1 through to 5.6.2.7. 
 
5.6.2.1 Type I PKS 
 
Alternatively known as Modular Polyketide synthases due to their characteristic orientation of the 
individual modules, Type I PKSs are also known to produce potent bioactive compounds and 
they are encoded by the T1PKS gene (Beta-ketoacyl synthase) (Figure 5.4 Image A) (Chen & 
Du, 2016). Just as their Type II counterparts, Type I polyketides are a matter of research 
relevancy due to their diverse bioactivity in their application as antibiotics, antiparasitics, 
immunosuppressants and anti-tumour agents (Fischbach & Walsh 2006). Examples of Type I 
PKS compounds that are sourced from actinobacteria are Avermectin (Figure 5.4 Image B) 
which is sourced from Streptomyces avermitilis and Calicheamicin (Figure 5.4 Image C) from 
Micromonospora calichensis (Chen & Du, 2016). 
 
 
 
T1PKS gene  
 
Image A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Beta-ketoacyl synthase BGC 
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Image B)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Avermectin B1a 
 
 
 
 
Image C)  
 
 
 
 
 
 
 
 
 
 
 
 
 
Calicheamicin 
 
 
 
Figure 5.4: Image A) An antiSMASH extract showing the genomic region housing the Beta-ketoacyl 
synthase core biosynthetic gene encoding the Type I PKS gene in M. aurantiaca WMMB 235 T. All other 
genes associated with the core BGCs such as transport-related, regulatory, resistance and other genes 
are also shown in the figure. Image B and Image C: The chemical structures of Avermectin B1a (an 
anthelmintic and insecticidal agent) and Calicheamicin (an antitumor antibiotic) respectively. These two 
compounds are typical examples of compounds that have biosynthesis in which the T1PKS gene plays a 
pivotal role. 
 
In the molecular screen for BGCs, there was no evidence of the presence of the Type I PKS 
BGC amongst the 30 Micromonospora strains screened. It was important to screen for the 
presence of Type I PKSs since their range of activity covers both fungi and bacteria, thus 
iterative Type I PKSs and Non-Type I PKSs respectively (Cox, 2007; Hertweck, 2009). 
 
5.6.2.2 Cytochrome P450 hydroxylase 
 
The Cytochrome P450 hydroxylases (P450s) are a group of enzymes that are usually found 
within specific BCGs in Micromonospora species, whereby they play a role in the synthesis of 
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bioactive metabolites. Two examples of this group of enzymes are MycG and MycCI which play 
a pivotal role in Micromonospora griseorubida’s biochemical pathway for the synthesis of 
mycinamicin II, a macrolide antibiotic (Anzai et al., 2012). It is important to note that the genes 
that encode for the P450s are embedded within other BGCs. P450s are also known to be 
associated with polyene antibiotics that are potent antifungal agents (Demain & Sanchez, 2009). 
From our findings, as shown in Table 4.4, none of our strains contained a BGC that housed the 
particular genes encoding the Cytochrome P450 hydroxylase. 
 
5.6.2.3 Polyether ionophore 
 
Amongst the vast array of bioactive compounds that are produced by Actinomycetales, polyether 
ionophores stand out as a unique group of compounds synonymous with this order. They are a 
special type of Type I polyketides with a proven record of broad-spectrum activity (Dutton et al., 
1995). Polyether ionophores are part of the broader ionophores family that have their bioactivity 
and antibiotic potency centred upon their ability to use their distinct structural components in 
enabling them to interact effectively with metal species (Kevin et al., 2016). It was very important 
in our study to include the screening for the BGC encoding these compounds since they are 
produced exclusively by actinobacteria (Wang et al., 2011). 
 
5.6.2.4 P450 monooxygenase – glycopeptide 
 
The screen for the BGC encoding for the Cytochrome P450 monooxygenase, involved in 
glycopeptide production, resulted in a negative result for all 30 strains, as shown in Table 4.4. 
The inclusion of this gene cluster in the molecular screen was chiefly based on the known 
activity of the P450 monooxygenase, especially in the biosynthesis of glycopeptide antibiotics. 
Actinobacteria are known to be the source point of glycopeptide antibiotics, which inhibit 
pathogenic bacterial cell wall biosynthesis as their mode of action (Beltrametti et al., 2007). 
 
Examples of glycopeptide antibiotics in which P450 monooxygenase enzymes play a part in their 
biosynthesis are Vancomycin and Teicoplanin. Vancomycin is sourced from the actinobacterium 
Amycolatopsis orientalis while teicoplanin, a semisynthetic glycopeptide, is derived from 
Actinoplanes teichomyceticus (de Lalla et al., 1992). These two antibiotics are effective against 
Gram-positive infections such as those caused by Enterococcus faecalis and MRSA (ibid). 
 
5.6.2.5 Ansamycins 
 
Ansamycins are macrolide antibiotics that are derivatives of compounds produced by 
actinobacteria (Vardanyan & Hruby, 2016). They are well noted in literature as potent biological 
compounds that display antibacterial, anticancer as well as antiviral properties (ibid). 
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Ansamycins have a wide spectrum of activity since they have demonstrated efficacy against 
both Gram-positive and Gram-negative bacterial strains (Floss & Yu, 1999). In our study, we 
targeted the BGC encoding the 3-amino-5-hydroxybenzoic acid (AHBA) synthase enzyme using 
the ANSA-F and ANSA-R degenerate primers as described by Wood et al. (2007). The screen 
for the AHBA synthase-encoding BGC was found to be negative amongst all 30 strains under 
study. 
 
5.6.2.6 β-lactams 
 
β-lactam antibiotics are a group of antibiotics that contain a highly reactive and specialized cyclic 
amide ring within their molecular structures called the β-lactam ring (Holten & Onusko, 2000). 
Ever since the discovery of penicillin in 1928, they have been one of the most prescribed groups 
of antibiotics. Their mode of action is based upon their ability to interfere with the peptidoglycan 
cell wall synthesis in pathogenic bacteria (Elander, 2003). This mode of action makes them 
potent mainly against Gram-positive microorganisms as opposed to Gram-negative 
microorganisms since the former have peptidoglycan as a structurally key component of their 
cell walls (ibid). 
 
β-lactam antibiotics constitute the majority of commercially available antibiotics and they consist 
of broader families such as penicillins, cephalosporins and cephamycins, which are produced by 
actinobacteria species (Liras & Martin, 2006). Our screen for the β-lactam BGC gave a negative 
result, hence it can be concluded that although there was evidence of bioactive metabolites in 29 
of our 30 strains, these certainly did not have characteristics of β-lactams at the molecular level. 
 
5.6.2.7 Aminoglycosides 
 
The BGC encoding for aminoglycosides was also screened for and the result amongst all 30 
strains was negative. However, similar to β-lactam antibiotics, the rationale behind screening for 
aminoglycosides was mainly because they are also derived from actinobacterial species (Krause 
et al., 2016). Antibiotics of this class have broad-spectrum potency, which is based on their 
ability to dismantle the protein synthesis machinery within pathogenic bacteria (ibid). 
Aminoglycoside antibiotics are effective against both Gram-positive and Gram-negative 
microorganisms such as the Enterobacteriaceae, Yersinia pestis, Staphylococcus aureus, 
Mycobacterium species and Proteus species among many others (Waksman et al., 2010). 
 
Examples of actinobacteria from which aminoglycoside antibiotics have been isolated include 
Streptomyces griseus, which is famous for being the source microorganism of the first 
Aminoglycoside, Streptomycin (Dutton et al., 1995). Another justification for including the screen 
for Aminoglycoside BGC in our study was that gentamicin, a famous and widely used 
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aminoglycoside antibiotic, is a known compound produced by Micromonospora purpurea 
(Waksman et al., 2010). This subsequently meant that a positive screen of the aminoglycoside 
BGC in any of our Micromonospora strains, would also have been of immense interest. 
 
5.7. Primer design outcome and oligo-analysis 
 
The outcome of the primer design process was pertinent for the successful screening of the 
Bacteriocin and Lanthipeptide BGCs. Borah (2011) highlighted that critical to the success of any 
PCR is the use of primers of good design and quality. Certain considerations should have been 
taken into account in designing the primers, as shown in Table 4.5. These include the length of 
the primers, melting temperature, GC content, annealing temperature and the possibility of 
formation of secondary structures (Patricia et al., 2009). 
 
5.7.1 Lanthipeptide and Bacteriocin genes 
 
Given that many of the BGCs that were predicted within the genomes of Micromonospora 
species analysed were not covered by the PCR-based screening, it was imperative to close this 
gap by identifying BGCs that could be targeted for primer design. The designed primers would 
be different from the primer sets used in the PCR-based screening since they would be designed 
specific to Micromonosporaceae. This is the reason why antiSMASH analysis of 
Micromonospora genomes was performed and served as the basis of primer design, as outlined 
in section 4.8 (Chapter 4). One of the most important questions upon which this research project 
was founded upon, sought to address whether the primer design exercise contributed to the 
fulfilment of the main aim of the study, as outlined in the project title. 
 
It is important to note that most of the primer sets that were used in the PCR screen for BGCs 
were previously designed based on sequences from streptomycete species. This is the most 
probable reason why there was no amplification of the seven BGCs, which were being targeted 
within the Micromonospora strains. Having established this, a decision to target BGCs for which 
primers have not been designed for was taken, specifically for the genus Micromonospora. This 
led to the design of primer pairs for targeting lanthipeptide and bacteriocin. It was important to 
assess how these designed primers would assist in determining the antibiotic biosynthetic 
potential of the selected marine Micromonosporaceae species under study. After designing and 
synthesising primers to target lanthipeptide and bacteriocin BGCs (specifically Lant_dehydr_C 
and the DUF692 genes), it was important to investigate the presence of any of these within the 
genomes of at least five of the Micromonospora strains under study. 
 
5.7.1.1 Lanthipeptides 
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From the information given in the outcome of primer design, it was expected that successful 
amplification of the lanthipeptide gene would yield bands with a length of about 850 bp upon 
successful agarose gel electrophoresis. This was, therefore, a starting point in answering the 
question whether any or all of the Micromonospora strains housed the lanthipeptide genes within 
their genomes. After performing the PCR and running the agarose gel, no bands were observed. 
Optimisation was attempted from different angles that firstly included repetition of the PCR runs 
with a fresh set of reagents. The PCR run with the fresh stock of reagents was performed as a 
gradient PCR with a gradient of 10oC. This also did not yield any result. The reaction was also 
supplemented in another run with BSA to counteract any accumulated inhibitors as outlined by 
Lorenz (2012). After all these optimisation studies, it was concluded that there was no evidence 
of the existence of BGCs encoding for lanthipeptides in our five selected Micromonospora 
strains. 
 
The focus on targeting the lanthipeptide gene in a bid to qualify our Micromonospora strains as 
potentially novel from a bioactivity standpoint, was chiefly due to the reputation of these 
compounds. Ongey and Neubauer (2016) highlighted that being natural peptide products, 
lanthipeptides make prospective alternatives to antibiotics currently in the clinical space due to 
their unique structural composition and accessibility. The lanthipeptide, nisin, discovered by 
Rogers in 1928, went on to be an important food preservation agent and its FDA approval in 
1988 sparked research interest of lanthipeptides amongst generally regarded as safe (GRAS) 
microbes (McAuliffe et al., 2000). Also, worth noting is the fact that the majority of known 
lanthipeptides depict antibacterial activity and are sourced from Gram-positive microorganisms 
hence the pursuit of these compounds in our study (Bierbaum & Sahl, 2009). 
 
5.7.1.2 Bacteriocins 
 
The expected amplicon size from the amplification of the bacteriocin gene was 400 bp as given 
in Table 4.5. On viewing the agarose gel that was run after amplifying the bacteriocin gene, 
multiple bands were observed under UV light. There are a couple of inferences that can be 
made in interpreting the respective agarose gel image given in Figure 4.16. The first observation 
was the formation of multiple bands of different sizes for each of the five strains. Troubleshooting 
and optimisation of many aspects of the PCR such as reagent components, annealing 
temperature and reaction stringency were performed as suggested by Lorenz (2012). However, 
the best outcome is shown in Figure 4.16. 
 
The multiple bands on the agarose gel were highly likely due to the primers’ lack of absolute 
binding specificity (Lorenz, 2012). Despite such flaws, a considerable number of important 
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inferences can be drawn from the gel picture. Firstly, our target gene was of an expected 
amplicon size of 400 bp as established from the primer design analysis. From the image, strains 
1, 2, 4 and 5 were observed to produce an amplicon of approximately 400 bp within their 
genomes, hence concluded to be highly likely positive for the DUF692 Bacteriocin gene (Figure 
5.5). This is however not exclusive evidence of the presence of the targeted BGC. 
 
 
 
Bacteriocin gene  
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Figure 5.5: An antiSMASH extract showing the genomic region housing the DUF692 gene encoding for 
bacteriocin in M. aurantiaca NRRL B-2673T. The figure shows an example of the location of the 
Bacteriocin gene within a genomic region, which also houses the Terpene biosynthetic genes. All other 
genes associated with the core BGCs such as transport-related, regulatory, resistance and other genes 
are also shown in the figure. 
 
The 400bp-long bands were specifically extracted from the gel by the “gel-cutting” technique and 
processed for sequencing. This enabled us to determine whether indeed these bands 
represented genes encoding bacteriocins or related compounds. 
 
5.7.2 Outcomes of the Blastx Bacteriocin sequence enquiries 
 
Cotter et al. (2012) defined bacteriocins as bacterial-originating toxins of a peptidic nature that 
are produced in order to halt the growth of other bacteria. The bacterial strains targeted by 
bacteriocin compounds are usually closely similar to those which are the sources of these 
bacteriocins. 
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It was, therefore, established that some of the Micromonospora strains under study likely housed 
the bacteriocin-encoding BGC. A critical question that arises would focus on the relevance of this 
finding. The binding specificity of the designed primer pairs was going to be a critical factor in 
their successful function. It is not uncommon that when gene-specific primer sets are designed, 
non-specific binding can occur (Borah, 2011). To investigate the specificity of our designed 
primer pairs, the sequences were first submitted to Primer-BLAST. Detailed primer reports were 
generated for both the bacteriocin and lanthipeptide primer pairs and from these it was seen that 
an element of non-specificity was observed. It is important to note that the primer designs had 
been refined thoroughly, therefore, reaction optimisation was the most suitable avenue to 
explore to improve primer functionality. 
 
The sequence results given in Table 4.6 were therefore not much of a surprise considering that 
our investigations had hinted on the possibility of non-specific binding. However, certain 
measures could be taken to improve optimisation and broaden troubleshooting. Such 
interventions would include reducing number of cycles in the PCR phases, reducing the 
extension and annealing times, relooking the annealing temperature as well as adjusting the 
thermo-cycler ramping speed (Borah, 2011). 
 
5.10 Antimicrobial activity studies 
 
The current study mainly focused on investigating the ability of the 30 Micromonospora strains to 
produce bioactive metabolites. Therefore, it meant that we had to establish laboratory evidence 
of any form of efficacy of the Micromonospora strains against known pathogenic 
microorganisms. The test strains that were selected for this investigation were Escherichia coli 
ATCC 25922, Bacillus cereus ATCC 10876 and Candida albicans ATCC 24433. The rationale 
behind the selection of these strains was to cover as wide a spectrum of activity as possible. 
With E. coli being a Gram-negative bacterium, B. cereus being a Gram-positive microorganism 
and C. albicans being a yeast, it meant that the analysis of antimicrobial activity indeed covered 
a broad range of microorganisms to a reasonable extent. Specifically, in liquid cultures, 
bioactivity was investigated by performing bioautography as opposed to solid culture overlay 
studies. This would be beneficial in the analysis of bioactivity for those strains that did not 
produce metabolites on solid agar. Further to this, the other aim of performing bioautography 
studies was to establish the specific days on which the Micromonospora strains effectively 
produced their antibiotic compounds. These were going to be useful as optimum incubation 
periods in performing liquid culture bioactivity analysis using multiple extraction techniques. 
Bioautography is a more specific bioactivity tool and it was useful in corroborating the analysis of 
the strains’ antibacterial activity by solid agar overlays in our study. 
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5.10.1 Solid agar overlay studies 
 
The results shown in Tables 4.6, 4.7a, 4.7b, and 4.8 are only for the instances whereby any 
antimicrobial activity was observed by means of clear zones of inhibition on the solid agar plates 
after overlaying. The extent of antibacterial activity in this section was determined by paying 
reference to arbitrary assignment of strength of activity (Table 5.2) as highlighted by Kirby and 
Le Roes-Hill (2009). 
 
Table 5.2 Arbitrary assignment of strength of antibacterial activity 
 
Antimicrobial activity Zone area (mm2) 
  
VW (Very weak) <100 
  
W (Weak) 100-1000 
  
M (Moderate) 1001-2000 
  
S (Strong) 2001-3000 
  
VS (Very strong) >3000 
  
 
 
5.10.1.1 Activity of Micromonospora strains against E. coli ATCC 25922 
 
According to Kirby and Le-Roes-Hill (2009), the commencement of development of aerial 
mycelia on the surfaces of actinobacterial colonies is often associated with antibiotic production. 
This is consistent with what was observed in the experiment, whereby mycelial growth was 
recorded in fifteen out of seventeen Micromonospora colonies that depicted activity against E. 
coli ATCC 25922. 
 
The E. coli ATCC 25922 used in this experiment is the recommended strain because it is 
susceptible and does not produce endotoxins (Chen et al., 2017). E. coli is a known pathogenic 
causative of ailments such as septicaemia and other related infections, including urinary tract 
infections (Chen et al., 2017). The observation of bioactivity of the twelve strains against E. coli 
ATCC 25922 suggests that either these strains produced bioactive metabolites that inhibit β-
lactamase activity, or they resisted the hydrolysis effect of β-lactamase (Babic et al., 2006). The 
production of the enzyme β-lactamase by bacteria such as E. coli ATCC 25922 leads to the 
hydrolysis of the β-lactam ring, prior to their binding to a penicillin-binding protein (PBP). This 
subsequently renders antibiotic compounds completely inactive (Hidayati et al., 2013). Analysis 
of bioactivity was performed both in solid and liquid cultures. 
 
A very good example of a Micromonospora isolate antibiotic that is potent against E. coli is 
gentamicin, which is isolated from Micromonospora purpurea (Wagman & Weinsten, 1980). 
Another antibacterial compound, butremycin, isolated from Micromonospora sp. K310 by 
116 
Kyeremeh et al. (2014) also showed similar bioactivity against the same E. coli ATCC 25922 
strain that we used in our study. 
 
This background consequently validates the significance of the activity observed amongst the 
Micromonospora strains against the E. coli ATCC 25922 strain. It can be concluded, in general, 
that twelve of the 30 Micromonospora strains under study have demonstrable potency against a 
Gram-negative microorganism such as E. coli, with strain 02-128*#1 being the most the active, 
as shown by the areas of inhibition zone values. 
 
5.10.1.2 Activity of Micromonospora strains against B. cereus ATCC 10876 
 
Bacillus cereus is a Gram-positive microorganism that is commonly associated with food 
poisoning in its pathogenic form (Guinebretiere et al., 2013). Its pathogenicity is based on the 
bacterium’s ability to produce toxins which are considerably thermo-resistant, hence causing 
poisoning in undercooked food such as fried rice (ibid). Being β-lactamase producers, B. cereus 
strains show resistance to β-lactam antibiotic therapy such as that of cephalosporins and 
Penicillins. Some strains of B. cereus also show elements of resistance towards conventional 
non-β-lactamase antibiotics which builds up progressively from tolerance due to overuse from 
over-prescription (Chen et al., 2017). 
 
In an attempt to correlate aerial mycelium presence and antimicrobial activity, it was observed 
that although other isolates were characterised by antimicrobial activity coupled with aerial 
mycelium production, antibacterial activity was also observed around some colonies where no 
aerial mycelium was observed. These mycelia-related observations are in sync with the known 
behaviour of actinobacteria as they produce antibiotics, as highlighted by Kirby and Le Roes-Hill 
(2009). 
 
With reference to the arbitrary assignment of strength of antibacterial activity (Table 5.2), activity 
against B. cereus ranged from very weak, weak to moderate. The strain that showed the most 
activity against B. cereus ATCC 10876 was strain 02-128*#3 which showed moderate activity 
with a calculated area of inhibition of 1178mm2. The antibacterial compound Butremycin, 
isolated from Micromonospora sp. K310 by Kyeremeh et al. (2014) was reported to depict 
bioactivity against the strain S. aureus ATCC 25923, a Gram-positive test strain. The 
microorganism Micromonospora sp. K310 is, therefore, a good example of the broad spectrum 
bioactive ability associated with some strains of this genus since it showed such activity against 
both Gram-positive and Gram-negative test strains (Wang et al., 2019). Another example of 
similar bioactivity was reported by Talukdar et al. (2016) when they demonstrated the 
antibacterial activity of Micromonospora auratinigra against Bacillus subtilis, a Gram-positive 
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pathogen. Gentamicins are an example of a group of commercial antibiotics on the 
pharmaceutical market since 1971 with broad-spectrum activity. Ever since the discovery of 
antibiotics from Micromonosporaceae, the gentamicins have proven to be the most popular and 
they are sourced from M. echinospora NRRL 2953 (Boumehira et al., 2016). 
 
5.10.1.3 Activity of Micromonospora strains against Candida albicans ATCC 24433 
 
The antagonistic activity of Micromonospora strains against C. albicans was investigated and the 
results are tabulated in Table 4.8. C. albicans is an opportunistic commensal that is a causative 
agent of the fungal infection candidiasis, in its pathogenic form (Kabir et al., 2012). It is noted in 
literature that about three quarters of women suffer from candidiasis at least once in their lifetime 
and in immunocompromised patients, the condition presents itself in its most severe form 
(Ruhnke & Maschmeyer, 2002; Schulze & Sonnenborn, 2009). Although this study chiefly 
focused on the “antibiotic” biosynthetic potential of Micromonospora strains, inclusion of fungi in 
the investigation of production of bioactive metabolites was justifiable. As reported by Zhao et al. 
(2017), some Micromonospora strains such as Micromonospora parathelypteridis have potency 
against fungi. Therefore, to have any of our strains depicting antifungal activity further to 
antibacterial activity would be an incentive on the aim of our study. This was the basis for 
investigating antifungal activity of our strains, specifically against a virulent strain of C. albicans. 
 
As shown in Table 4.8, a total of ten out of a possible 30 Micromonospora strains showed some 
form of activity against C. albicans. By use of the arbitrary assignment of strength of antibacterial 
activity as given in Table 5.2, the activity observed ranged from very weak to weak. Strains 02-
118#5, 02-118#4, 02-138#6 and 02-251*#36 are the ones that had calculated areas of inhibition 
zones corresponding to very weak activity while the rest of the strains showed weak activity. 
Even though there was no strain showing activity ranging from moderate through to very strong, 
the observation that ten Micromonospora had some form of antifungal activity was a significant 
one for our study. Kim et al. (1999) reported the isolation and structural elucidation of the 
antibiotic streptimidone from Micromonospora coerulea, which showed antifungal activity against 
the plant fungi Didymella bryoniae and Magnaporthe grisea. Two other antibiotics spartanamicin 
A and B, isolated from Micromonospora strain no. MSU-43097, have also been reported to 
exhibit activity against C. albicans as well as Cryptococcus, Aspergillus and Cladosporium 
species (Nair et al., 1992). 
 
It is important to look at other factors that might have influenced the bioactivity results that were 
observed. One very pertinent example is the effect of culture media used in investigating 
antibiotic production by actinobacteria. Kiranmayi et al. (2011) corroborated with this notion and 
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highlighted that cultivation and nutrition significantly influence the synthesis of bioactive 
metabolites. Carbon and nitrogen sources within media constituents as well as how these are 
optimised can influence how actinobacteria produce their bioactive metabolites (Souagui et al., 
2019). Without media optimisation, we cannot conclude that the bioactivity observed, for 
example, with the yeast, is the only possible activity possessed by a strain. Zeeck and 
colleagues conceptualised the one strain many compounds theory (OSMAC) which rightfully 
postulates that a vast array of secondary metabolites can be sourced from a single microbial 
strain, but only a subset of these will be produced under specific culture conditions (Bode et al., 
2002). Therefore, variation of culture aspects such as carbon and nitrogen source and 
concentration, temperature of incubation, salinity and aeration could have led to the accessing of 
more metabolites (ibid). 
 
5.10.2 Bioautography 
 
5.10.2.1 Principle and relevance of bioautography 
 
Interpretation of the TLC plates in bioautography was based on the principle that tetrazolium 
salts such as MTT turn purple upon reduction by dehydrogenases of thriving cells (metabolically 
active cells) (Balouiri et al., 2016). The MTT used in bioautography contains formazan dye, a 
known indicator of bacterial growth. A purple colour on the TLC plate would, therefore, indicate 
presence of living cells (Kirby & Le Roes-Hill, 2009). In essence, this meant that observation of 
any spots on the TLC plates with purple discolouration signified failure of the spotted bacterial 
extracts, to elicit antibiotic activity. An observation of white or cream clear areas on the TLC 
plates signified the killing of bacterial test strains by the antibiotic compounds produced by the 
Micromonospora strains as no dehydrogenases were produced. 
 
The relevancy of bioautography in investigating the production of antibiotic compounds in our 
Micromonospora liquid cultures was centred upon the technique’s efficacy as a bioassay. Such 
efficacy is primarily attributed to the ability of the technique to localise bioactivity, despite 
formation of complexities at the molecular level, hence allowing for specificity in targeting the 
bioactive compounds (Suleiman et al., 2010). Sharverdi et al. (2007) corroborated with this 
comment and further pointed out the use of bioautography as a fast, efficient and cost-effective 
way to isolate only the relevant and bioactive compounds on a TLC plate. 
 
5.10.2.2 Bioactivity against C. albicans ATCC 24433 
 
Figure 4.21 shows an image of the TLC plate whereupon the activity of the five Micromonospora 
strains was investigated for production of antibacterial compounds against C. albicans ATCC 
24433. The isolates that were spotted on the TLC plate had been prepared from serial extracts 
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obtained over a 12-day incubation period. From the image, all strains showed some form of 
activity against the test strain as shown by the white spots labelled by the yellow arrows. It is, 
however, important to note that the activity was not as distinct and clear-cut as compared to bio-
activity of these strains against other test strains. No activity was observed amongst the negative 
controls, thereby validating the experiment. Most importantly, the growth days that the strains 
produced their antibiotic compounds were noted, as these would play a pivotal role in 
investigating antibacterial activity using multiple extraction techniques. 
 
5.10.2.3 Bioactivity against E. coli ATCC 25922 
 
A clearer and more typical picture of the activity of Micromonospora in liquid cultures is given as 
Figure 4.19, where E. coli ATCC 25922 was used as the test strain. Without any ambiguity, the 
white spots on the TLC plate show that all the strains do show activity against the E. coli ATCC 
25922 test strain. It is interesting to note that the antibacterial activity shown by these strains 
was between 3 days and 7 days of incubation. No activity was observed from isolates that were 
spotted onto the TLC on incubation days 10 and 12. 
 
5.10.2.4 Bioactivity against B. cereus ATCC 10876 
 
There was no activity observed amongst the Micromonospora strains against the test strain B. 
cereus ATCC 10876 as signified by a TLC plate that did not show any colour change during 
incubation. However, in section 5.10.2, it was observed and noted that the Micromonospora 
strains show antibacterial activity against the same B. cereus strain using the solid agar overlay 
method. The difference in activity against the same test strain between solid and liquid media 
can be explained by the fact that metabolite profiles of strains grown in these two media differ 
due to differences in growth parameters such as aeration. 
 
5.10.3 Multiple extraction techniques: bioactivity against C. albicans ATCC 24433 
 
Section 3.9.4 of the methodology chapter covered the use of different extraction techniques in 
pursuit of accessing antibiotic compounds. As highlighted by Betina (1973), the use of different 
extraction techniques is a time and cost-effective manner of simultaneously accessing bioactive 
compounds from liquid cultures. The value of combining these techniques is that gaps are 
bridged in the isolation of the variety of bioactive compounds, therefore a compound missed by 
one technique is highly likely to be picked up by some other isolation technique/s (ibid). 
 
Therefore, the use of multiple extraction techniques in our study was necessary in an attempt to 
cover a wide range of antimicrobial compounds as well as to establish the best extraction 
technique for each of the individual Micromonospora strains under study. TLC as the underlying 
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technique allowed for the separation of possible antibiotic compound mixtures from the strains 
(Betina, 1973). In Figure 4.18, the yellow arrows in the image highlight the white zones on the 
TLC plate, which signify production of bioactive antimicrobial compounds against C. albicans 
ATCC 24433. A summary of the bioactivities observed against C. albicans ATCC 2443 is given 
in Table 5.4. It is important to note that the incubation times for the liquid cultures that were 
employed before the extracts were accessed by the different extraction techniques found their 
basis from the experiment outcomes discussed in sections 5.12.2, 5.12.3 and 5.12.4. 
 
Table 5.3 Summary of the bioactivities observed against C. albicans ATCC 2443 using different 
extraction techniques 
 
    Extraction method  
Strain Culture Day of 
     
    Ammonium 
       
 media Growth Whole cell DIAION Cell Culture sulphate 
   
   extraction treatment extracts filtrate precipitation 
       & dialysis 
        
02-128*#1 172F 12
th 
Active Active Active Active Active 
        
     No  No activity 
04-015#16 172F 10
th 
Active Active activity Active  
        
     No   
02-128*#3 172F 5th Active Active activity Active Active 
     No  No activity 
02-251*#36 172F 3rd Active No activity activity Active  
        
     No  No activity 
02-209#4 172F 12
th 
Active Active activity Active  
        
 
 
The TLC plate’s results in Figure 4.21 were validated due to the negative result of the controls, 
that is to say, there was evidence that there were not any bioactive compounds in the liquid 
culture media before inoculation with Micromonospora strains. From Figure 4.21, it can also be 
concluded that the filtrate obtained via the filtration technique showed the most antifungal 
potency against the yeast C. albicans ATCC 24433. This is because in all five strains, this 
technique managed to unlock antimicrobial potency as shown by the white zones of clearance 
on the TLC plate. Treatment of the filtrate obtained from filtration by ethyl acetate produced 
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purer forms of extracts. These extracts had increased concentration of antibacterial compounds, 
hence showing significant activity on TLC plates (Valan Arashu et al., 2014). 
 
On the other hand, Figure 4.21 clearly shows that the cells obtained by the filtration technique 
did not have any active antibiotic compounds as shown by the lack of white zones on the purple 
background for all the spotted strains. All other extraction techniques such as the whole-cell 
culture, DIAION treatment and dialysis successfully extracted active compounds from some of 
the Micromonospora strains. In general, as shown in Table 5.4, the most activity was observed 
in extracts obtained by the ethyl acetate extraction technique (whole-cell culture) as well as the 
filtration technique. The diverse biological attributes of ethyl acetate as a solvent of extraction, 
which include average polarity and minimal toxicity towards test strains, makes extraction with 
ethyl acetate a reliable method for the extraction of both polar and non-polar antibacterial 
compounds (Valan Arasu et al., 2014). 
 
5.12.6 Multiple extraction techniques: bioactivity against E. coli ATCC 25922 
 
Figure 4.22 shows an image of a TLC plate whereupon the bioactivity of antibiotic compounds 
that were acquired by different extraction techniques was tested against E. coli ATCC 25922. As 
shown on the TLC plate, the controls showed negative results in the row that they were spotted 
meaning the culture media did not have any antimicrobial properties of its own that could 
influence the investigation (Waksman et al., 2010). This meant that there was compelling 
evidence to the fact that Micromonospora-derived compounds were responsible for the observed 
antibiotic activity on the TLC plate. 
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Table 5.4 Summary of the bioactivities observed against E. coli ATCC 25922 using different extraction 
techniques 
 
    Extraction method  
Strain Culture Day of 
     
Whole DIAION Cell Culture Ammonium 
   
 media Growth cell treatment extracts filtrate sulphate 
   
   extraction    precipitation 
       & dialysis 
        
02-128*#1 172F 12
th 
Active Active No Active Active 
     activity   
        
04-015#16 172F 10
th 
Active Active No Active No activity 
     activity   
        
02-128*#3 172F 5th No Active No Active Active 
   activity  activity   
        
02-251*#36 172F 3rd No Active No Active No activity 
   activity  activity   
        
     No   
02-209#4 172F 12
th 
No Active activity Active No activity 
   activity     
        
 
 
Similar to the patterns observed in their bioactivity against C. albicans ATCC 24433, the 
extraction by the filtration extraction, particularly the filtrate was the most effective method of 
accessing the antibiotic compounds produced by the Micromonospora species. All strains 
produced filtrate that evidently contained antibiotic compounds active against E. coli ATCC 
25922 as shown by the clear white spots against the purple background. Interestingly, the cells 
derived from the same filtration process did not show any antibiotic activity against the test 
strain. Antibiotic compounds accessed from strains 1, 4 and 8 by DIAION treatment also showed 
considerable activity against the test strain. From the TLC image (Figure 4.22), it can also be 
concluded that the whole-cell culture and dialysis techniques were less effective than the 
filtration technique in accessing antibiotic compounds in Micromonospora strains. 
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5.12.7 Micromonospora strains selected for further study 
 
Based on their bioactivity against the test strains used in the analysis of antimicrobial activity, the 
five best antibiotic compound-producing strains were found to be 02-128*#1, 04-015*#16, 02-
128*#3, 02-251*#36 and 02-209*#6. These strains were further investigated for phylogeny, as 
shown in section 3.6 of Chapter 3. 
 
Table 5.5 Summary Table of the bioactivities of the Micromonospora strains forming the main focus of this 
study. 
 
 Area of inhibition zone against test strain (mm2) 
Strain 
   
E. coli ATCC 25922 B. cereus ATCC 10876 C. albicans ATCC 
   24433 
    
02-128*#1 1130.99 273.77 No activity 
    
04-015*#16 701.99 No activity No activity 
    
02-128*#3 486.70 1178.09 436.26 
    
02-251*#36 417.62 75.56 51.03 
    
02-209*#6 689.09 No activity No activity 
    
 
 
After discussing the results obtained in this study, it is imperative to see if these have answered 
to the objectives of the study. In this regard, the last chapter of this thesis will summarise the 
findings of the study against the individual objectives set and outline concluding remarks. 
Recommendations for future studies as well as limitations of the current study are also outlined 
in the next chapter. 
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CHAPTER 6 
 
CONCLUSIONS AND RECOMMENDATIONS 
 
6.1 Conclusions 
 
Each objective proposed before the commencement of this study was pursued to as reasonable 
an extent as possible. The pursuit of these objectives generated results outlined in Chapter 4 
and subsequently discussed in Chapter 5. From the discussion, a number of conclusions can be 
drawn. 
 
Objective 1: To assess the viability of the Micromonosporaceae strains, stored as frozen 
cultures, on solid and in liquid cultures. 
 
Conclusion 1: The 30 strains that constituted the subjects of this study were successfully 
“woken up” to viability from their frozen state (-80oC) on the relevant agar media. Irrefutable 
evidence of viable Micromonospora strains on solid and in liquid cultures was presented in 
section 4.1 of this study. The culture media used in this study (SGG, SGG with artificial 
seawater-ASW, 172F and 172F with ASW) was observed to be favourable in bringing the strains 
to viability as well as growing them, in both their solid and liquid variations. 
 
Objective 2: To identify strains under study up to species level by performing 16S rRNA gene 
analysis and multi-locus sequence analysis (MLSA). 
 
Conclusion 2: 16S rRNA gene sequencing and analysis led to the conclusion that 28 of the 30 
strains under study belong to the genus Micromonospora while two belong to the genus 
Jishengella. However, all strains were concluded to belong to the family Micromonosporaceae. 
MLSA studies concluded that the five strains chosen for further analysis could represent novel 
species, with ancestry very closely related to the Micromonospora aurantiaca ATCC 27029T 
strain. However, tools such as DNA-DNA hybridisation or whole-genome sequencing could be 
employed to aid in the speciation of the strains hence answering the question on strain novelty. 
 
Objective 3: To perform a molecular screen of the marine Micromonosporaceae strains present 
in the BTB culture collection for selected BGCs. 
 
Conclusion 3: A total of eight BGCs were targeted within the genomes of the 30 
Micromonospora strains under study. Only one of the eight BGCs, the Type II PKS BGC was 
positive in 28 of the 30 strains, thus showing antibiotic biosynthetic potential of these strains. 
This BGC was also predicted in almost all of the 44 validly published Micromonosporaceae 
genomes that were analysed. 
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Objective 4: To analyse the genome sequences of Micromonosporaceae strains to assist with 
the design of new primer sets. 
 
To identify gaps in the current knowledge around primer sets available for the molecular 
screening of antibiotic biosynthetic gene clusters and the design of new primer sets. 
 
Conclusion 4: 44 validly published Micromonosporaceae type strains were successfully 
analysed at genomic level to aid in the design of new primer sets. This information was used in 
conjunction with the current knowledge around primer sets for the molecular screening of the 
antibiotic BGCs used in this study. Ultimately, two sets of new primer pairs (BAC-F/BAC-R and 
LAN-F/LAN-R) were successfully designed. 
 
Objective 5: To test all new primer sets designed on the top five Micromonosporaceae strains 
used in this study. 
 
Conclusion 5: The primer sets that were designed were tested, as intended, on the five 
Micromonosporaceae strains to see if they yielded any product. The primer set targeting the 
bacteriocin BGC gave multiple PCR products on agarose gel electrophoresis signifying non-
specific binding of primers. Despite being hopeful, there is need to refine the design of the 
primers; possibly considering the use of degenerate primer sets to improve on primer function. 
 
Objective 6: To assess the antibacterial activity of strains under study against selected test 
strains on solid and in liquid media. 
 
Conclusion 6: Antibacterial activity analysis was successfully performed in liquid and on solid 
media. On solid media analysis, twelve Micromonosporaceae strains showed bioactivity, which 
ranged from weak to moderate against Escherichia coli ATCC 25922. Analysis of bioactivity 
against Bacillus cereus ATCC 10876 revealed that twelve strains showed some form of 
bioactivity that ranged from very weak, weak to moderate. Ten strains showed bioactivity against 
Candida albicans ATCC 24433 and with such activity ranging from very weak to weak. 
 
Bioautography studies conducted for the five best Micromonosporaceae strains showed that 
they all produce antibacterial substances against C. albicans ATCC 24433, albeit after different 
days of incubation. All strains also showed activity against E. coli ATCC 25922 after three to 
seven days of incubation. The filtration technique was found to be the most effective in 
accessing antibiotic compounds amongst the multiple extraction techniques used. 
 
6.2 Recommendations 
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The primer sets designed in this research study proved to be promising in targeting the 
bacteriocin BGC. The other primer set did not yield any product on attempted amplification of the 
target lanthipeptide BGC within the five Micromonosporaceae strains analysed. For the sake of 
future research, optimisation using other parameters (such as range of MgCl2, other additives 
such as glycerol, DNA concentration) could be tested. These primer sets would possibly locate 
the lanthipeptide and bacteriocin BGCs within genomes of many other strains of interest. 
 
6.3 Limitations and highlights of the study 
 
In our PCR-based screening of novel BGCs, we had to have gene sequence information first to 
enable the designing of primers. This subsequently means that truly novel sequences are highly 
likely to be missed using such an approach, hence a limitation. In the same vein, primers may 
only function within a specific genus hence their scope becomes limited. Another major 
challenge that comes with PCR-based screening is the fact that even if a strain gives amplicons 
for a particular gene, it does not mean it possesses the entire pathway needed to produce the 
corresponding compound. In other cases, the entire pathway might be present and still, the 
compound might not be produced. 
 
Despite the limitations of the study, PCR-based screening (particularly coupled with other 
genomic methods) has the potential to reveal a plethora of unknown bioactive compounds. 
Another quite interesting highlight of this study is the fact that so many of the strains studied 
seem to be phylogenetically related to Micromonospora aurantiaca. This microorganism has 
been shown to exhibit biotechnological potential. The outcomes of this study can therefore also 
serve as a basis for future studies focused on this interesting group of strains that seem to be 
associated with different sea sponges and sea squirts collected from the Algoa Bay region. 
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ANNEXURE A 
 
16S rRNA gene phylogeny: Maximum likelihood and minimum evolution trees 
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Figure An1: The phylogenetic relationships between the 16S rRNA gene sequences of the 
Micromonospora strains 02-128*3, 02-209#4, 02-128*1, 02-251*36, 04-015#16 with 30 other type strains 
of other Micromonospora species are shown in the Maximum likelihood evolution tree (Saitou & Nei, 
1987). The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary 
distances used to infer the phylogenetic tree. This analysis involved 36 nucleotide sequences. There were 
1338 positions in the final dataset. Evolutionary analyses were conducted in MEGA X (Kumar et al., 
2018). 
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Figure An2: The phylogenetic relationships between the 16S rRNA gene sequences of the 
Micromonospora strains 02-128*3, 02-209#4, 02-128*1, 02-251*36, 04-015#16 with 30 other type strains 
of other Micromonospora species are shown in the Minimum evolution tree (Saitou & Nei, 1987). The tree 
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is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to 
infer the phylogenetic tree. This analysis involved 36 nucleotide sequences. There were 1338 positions in 
the final dataset. Evolutionary analyses were conducted in MEGA X (Kumar et al., 2018). 
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ANNEXURE B 
 
gyrB phylogeny: Maximum likelihood and minimum evolution trees 
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Figure An3: The phylogenetic relationships between the gyrB gene sequences of the 5 Micromonospora 
strains (02-128*3, 02-209#4, 02-128*1, 02-251*36, 04-015#16) and strains of other Micromonospora 
species are shown in the Maximum likelihood tree (Saitou & Nei, 1987). The tree is drawn to scale, with  
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branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic 
tree. This analysis involved 32 nucleotide sequences. There were 987 positions in the final dataset. 
Evolutionary analyses were conducted in MEGA X (Kumar et al., 2018). 
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Figure An4: The phylogenetic relationships between the gyrB gene sequences of the 5 Micromonospora 
strains (02-128*3, 02-209#4, 02-128*1, 02-251*36, 04-015#16) and strains of other Micromonospora 
species are shown in the Minimum evolution tree (Saitou & Nei, 1987). The tree is drawn to scale, with  
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branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic 
tree. This analysis involved 32 nucleotide sequences. There were 987 positions in the final dataset. 
Evolutionary analyses were conducted in MEGA X (Kumar et al., 2018). 
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ANNEXURE C 
 
rpoB phylogeny: Maximum likelihood and minimum evolution trees 
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Fig An5: A Maximum-likelihood phylogenetic tree (Saitou & Nei, 1987), is shown between the rpoB gene sequences 
of the 5 Micromonospora strains (02-128*3, 02-209#4, 02-128*1, 02-251*36, 04-015#16) and strains of other 
Micromonospora genus. The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary 
distances used to infer the phylogenetic tree. This analysis involved 24 nucleotide sequences. There were 602 
positions in the final dataset. Evolutionary analyses were conducted in MEGA X (Kumar et al., 2018). 
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Fig An6: A Minimum evolution phylogenetic tree (Saitou & Nei, 1987), is shown between the rpoB gene sequences of 
the 5 Micromonospora strains (02-128*3, 02-209#4, 02-128*1, 02-251*36, 04-015#16) and strains of other 
Micromonospora genus. The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary 
distances used to infer the phylogenetic tree. This analysis involved 24 nucleotide sequences. There were 602 
positions in the final dataset. Evolutionary analyses were conducted in MEGA X (Kumar et al., 2018). 
 
 
 
 
 
 
 
 
 
153 
ANNEXURE D 
 
Concatenated sequences: Maximum likelihood and minimum evolution trees 
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Figure An7: A Maximum likelihood phylogenetic tree (Saitou & Nei, 1987), is shown between the MLSA 
derived composite sequences of the 5 Micromonospora strains (02-128*3, 02-209#4, 02-128*1, 02-
251*36, 04-015#16) and Type strains of other Micromonospora genus. During the construction of this tree, 
the 5 Micromonospora strains were presented as concatenated sequences obtained by combining their 
individual 16S sequences, gyrB and rpoB gene sequences from the MLSA study. The same order of 
sequence assembly was maintained for all the strains. The tree is drawn to scale, with branch lengths in 
the same units as those of the evolutionary distances used to infer the phylogenetic tree. The evolutionary 
distances were computed using the Maximum Composite Likelihood method and are in the units of the 
number of base substitutions per site. This analysis involved 24 nucleotide sequences. All ambiguous 
positions were removed for each sequence pair (pairwise deletion option). There were a total of 2837 
positions in the final dataset. Evolutionary analyses were conducted in MEGA X (Kumar et al., 2018). 
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Figure An7: A Minimum evolution phylogenetic tree (Saitou & Nei, 1987), is shown between the MLSA 
derived composite sequences of the 5 Micromonospora strains (02-128*3, 02-209#4, 02-128*1, 02-
251*36, 04-015#16) and Type strains of other Micromonospora genus. During the construction of this tree, 
the 5 Micromonospora strains were presented as concatenated sequences obtained by combining their 
individual 16S sequences, gyrB and rpoB gene sequences from the MLSA study. The same order of 
sequence assembly was maintained for all the strains. The tree is drawn to scale, with branch lengths in 
the same units as those of the evolutionary distances used to infer the phylogenetic tree. The evolutionary 
distances were computed using the Maximum Composite Likelihood method and are in the units of the 
number of base substitutions per site. This analysis involved 24 nucleotide sequences. All ambiguous 
positions were removed for each sequence pair (pairwise deletion option). There were a total of 2837 
positions in the final dataset. Evolutionary analyses were conducted in MEGA X (Kumar et al., 2018). 
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 ANNEXURE E: BACTERIOCIN PRIMER SYNTHESIS 
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 ANNEXURE F: LANTHIPEPTIDE PRIMER SYNTHESIS 
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